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Oncolytic viruses (OV) represent an emerging modality in cancer therapy. 
Antiviral immunity is currently viewed as a barrier to systemic OV efficacy. 
Approaches have been taken to promote OV activity by attenuating virus-
neutralising antibodies (NAb). However, the presence of NAb does not prevent 
intravenously administered OV, such as reovirus, reaching tumours in patients. 
Recent evidence suggests that NAb may in fact support virotherapy in mice by 
facilitating reovirus carriage upon circulating immune cells, principally 
monocytes. 
In this thesis, the applicability of these observations to the human setting is 
examined, modelling the loading of monocytes with reovirus in virus-immune 
patients. A novel in vitro cell carriage assay was employed, involving clinical 
trial patient-derived sera, isolated primary human monocytes, and human 
tumour cell lines. It was discovered that monocytes treated with fully neutralised 
reovirus reliably delivered the virus to kill melanoma targets. This was 
transferable across target cell histologies, and applicable to another OV, 
CVA21. Neutralised reovirus successfully accessed syngeneic melanoma flank 
tumours in mice. 
Prior murine studies suggested a role for surface Fc receptors in facilitating the 
antibody-dependent enhancement (ADE) of monocyte infection. A major role for 
Fc receptors in antibody-mediated entry of neutralised reovirus to human 
monocytes was confirmed. Yet no overall enhancement of virus loading or 
hand-off was conferred by the presence of NAb, in contrast to existing 
observations from mouse monocytes.  
Transcriptomic and secretory profiling identified discrete variations in the effects 
of free and neutralised reovirus upon monocyte phenotype. NAb significantly 
attenuated the monocyte IFN response to reovirus in vitro. However, in the 
presence of monocytes, reo-NAb successfully induced NK cell degranulation 
and killing of melanoma targets. Therefore this study identifies a mechanism by 
which, following neutralisation, reovirus may rely on circulating monocytes to 
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The global incidence of melanoma is rising. Over the last three decades, 
incidence has increased by approximately 3% per year, and nearer 5% per year 
in the fair-skinned Caucasian population (DeSantis et al., 2014; Ferlay et al., 
2015; Guy and Ekwueme, 2011). This rise equates to the probability of a fair-
skinned individual developing melanoma rising from 1 in 1,500 in 1935, to 1 in 
50 today (Sandru et al., 2014). Cutaneous melanoma, originating in the skin, 
accounts for well over 90% of all melanoma cases (Chang et al., 1998). Despite 
representing less than 1% of all cases of skin cancer, melanoma causes the 
vast majority of deaths. 
Although only the 19th most prevalent indication worldwide, in 2012 there were 
an estimated 232,000 new cases of cutaneous melanoma diagnosed, and 
55,000 deaths, according to GLOBOCAN data (Ferlay et al., 2015). Globally, 
the spatial distribution of melanoma varies considerably, according to patterns 
of exposure to sunlight and racial skin phenotype. Incidence is highest in 
Australia, where fair-skinned populations experience high exposure to the 
subtropical sun (Erdmann et al., 2013).  
The UK experiences a relatively high burden from melanoma. In 2014, over 
15,000 new diagnoses of melanoma were made. Incidence has more than 
doubled in the past quarter of a century, with melanoma representing 4% of all 
new cases. This makes melanoma the fifth most common cancer in the UK. 
Approximately 2,500 deaths occurring in 2014 were due to malignant 
melanoma, making it the 18th most common cause of cancer death in the UK. 
This discrepancy is due to the high proportion of patients in whom detection and 
treatment at an early stage permits long-term survival; currently, 90% of 
melanoma patients survive beyond 5 years (www.cancerresearchuk.org). 
Although UK incidence is expected to continue to rise in the coming decades, 
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mortality rates are projected to fall by 15% by 2035, largely through improved 
detection and improved therapeutics (Smittenaar et al., 2016). 
Melanoma is more common in men; globally, the male/female ratio is 
approximately 1.2, although substantial variation exists between continents 
(Ferlay et al., 2015). Unlike many cancers which are typically rare until later in 
life, melanoma is increasingly common in younger adults and even adolescents, 
and has become the leading cause of cancer-related death in subgroups of 
young adults in some nations (Iannacone et al., 2015; Smittenaar et al., 2016; 
Weir et al., 2011). In a study evaluating data on melanoma incidence over 
recent decades from 19 national registries, values for the 25-44 age group were 
highest in England, with an estimated relative increase of 5.8% per annum 
(Erdmann et al., 2013). Combined with the aggressive nature of the disease, 
this unusual age demographic means that the number of years of potential life 
lost to melanoma is considerable, at an average of 15-20 (Guy and Ekwueme, 
2011; Thiam et al., 2016). 
 
2.1.2 Aetiology 
Cutaneous melanoma originates from melanocytes, melanin-generating cells 
derived from the neural crest. Positioned in the basal epidermis, where they 
comprise 5-10% of the cell population (Cichorek et al., 2013), melanocytes 
shield keratinocytes from DNA damage induced by ultraviolet radiation (UV) 
(Abdel-Malek et al., 2010). In performing this protective role, melanocytes are 
subjected to solar (and artificial) UV wavelengths, which are primarily 
responsible for their malignant transformation and consequently the genesis of 
frank melanoma. 
Given that the major modifiable risk factor for melanoma is UV exposure, the 
disease is eminently preventable (Armstrong et al., 1997; Chang et al., 2009). 
Epidemiological studies demonstrate a robust association between melanoma 
incidence and temporal and spatial patterns of sun exposure (Elwood and 
Jopson, 1997). In addition to overall exposure, the number of sunburns appears 
to be a particularly pertinent risk factor (Dennis et al., 2008). Exposure to 
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artificial, non-solar UV insult through the use of sunbeds also carries a 
significantly increased risk of developing melanoma (Gallagher et al., 2005).  
Melanocyte transformation is now widely regarded as a multiple-step process. 
Incoming UV-A or UV-B radiation is absorbed by genomic DNA, generating 
lesions such as pyrimidine dimers and 6-4 photoproducts (You et al., 2001). 
These DNA changes can accumulate when the cell’s endogenous repair 
mechanisms, orchestrated by the p53 protein and aided by cell cycle arrest, fail 
to ameliorate the damage in a prompt and accurate manner. For instance, 
resolution of pyrimidine dimers by nucleotide excision repair often yields 
cytosine-to-thymine substitutions, characteristic UV-induced point mutations 
(Daya-Grosjean and Sarasin, 2005). Mutations in specific proto-oncogenes or 
tumour suppressor genes can thus become initiating events for oncogenesis, 
driving uncontrolled replication and thus neoplastic growth. 
Unlike the common benign melanocytic nevus, these ‘nests’ of transformed 
melanocytes proliferate to form a malignant nevus within the epidermis, termed 
melanoma in situ. This is clinically classified as stage 0 disease under the AJCC 
‘TNM’ staging system, in its 8th edition this year (Gershenwald et al., 2017), 
which includes metrics of tumour thickness and ulceration (T), and spread to 
regional lymph nodes (N) and distant organs (metastasis, M) (Balch et al., 
2009). The proliferating cells penetrate in the vertical plane through the dermal-
epidermal junction and subsequently the dermis, and potentially cause 
ulceration; these lesions are progressively classified as stage I and II 
melanoma.  
The progression to more advanced disease requires melanoma cells to acquire 
a migratory phenotype and to transit away from the initial neoplastic site. Thus 
stage III melanoma is broadly characterised by the malignant colonization of 
adjacent tissues and/or lymph nodes. Stage IV disease represents metastatic 
melanoma, in which malignant cells have spread to distant lymph nodes or 
organ sites – most often the liver, lungs, bone and brain (Tas, 2012).  
The staging of melanoma at diagnosis is the key determinant of outcome. Along 
with the molecular factors of lactate dehydrogenase (LDH) level and mitotic 
index, the  anatomical TNM metrics included in the staging system are pivotal 
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prognostic factors (Crowson et al., 2006). The presence of metastasis is 
undoubtedly the strongest of these; while 5-year survival for the whole 
melanoma patient population exceeds 90%, this drops to approximately 16% in 
those with stage IV melanoma (DeSantis et al., 2014). Consequently, early 
detection and treatment of local disease is a priority. 
 
2.1.3 Treatment 
The stage of melanoma diagnosed largely dictates the course of treatment. 
Surgical excision of the primary tumour proves curative in most cases of the 
less advanced stages of melanoma; this can be supplemented with 
lymphadenectomy to address lower levels of nodal disease. It is in the later 
stages of melanoma that available treatments are considerably less effective, 
forming a clear unmet need. 
These patients, and in particular those with stage IV melanoma, typically require 
systemic treatment. Cytotoxic chemotherapy, mostly reliant on dacarbazine 
(DTIC), yields a response rate – that is, the proportion of patients experiencing 
a substantial reduction in tumour volume – of approximately 10%, with complete 
responses in below 5% (Eigentler et al., 2003; Mandarà et al., 2006). 
Chemotherapy, even in combination, has failed to generate a proven survival 
benefit in randomised phase III trials (Lui et al., 2007). Nevertheless, despite 
these poor response rates over more than two decades, DTIC – along with 
interleukin (IL)-2 – remained standard treatment as late as 2008 (Wilson and 
Schuchter, 2016). Temozolomide, another DNA alkylating agent often used in 
the treatment of brain metastases, exhibits similar response rates to DTIC 
(Middleton et al., 2000).  
Conventional single-agent chemotherapy regimens are now widely relegated to 
the second- or third-line setting, or discarded altogether, in favour of novel 
therapeutic approaches emerging over the past decade. Clinical strategies have 




As an indication, melanoma was not a major focus of research until around 
2002. It was at this point that the Cancer Genome Project identified the 
presence of oncogenic mutations in the BRAF (rapidly accelerated fibrosarcoma 
kinase B) gene in over 50% of melanoma cases (Davies et al., 2002). The 
BRAF protein, a serine-threonine kinase, is a key link in the RAS/MAPK (rat 
sarcoma/mitogen-activated protein kinase) signalling cascade underlying 
cellular patterns of differentiation and proliferation (Pearson et al., 2001). Since 
then, research into the dysregulation of the MAPK pathway has made 
melanoma one of the most heavily studied tumour types. 
Activating mutations in the MAPK pathway are key to melanomagenesis (Cohen 
et al., 2002; Hocker et al., 2008; Wellbrock and Arozarena, 2016). In sum, 
mutations within this cascade – typically in NRAS or BRAF – are present in 
around 90% of melanomas. Notably, mutations in BRAF are also common in 
benign melanocytic nevi, suggesting that activation of BRAF is insufficient for 
transformation in isolation, but may represent an important contributory step in 
this direction (Pollock et al., 2003). 
Over 90% of activating mutations in the BRAF gene in melanoma comprise a 
single nucleotide change encoding for the substitution of glutamine at codon 
600 for valine (V600E), while around 5% result in substitution by lysine (V600K) 
(Klinac et al., 2013; Platz et al., 2008). These mutations promote the 
constitutive activation of BRAF, and ultimately downstream molecular sequelae 
leading to unchecked proliferation, invasive capacity, avoidance of apoptosis 
and even immune evasion, all hallmarks of a malignant cell population (Maurer 
et al., 2011). The isolation of these mutations exposed BRAF as a principal 
target for therapeutic inhibition. 
Sorafenib, the first-generation BRAF inhibitor, showed promise in Phase I and II 
trial with response rates over 30% against melanoma. Its eventual failure in 
both pre-treated and treatment-naïve patients with advanced melanoma in 
confirmatory Phase III trial stimulated the development of more specific and 
potent inhibitors (Eggermont and Robert, 2011). The first of these, vemurafenib, 
demonstrated superior efficacy versus sorafenib and DTIC (Chapman et al., 
2011; Young et al., 2012) and in light of the unprecedented outcomes 
subsequently gained regulatory approval for V600E-mutant advanced 
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melanoma in 2011 and 2012 (Dias et al., 2013; Kim et al., 2014). Other BRAF 
inhibitors such as dabrafenib have since been approved in these patients 
(Hauschild et al., 2012).  
The MEK (MAPK kinase)-ERK (extracellular signal-related kinase) pathway 
represents a group of effectors immediately downstream of RAS. As with MAPK 
blockade, the inhibition of MEK using trametinib is effective against V600-
mutant melanoma (Flaherty et al., 2012). These small molecule inhibitors 
against BRAF and MEK generate impressive speed and scale of response, 
heightened when deployed together (Flaherty et al., 2012). Yet the majority of 
patients relapse within a year with BRAF inhibitor-resistant disease, even when 
these agents are used in combination (Larkin et al., 2014; Long et al., 2015). 
Thus although targeted inhibitors can achieve an initial rapid benefit, durable 
responses are limited to small minority and come at the expense of 
considerable toxicity (Sznol et al., 2017). 
Since 2008, immunotherapy agents have commanded an ever-increasing share 
of the market in melanoma therapy. Although the majority of these drugs are 
new, the first immunotherapy agent in widespread use was the T cell stimulant 
IL-2, originally deployed successfully against melanoma in 1984 (Rosenberg et 
al., 1985). This first melanoma patient – and many since – have experienced 
long-term remission through its use (Agarwala, 2009; Rosenberg, 2014). The 
durability of response and distinctive patterns of toxicity observed with 
immunotherapies such as IL-2 are products of their broader modus operandi, 
which is discussed below. 
Following the robust success of IL-2 in a very small subset of patients, further 
waves of immunotherapy agents have made incremental progress in improving 
prognosis for melanoma patients: first interferon (IFN), then more recently a 
cadre of ‘checkpoint inhibitor’ antibodies including ipilimumab and subsequently 
pembrolizumab and nivolumab (Blumenthal and Pazdur, 2017). While IFN and 
IL-2 often elicit tumour responses, they generally fail to enhance overall survival 
versus chemotherapy (Ives et al., 2007). By contrast, checkpoint inhibitor 
therapy is revolutionising outcomes: while only around 12% of advanced 
melanoma patients are alive 3 years after commencing DTIC (Maio et al., 
2015), this figure expands to over 50% in pembrolizumab- or nivolumab-treated 
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populations, according to most recent reports (Robert et al., 2017; Wolchok et 
al., 2017).  
Checkpoint inhibitors and targeted drugs have rapidly surpassed their 
predecessors as standard of care in melanoma. In the UK, according to NICE 
guidelines, surgical excision of the primary tumour remains default treatment for 
local disease (stages 0, I and II). The biopsy of sentinel lymph nodes is 
common for more invasive primary lesions. ‘Loco-regional’ or locally advanced 
(stage III) melanoma is managed by additional lymphadenectomy (Essner et al., 
1999). While the use of adjuvant (post-surgical) radiotherapy, IFN or ipilimumab 
is now commonplace (Eggermont et al., 2016), the use of newer checkpoint 
inhibitors in the adjuvant and neo-adjuvant (pre-surgical) settings appears 
inevitable in efforts to evade progression to stage IV (Rozeman et al., 2017; 
Weber et al., 2017). 
In patients with systemic dissemination of melanoma, a wide range of treatment 
options are now approved for use. In BRAF-mutant patients, genetics dictate 
the use of targeted agents against BRAF and MEK; checkpoint inhibitor use is 
indicated regardless of BRAF status (Larkin et al., 2015b; Schachter et al., 
2017). An avalanche of ongoing studies seek to address the superiority of 
targeted agents or checkpoint inhibitors in the BRAF-mutant setting, emerging 
immunotherapies, the optimal sequencing of existing agents, and the delicate 




2.2 Cancer and the immune system 
 
2.2.1 Anti-tumour immunity 
It is increasingly well recognised that the immune system plays a dual role in 
the development of cancer, with elements that can quash or encourage 
neoplastic growth. Our knowledge of the involvement of the immune system in 
both the genesis and potential treatment of cancer has not always been so 
secure. The first evidence for the relevance of immunity came from disparate 
anecdotal reports, associating acute infection with the onset of spontaneous 
tumour regression (Hoption Cann et al., 2002). The infecting agents implicated 
were diverse, and included bacterial, viral, fungal and protozoan organisms 
(Rohdenburg, 1918). This phenomenon was even observed in the disease 
course of Peregrine Laziosi, the patron saint of cancer patients, in whom 
rejection of a tibial tumour appeared to be triggered by severe infection 
(Jackson, 1974). 
Although not yet formally examined, these reports encouraged some the more 
innovative 19th-century physicians to actively promote sepsis in the peri- or 
post-surgical period, which did yield apparent delays in tumour recurrence 
(reviewed in Jessy, 2011; Thiery, 1909). Such spontaneous regression events 
subsequently inspired what might today be called basic immunotherapies 
(Coley, 1891). Around the turn of the century, the American surgical pioneer 
William Coley employed a ‘vaccine’ comprising inactivated bacterial strains – 
now known as ‘Coley’s toxins’ – to treat cancer lesions, with some evidence of 
regression in sarcoma and lymphoma (Coley, 1910, 1928). However, with the 
rise of chemo- and radiotherapies, and the increasing importance placed on 
surgical asepsis in general, such approaches fell from favour during the 20th 
century. 
Further observational studies broadly corroborate the link between cancer and 
the immune system. The prevalence of cancer is higher in immunodeficient 
mice (Shankaran et al., 2001). This is mirrored somewhat in humans; for 
instance, those prescribed immunosuppressive agents following solid organ 
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transplant are at higher risk of cancer (Euvrard et al., 2003; London et al., 
1995). Similarly, the compromised immune system of HIV-positive patients 
yields a higher incidence of cancers such as Kaposi’s sarcoma (Rabkin et al., 
1991). Collectively, these reports are indicative of a clinically meaningful 
association between a competent and active immune system and the 
prevention of cancer. 
There have been a number of attempts to justify these observations with a 
functional model for immune involvement in cancer. It has long been recognised 
that the immune system exists primarily as a surveillance system for pathogens. 
This dogma was manifested as the ‘self/non-self model’ (Burnet and Fenner, 
1949). The dominance of this model subsequently presented a major obstacle 
to the rationale behind the burgeoning field of cancer immunology. The model, 
based on the endogenous (‘self’) or exogenous (‘non-self’) source of material, is 
well suited to account for the evolved role for the immune system against 
pathogens. It is less well suited to addressing its role against cancer, which 
originates from healthy endogenous cells and is genetically similar. Wouldn’t 
cancer be subject to the same evolved constraints preventing immune assault 
on ‘self’ tissues? 
A subsequent attempt to crystallise our understanding of the immune system 
gave rise to the ‘danger model’ (Matzinger, 1994, 2002). Largely a critique of 
the self/non-self model, this approach identifies ‘alarm’ signals from 
endogenous or exogenous tissue, including cellular proteins such as heat-shock 
proteins (HSP) and interferon α (IFN-α), as requirements for immune activation. 
While the danger model accounts well for various modes of cell death in which 
these factors are implicated, its proposition that tumours do not elicit immune 
responses (Matzinger, 1998) has subsequently been dismantled by 
comprehensive evidence for anti-tumour immunity, often in response to specific 
molecular modifications rather than overt damage (Dunn et al., 2006). So how 
are immune effectors able to detect aberrant malignant cells? 
It was around the time of Coley that the pioneering German physician Paul 
Ehrlich suggested that host defences actively suppress neoplastic cell growth 
(Ehrlich, 1909). It was over half a century later that this belief was reinforced by 
systematic evidence and formal theory. The ‘immune surveillance model’ 
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proposed by Frank MacFarlane Burnet was predicated upon novel antigens 
which “provoke an effective immunological reaction with regression of the 
tumour” (Burnet, 1970). The model was based upon the rejection of tumour 
tissue – but not normal tissue – in syngeneic transplants, and thus the 
implication of tumour-specific antigens. 
Indeed, Burnet’s concept was to be substantiated by the first identification of a 
human tumour-specific antigen, melanoma antigen 1 (MAGE-A1), recognised 
by cognate T cells (van der Bruggen et al., 1991). The idea of immunity against 
a tumour-specific antigen constitutes a violation of the self/non-self model; 
cancer cells are of course self-derived, but due to their (often causative) 
mutations they are genetically aberrant, a state termed ‘altered self’ (Medzhitov 
and Janeway, 2002). Further, the immune surveillance model is supported by 
the increased incidence of cancer in mouse models deficient in specific aspects 
of immunity, particularly those centred around the activity of T cells (Brennan et 
al., 2010; Smyth et al., 1999).  
T cells are CD3+ lymphocytes derived from the thymus, which are essential 
mediators of tumour surveillance. The genetic deletion of activatory T cell 
populations renders mice acutely susceptible to cancer, while their artificial 
depletion promotes progression (Andreasson et al., 2010; Haines et al., 2006; 
Knocke et al., 2016). The successful use of adoptive T cell transfer as a therapy 
for metastatic melanoma patients demonstrates the potency of this cell 
population (Rosenberg et al., 2011). T cells are pivotal in the ability of the 
immune system to respond flexibly to temporal changes in exogenous 
pathogens and other immune stimuli – the cell-mediated aspect of the adaptive 
immune response. Naïve T cells, once briefed or ‘primed’ against a particular 
antigen, can mount a rapid and specific response upon subsequent exposure, 
and thus can carry ‘immunological memory’. 
Antigens linked with tumours, some of which are tumour-specific, are more 
broadly known as tumour-associated antigens (TAA). Those that are indeed 
tumour-specific are commonly neoantigens arising directly from mutations. 
While many of the most common melanoma ‘driver’ mutations in genes such as 
NRAS appear to yield poorly immunogenic antigens, other ‘passenger’ 
mutations in genes such as CDK4 also occur which enable this type of TAA to 
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account for often the majority of tumour-targeted T cells (Lennerz et al., 2005; 
Linard et al., 2002). Other TAA are more subtle in their violation of immune 
surveillance mechanisms. For instance, germ cell antigens result from the 
expression of transcripts that are present in germline tissues but are usually 
silenced in adult somatic cells, unless reactivated; these include the well-known 
cancer/testis antigens MAGE-A1 (van der Bruggen et al., 1991) and NY-ESO-1 
(Chen et al., 1997).  
The differentiation antigens, such as TRP-1 and MART-1, are present on 
normal melanocytes as well as melanoma cells, and this lack of cancer 
specificity means that these TAA enjoy a degree of immune tolerance (Coulie et 
al., 1994; Wang et al., 1995). However, the observation of T cell responses to 
such peptides in patients suggests that such tolerance is not insurmountable 
(Kawakami et al., 1994). The onset of skin depigmentation (vitiligo) is attributed 
to responses against differentiation antigens, and is a positive prognostic 
marker (Yee et al., 2000). Similarly, other shared antigens are expressed to a 
significantly higher level in melanoma cells versus untransformed melanocytes, 
potentially enabling an antigen-specific response in the event that this exceeds 
the threshold required for T cell recognition (Fisk et al., 1995). 
For primed T cell responses to antigen to occur, the offending antigen must be 
processed and constituent epitopes presented appropriately to the T cell 
receptor (TCR). The major type of antigen-presenting cell (APC) responsible for 
this process is the dendritic cell (DC), a key linker of innate and adaptive 
immunity. After taking up and degrading antigen, DC supply epitopes to T cells 
by their presentation on major histocompatibility complex (MHC) molecules, to 
which the antigen-specific TCR can bind. Classically, CD8+ cytolytic T 
lymphocytes (CTL) recognise epitopes loaded on MHC class I, while the CD4+ 
helper T cells recognise those on MHC class II.  
Ligation of the cognate TCR, supplemented by a second signal between APC 
co-stimulatory molecules and T cell CD28 (Lafferty and Cunningham, 1975), 
stimulates the conversion of naïve T cells into effectors and induces clonal 
expansion. On encountering cells expressing antigen, effector CTL can then 
launch an assault in order to induce apoptotic cell death, either through the 
release of cytolytic granules containing proteolytic granzymes and perforin, or 
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through the contact-dependent engagement of death receptors such as Fas on 
the cell surface. Upon stimulation, CD4+ T cells can differentiate into two types 
of effector helper cells, termed TH1 and TH2, which facilitate the activation of 
CTL and macrophages, or antibody-producing B cells, respectively. TH1 cells 
therefore promote cell-mediated immunity, while TH2 cells support the humoral 
arm of the adaptive immune response. 
Adaptive immunity therefore enables us to keep pace with the ‘moving target’ of 
a genetically unstable tumour, but takes time to react. The innate immune 
system is indispensable as the first line of defence, not only against exogenous 
pathogens but also endogenous malignant cells. It includes a battery of 
‘response-ready’ effectors, which include DC, neutrophils, macrophages, 
natural killer (NK) and NKT cells. These generally respond to evolutionarily 
conserved features of pathogens; for instance, the pattern recognition receptors 
(PRR) expressed by DC and macrophages enable them to react to foreign 
nucleic acid and protein motifs, by cytokine secretion or phagocytosis. With the 
help of humoral immune elements, they are also able to bring these functions to 
bear upon tumour cells through complement- or antibody-dependent cytotoxicity 
(ADCC) and phagocytosis (ADCP). 
It is NK cells, lymphocytes expressing CD56 but no CD3, that are best equipped 
to respond immediately to challenge with a transformed cell. Tumours seek to 
avoid the adaptive immune response by downregulating MHC-I and minimizing 
exposure of TAA. This so-called ‘missing self’ causes insufficient binding to 
inhibitory receptors on the NK cell surface (Ljunggren and Kärre, 1985). Aided 
by simultaneous ligation of stress ligands, this triggers cytolytic activity via 
similar mechanisms to T cells, and the secretion of stimulatory factors such as 
IFN-γ which support T cell activation. MHC-I loss is observed in melanoma 
(Garrido et al., 2012), and therapeutic strategies aimed at targeting this and 
other aspects of NK-mediated anti-tumour immunity have been deployed with 






2.2.2 Immune evasion and suppression 
The tumour stroma includes all the non-malignant cells of the tumour, such as 
immune cells, fibroblasts, components of the vasculature, and elements of the 
extracellular matrix, and frequently comprises over 50% of the cells within a 
solid tumour (Wu et al., 2016). Over the entire course of the initiation and 
progression of a tumour, its malignant cells are involved in intimate cross-talk 
with these cells. Tumour cells can corrupt and elicit the support of the immune 
system in order to aid tumour persistence and growth. This immunosuppressive 
capacity is a key hallmark of cancer (Hanahan and Weinberg, 2011). 
Only recently has the ability of cancer to evade immunity been modelled in 
significant detail. Building upon the framework of the broad theory of immune 
surveillance, the ‘cancer immunoediting’ model describes discrete stages which 
are defined by the state of the dynamic bidirectional relationship between 
transformed cells and their stromal neighbours (Dunn et al., 2006). The model 
provides molecular rationale for clinical phenomena, such as stochastic periods 
of tumour dormancy and growth, and tumour progression in spite of functional 
immune effectors (Croci et al., 2007). 
The three ‘E’s’ of immunoediting are as follows. In the ‘elimination’ phase, the 
immune system is readily able to ablate the most immunogenic tumour cells, 
such as those with high levels of surface tumour antigen expression. Those 
variants that are less immunogenic, by virtue of genetic instability within the 
heterogenous tumour, are not so readily recognised and can persist and 
proliferate. This process of editing yields a state of ‘equilibrium’ – continued 
division of some clonal subpopulations is balanced by clearance of others, 
giving the impression of dormancy. Prolonged dormancy gradually promotes 
immunosuppressive changes in the tumour microenvironment, and these permit 
the renewed progression of overt cancer, or ‘escape’. 
A variety of cell populations and the factors they secrete are implicated in 
tumour immune evasion. Regulatory T cells (Treg) are foremost amongst these. 
In normal physiology, Treg are key in maintaining the balance of immunity and 
tolerance to ‘self’ to avoid destructive autoimmunity. Treg are commonly induced 
from helper T cells by secreted factors such as transforming growth factor β 
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(TGF-β) derived from macrophages and other cell types in the tumour milieu 
(Chen et al., 2003); they are also drawn there by chemokines released from 
tumour cells (Curiel et al., 2004). The Treg population in the tumour, which is 
more concentrated and more suppressive than elsewhere (Miracco et al., 2007; 
Yokokawa et al., 2008), limits immune activation in various ways. These broadly 
involve the surface expression or short-range secretion of molecules which 
suppress (or even kill) APC and T cells with activatory potential (reviewed in 
Sakaguchi et al., 2009). The depletion of Treg enhances the rejection of murine 
melanoma and prolongs survival (Nizar et al., 2010) while Treg infiltration – and 
particularly the ratio of CD8+ T to regulatory T cells – represents a meaningful 
prognostic factor in melanoma patients (Knol et al., 2011; Miracco et al., 2007).  
In addition to lymphocytes, myeloid immune cells also comprise a numerically 
and functionally significant proportion of a tumour mass. Many of these, derived 
from the monocyte population circulating in blood, will be DC and pro-
inflammatory (‘M1’) macrophages with anti-tumour functionality. However, the 
exposure of other monocytic cells to soluble factors such as TGF-β, or 
granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-4, 
promotes the development of myeloid-derived suppressor cells (MDSC) and 
‘M2’ macrophages respectively.  
MDSC quash T cell responses by the expression of arginase 1 (Arg-1) and 
inducible nitric oxide synthase (iNOS). L-arginine, an amino acid required for T 
cell proliferation and TCR expression, is degraded by these molecules – in the 
case of iNOS, into nitric oxide, which dampens T cell activity (Bronte and 
Zanovello, 2005). MDSC are of functional relevance to the extent that their 
numbers are inversely correlated with survival in melanoma patients (Weide et 
al., 2014). Meanwhile, tumour-associated macrophages (TAM), which typically 
represent a significant minority of cells in the tumour mass, are commonly of the 
alternatively activated, M2-polarized phenotype. After being guided towards this 
phenotype by tumour-derived factors, M2 macrophages actively contribute 
towards the immunosuppressive tumour microenvironment by secreting TGF-β, 
IL-1β, IFN-γ and other cytokines, which promote angiogenesis and invasion 
(Gehrke et al., 2014; Sica et al., 2006; Tanese et al., 2015). Consequently, M2 
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macrophages progressively accumulate throughout melanoma progression, and 
are associated with poor outcomes (Falleni et al., 2017). 
Transformed cells themselves boast a variety of traits which enable their 
evasion of immune clearance. Arguably more influential than the suppression of 
a cell’s functionality is its ablation. Melanoma cells commonly display some 
resistance to apoptosis by their downregulation of death receptors such as Fas 
and TRAIL-R, or upstream effectors including caspase-8, which are central to 
its induction (reviewed in Hersey et al., 2006). Moreover, cancer cells are 
capable of ‘counter-attack’ against infiltrating immune cells. Their expression of 
Fas ligand (FasL) can induce apoptosis in neighbouring T cells, thereby 
contributing to the establishment of poorly regulated, ‘immune-privileged’ niches 
where tumours can grow unchecked (Strand et al., 1996). 
Although it does provide an opportunity for NK cells, the progressive loss of 
melanoma MHC-I expression to impair antigen presentation provides a virtual 
‘invisibility cloak’ against T cell recognition, and is a prime example of 
immunoediting in action (del Campo et al., 2014; Rees and Mian, 1999). 
Similarly, tumour cells commonly lack the co-stimulatory molecules CD80 and 
CD86; by permitting TCR engagement without the necessary ‘signal 2’, they 
foster a state of tolerance or anergy in antigen-specific T cells (Staveley-
O’Carroll et al., 1998). 
However, it appears to be the active expression of immunosuppressive 
molecules by malignant cells that is particularly influential in driving immune 
evasion. At present, the most clinically relevant example of this phenomenon 
involves the expression of programmed death ligands PD-L1 and PD-L2, which 
bind to their receptor PD-1 on tumour-infiltrating lymphocytes. In effector T cells, 
PD-1 ligation provides a powerful ‘off’ signal, preventing cytolytic activity, 
cytokine release, proliferation and even T cell survival (Dong et al., 2002; 2016). 
The chronic exposure of melanoma-specific CTL to tumour antigen upregulates 
PD-1, making them more sensitive to PD-1 ligands and promoting a state of T 
cell exhaustion (Ahmadzadeh et al., 2009). The PD-1 axis represents one of an 
increasing number of ‘immune checkpoints’ limiting anti-tumour immune 
programs which are the subject of intense therapeutic development.  
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2.2.3 Emerging immunotherapies 
Conventional approaches to cancer therapy, dominated by chemo- and 
radiotherapy, are associated with poor outcomes and substantial toxicity. These 
modalities have attributes which work with and against the immune system. 
Although radiotherapy boasts a well-described immune-mediated abscopal 
effect, it also has long-term lymphotoxic effects (Campbell et al., 1976). While 
cytotoxic chemotherapy can promote the cytolytic potential of CD8+ T cells, it 
too yields T cell immunodeficiency (Mackall, 1999). Even the surgeon’s scalpel 
is immunosuppressive (Kadosawa and Watabe, 2015).  
The success of this century’s immuno-oncology agents is reliant upon a 
different approach: harnessing the patient’s own immune system against the 
tumour. The commitment of the field to this paradigm is encapsulated in 
increasingly complex models, the latest being the ‘cancer immunogram’ 
framework designed to address all known immune facets of a target lesion 
(Blank et al., 2016). 
As an indication, melanoma has become the ‘poster child’ for immunotherapy 
for a number of reasons. Firstly, melanoma is intrinsically resistant to chemo- 
and radiotherapy (Pawlik and Sondak, 2003). This likely encouraged 
investigators to pursue other therapeutic avenues; even, cynically, for the 
opportunity to test against less effective comparators. Melanoma also has a 
reputation for being a tumour type with perhaps the highest immunogenicity, or 
potential to induce an immune response. It demonstrates a uniquely high 
somatic mutation rate and neoantigen burden, a product of its UV-linked 
aetiology (Berger et al., 2012; Rajasagi et al., 2014). Multiple melanoma-
associated antigens have been found to be clinically relevant (Barrow et al., 
2006), and lymphocytic tumour infiltration is a positive prognostic factor (Oble et 
al., 2009), both implicating T cell activity in the disease course. The tendency of 
melanoma lesions to undergo spontaneous regression is also suggestive of an 
undercurrent of anti-tumour immunity (Printz, 2001). 
The first robust clinical evidence of success in targeting melanoma 
immunologically was manifested in the durable remissions observed in 
response to toxic doses of IL-2 (Rosenberg, 2014). This formed proof of 
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principle for immune – and particularly T cell – activation as a viable therapeutic 
strategy. Subsequently, the use of adjuvant interferon to promote the immune-
mediated clearance of residual and micro-metastatic disease after resection 
was based on the same broad rationale. Albeit more sophisticated, newer 
vaccination strategies using immunostimulatory peptides or DC also fall under 
this premise. 
The oncology market is increasingly inundated with a class of molecules termed 
immune checkpoint inhibitors (ICI). These agents target natural molecular 
‘checkpoints’ designed to limit immune activation and prevent damaging 
autoimmunity. The two checkpoint molecules most successfully targeted to date 
are cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death 
protein 1 (PD-1), both present on T cell populations. Predominantly on CD4+ 
helper T cells but also Treg, CTLA-4 mimics and is able to outcompete CD28 for 
their common ligands CD80 and CD86, present on APC (Yokosuka et al., 
2010). While it was thought that this allows CTLA-4 to replace stimulatory CD28 
signalling with its own inhibitory signalling, it is now considered that it functions 
primarily on Treg by regulating the access of CD28 to their shared ligands 
(Walker and Sansom, 2015). This process retards the ability of APC to promote 
activation of T cells during antigen presentation in the periphery.  
A similar mechanism underlies the PD-1 checkpoint operating at the tumour 
site. The ligation of T cell PD-1 by PD-L1/2 largely present on malignant cells 
also dampens T cell stimulation; this pro-tumour checkpoint therefore functions 
more directly by preventing the elimination of ligand-expressing tumour cells 
themselves. Consequently both CTLA-4 and PD-1 proteins supply inhibitory 
signals to specific T cells at two key points of antigen exposure: during 
presentation in the periphery, and subsequent recognition within the tumour bed 
(reviewed in Pardoll, 2012). 
Antibodies designed to block these molecular interactions and revitalise anti-
tumour T cell activity have entered the clinical arena in the past decade. The 
first-in-class CTLA-4 inhibitor ipilimumab was the first checkpoint inhibitor to 
reach the clinic, gaining regulatory approval for metastatic melanoma in 2011 
(Cameron et al., 2011). Although response rates to ipilimumab were higher than 
with cytotoxic chemotherapy at around 20%, its real superiority was in the 
18 
 
durability of these responses (Hodi et al., 2010; Specenier, 2016). Subsequently 
ipilimumab was approved for use in the adjuvant setting for high-risk stage III 
melanoma in light of its benefit in regression-free and overall survival 
(Eggermont et al., 2016). 
The newer anti-PD-1 checkpoint inhibitors nivolumab and pembrolizumab 
exhibit even greater activity than ipilimumab, with overall response rates 
typically around 30-35% (Robert et al., 2015b; Topalian et al., 2012; Wolchok et 
al., 2017). The CheckMate-066, -067 and -037 trials demonstrated the 
superiority of nivolumab to chemotherapy and to ipilimumab respectively, both 
in pre-treated and treatment-naïve patients, and triggered its approval (Larkin et 
al., 2015a; Robert et al., 2015a; Weber et al., 2016; Wolchok et al., 2017). 
Similarly, the efficacy shown by pembrolizumab in the KEYNOTE-002 and -006 
studies brought about its approval in metastatic melanoma in second-line in 
2014, and subsequently as a first-line agent in 2015 (Barone et al., 2017; Chuk 
et al., 2017; Robert et al., 2015b). Both of these agents are now listed as 
preferred first-line therapies for advanced melanoma in the latest US NCCN 
guidelines (National Comprehensive Cancer Network, 2017). The PD-1 
inhibitors increasingly dominate the treatment of advanced melanoma, 
comprising 23% of the market share in 2015, projected to rise to 51% by 2025 
(Decision Resources Group, 2017). 
The efficacy of checkpoint inhibitors appears to be reliant upon a number of 
factors, including the total mutational load or neoantigen burden, across 
indications and specifically in melanoma (Le et al., 2015; McGranahan et al., 
2016; Van Allen et al., 2015). Other factors include inflammatory gene 
signatures (Jamieson and Maker, 2017; McGranahan et al., 2016). These 
elements may however represent general prognostic factors of survival rather 
than specific predictive factors for response to checkpoint inhibitor therapy 
(Hugo et al., 2016). Highly relevant in the context of PD-1 inhibitor therapy is the 
PD-L1 protein itself, which is overexpressed in melanoma (Hino et al., 2010; 
Oba et al., 2014). PD-L1 expression level is not only prognostic but is also 
predictive of response to PD-1 inhibitor therapy (Abdel-Rahman, 2016; Topalian 
et al., 2012; Weber et al., 2013). This and various other metrics are ultimately 
likely to contribute towards a multifactorial algorithm, like the recent ‘cancer 
19 
 
immunogram’ (Blank et al., 2016), used to predict the subsets of patients likely 
to respond to these agents. These would fall alongside existing tools such as 
testing for BRAF/MEK mutations, and for tumour PD-L1 status, which is already 
an important marker for anti-PD-1 patient selection. 
As it is often the testing ground for these agents, melanoma is an excellent 
prism through which to anticipate the future landscape of cancer 
immunotherapy. With the avalanche of trials underway and in development, this 
landscape is constantly evolving. In the short-term, the most significant change 
appears likely to be the spread of combination immunotherapy. The 
combination of ipilimumab and nivolumab, which markedly elevates both 
efficacy and toxicity, has already gained NICE approval in advanced melanoma 
(Postow et al., 2015; Wise, 2016; Wolchok et al., 2017). The publication of long-
term survival outcomes in melanoma will soon guide the uptake of combination 
immunotherapy in other indications. Other ongoing trials examine the 
combination of checkpoint inhibitors and tyrosine kinase inhibitors in suitable 
patient subgroups, with the optimal sequencing of combination agents an area 
of particular focus. 
In addition to combining agents which are already approved for use as 
monotherapy, the field will also expand through the addition of novel agents, the 
majority of which appear likely to be immunotherapies. As well as the now well 
(but not completely) understood CTLA-4 and PD-1 axes, other immune targets 
are under intense scrutiny. Foremost amongst these are other inhibitory 
checkpoints such as LAG-3 and TIM-3 (Anderson et al., 2016); others are 
stimulatory T cell molecules such as OX40, which may be exploited using 
ligand-mimicking agonists, rather than antagonistic antibodies (Linch et al., 
2015). This new wave of T cell modulators carries great momentum as it 
speeds through clinical trial. Other agents target tumour metabolism: 
epacadostat, an agent inhibiting the generation of the T cell suppressor 
kynurenine from tryptophan by the IDO-1 enzyme, demonstrates impressive 
efficacy with combination anti-PD-1 (Hamid et al., 2017). Indeed, the potential of 
these agents to synergise with immune checkpoint blockade is now of 
enormous therapeutic relevance. 
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The combination of checkpoint inhibitors is feasible, and is achieving 
unprecedented response rates; particularly when used early in the treatment 
pathway, but also against advanced disease (Rozeman et al., 2017; Wolchok et 
al., 2017). Although half of advanced melanoma patients still die within four 
years of commencing combination treatment (Wolchok et al., 2017), the 
remaining cohort demonstrate durable responses, as signified by a plateau in 
the survival curve, and can increasingly be termed ‘cured’ (McDermott et al., 
2013). Incremental gains are being made in ‘chasing the tail’ of this curve 
(Harris et al., 2016), whilst trying to evade the punishing toxicities associated 
with combination checkpoint blockade. Enter the oncolytic virus: an emerging 





2.3 Oncolytic viruses 
 
2.3.1 Background 
Various naturally occurring viruses show an intrinsic preference towards entry 
into, and replication within, transformed cells, as a direct consequence of their 
aberrant phenotype. Their ability to destroy the architecture of malignant cells 
affords these viruses the term oncolytic, or ‘cancer bursting’. This historical 
terminology is somewhat restrictive in describing the true mechanism of action 
of many viruses in clinical testing, but it has hitherto been adopted as a ‘one 
size fits all’ label for viruses with anti-cancer activity. 
Oncolytic viruses (OV) hold advantages over traditional modalities. In a field 
which increasingly aims to avoid the toxicities often seen with more 
indiscriminate agents such as cytotoxic chemotherapies, the tumour selectivity 
inherent to OV represents their defining trait. True cancer-selective activity also 
opens the door to the targeted delivery of other anti-cancer agents which can be 
encoded within an OV vector. The amplification of a replicating OV within the 
tumour itself should theoretically enable a lower amount of virus to be 
administered to the body, giving a good therapeutic index. Lastly, OV have the 
ability to reverse the immune suppression characteristic of the tumour 
microenvironment by promoting inflammatory activity, and to prime a long-
lasting immune response to the tumour. 
As with many therapeutic agents, the oncolytic properties of some viruses were 
first noted using anecdotal evidence. Dating back into the 19th century, historical 
reports typically describe the regression of tumours coinciding with 
environmental infection with pathogens now identified as viruses. One heavily 
cited report associated the remission of leukaemia with a presumed influenza 
infection (Dock, 1904). Along with some solid neoplasms including melanoma 
(Pack, 1950), these accounts most commonly involved short-lived remissions of 
haematological cancers (Dock, 1904; Pelner et al., 1958), with the lymphotropic 
measles virus particularly heavily implicated (Bierman et al., 1953; Taqi et al., 
1981). These case reports later led clinicians to conduct primitive, often 
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unethical clinical trials involving the transfer of crude bodily fluids as therapeutic 
material (Hoster et al., 1949). Although severe virus-induced pathology and 
death was reported in some patients, benefit was observed in others. In a series 
of pioneering human studies in the US, Southam and Moore spearheaded the 
use of West Nile virus isolates against various malignancies, yielding both fatal 
neurotoxicities and tumour regressions (Southam and Moore, 1952). 
Around the same time, the advent of human cell culture systems enabled 
viruses to be propagated ex vivo, triggering rapid progress in virology research, 
then centred around vaccine development (Sanford et al., 1948; Weller et al., 
1949). Indeed, vaccines themselves were already starting to be tested against 
human malignancies (Higgins and Pack, 1951). The cytopathic properties of 
various viruses in vitro were quickly noted. Simultaneously, following on from 
observations of the anti-neoplastic potential of vaccinia virus some decades 
earlier, viruses began to be tested more formally in new animal models of 
cancer (Levaditi and Nicolau, 1922). In a landmark paper of 1949, Moore 
showed that a complete remission of murine sarcoma – and subsequently other 
neoplasms – could be induced by Russian Far East encephalitis virus (Moore, 
1949, 1951). Such observations served to spawn broad interest in the field of 
virotherapy for cancer, with a variety of human and non-human pathogens 
scrutinised. Although it soon became clear that tumour regression in an animal 
model was no guarantee of success in humans, animal testing was quickly 
adopted as a prerequisite for clinical testing (Moore, 1952). 
The screening of potential OV was conducted on a large scale, with the 
emphasis firmly on safety as well as efficacy in light of the outcomes from the 
first experimental trials. A cadre of more favourable candidate viruses emerged, 
many of which remain in study today. For instance, having shown preclinical 
promise, one adenovirus was employed against cervical carcinoma; while it 
showed limited toxicity and some local tumour activity, virus treatment failed to 
improve survival (Georgiades et al., 1959). Contrastingly, a later (erratic and 
non-controlled) trial of the mumps virus in various malignancies produced 
remarkable results, with responses observed in nearly half of patients (Asada, 
1974). However, the use of such non-attenuated human viruses drew ethical 
concern and, combined with the uninspiring impact made on survival in the 
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majority of trials using naturally occurring viruses (Kelly and Russell, 2007), this 
allowed the OV as a modality to fall temporarily from favour in the 1970s and 
1980s. 
 
2.3.2 Interaction with host cells 
In the absence of malignant transformation, normal cells boast a number of 
conserved mechanisms for the clearance of viruses, their obligate intracellular 
pathogens. These comprise signalling cascades which lie dormant until their 
activation by viral PAMP. PAMP, such as viral nucleic acid or protein and 
envelope motifs, engage host cell PRR stationed within the cell and on the 
surface. Engagement of the major PRR, namely Toll-like receptors (TLR) and 
RIG-I-like receptors (RLR), triggers signalling via a multitude of intracellular 
adaptor and hub proteins which influence antiviral gene transcription. The TLR-
activated myeloid differentiation primary response protein MYD88 promotes the 
expression of pro-inflammatory cytokines via nuclear factor κ-B (NF-κB) (Hemmi 
et al., 2002). Simultaneously, adaptors such as TNF-associated factor 3 
(TRAF3) stimulate interferon response factors IRF3 and IRF7 to increase the 
expression of type I IFN (Oganesyan et al., 2006). 
The IFN proteins typically secreted from a cell as a consequence of viral 
detection influence neighbouring cells locoregionally and can even act in an 
autocrine manner. By binding IFN receptors at the surface, they mobilise a 
second wave of innate signalling which reinforces the antiviral state. The 
pathways involving proteins of the Janus kinase and signal transducer and 
activator of transcription (JAK-STAT) families are integral to this second wave, 
triggering transcriptional programs collectively termed IFN-stimulated genes 
(ISG). Control is further asserted at a translational level by the IFN-responsive 
protein kinase R (PKR). PKR itself identifies intracellular viral motifs like double-
stranded (ds)RNA and, via autophosphorylation, halts protein synthesis in order 
to restrict the generation of viral progeny. These comprise the major molecular 
mediators of antiviral defence in untransformed cells. 
To a greater or lesser extent, many naturally occurring viruses, by definition OV, 
boast a heightened ability to kill cancer cells. This is a consequence of the OV 
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being able to exploit molecular changes intrinsic to transformed cells which 
confer a shared phenotype, as follows. Firstly, cell entry – to access the 
transcriptional machinery the virus requires. Broadly, OV are able to enter both 
transformed and untransformed cells alike, as many viruses have evolved to co-
opt receptors that are common to many target cells. For instance, depending on 
their natural tropism, many use the adhesion molecules present on leukocytes 
and epithelial cells to gain entry. Reovirus hijacks junctional adhesion molecule 
A (JAM-A; gene F11R), while intercellular adhesion molecule 1 (ICAM-1; gene 
CD54) is the major receptor used by group A Coxsackieviruses and others 
(Barton et al., 2001; Shafren et al., 1997). Nevertheless, the aberrant 
expression of virus receptors by transformed cells can sometimes provide OV 
with an entry advantage. The CD46 protein exploited for measles virus entry is 
overexpressed in various cancer types (Anderson et al., 2004). The receptors 
which contribute towards the neurotropism of type 1 herpes simplex virus (HSV-
1), herpesvirus entry mediator (HVEM) and nectin-1, are also abundant on 
carcinoma and melanoma cells (Farassati et al., 2001; Yu et al., 2005). 
The selective advantage that OV hold for cancer cells is more typically due to 
abnormal elements within the cell which support viral replication: so-called 
‘post-entry tumour specificity’. These generally involve corrupted intracellular 
signalling pathways which promote malignant traits while simultaneously 
increasing vulnerability to viral threats. Perhaps the most universal example is 
the dampening or total loss of IFN signalling. Cancer cells either restrict their 
own generation of IFN, or restrict the effect of ‘incoming’ IFN by limiting IFN 
receptor expression or signalling cascade activity. These acquired defects in 
IFN signalling are useful in that they can facilitate the evasion of anti-tumour 
immunity, limit apoptotic signalling through the p53 protein, and release the 
‘brake’ on proliferation that IFN signalling can impose (Balkwill et al., 1978; 
Bidwell et al., 2012; Hasthorpe et al., 1997) – all changes that serve the viral life 
cycle too. 
Aside from IFN modulation, transformed cells exhibit other changes in growth 
and survival pathways which benefit OV. The constitutive activation of AKT, a 
protein kinase commonly dysregulated in human malignancies, can confer 
susceptibility to myxoma virus (Testa and Bellacosa, 2001; Wang et al., 2006). 
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Similarly, oncogenic mutations in the KRAS and NRAS genes have been linked 
to OV susceptibility. Activation of the Ras pathway, and in particular the pro-
proliferative repression of PKR, has long been considered a major determinant 
of reovirus replication (Shmulevitz et al., 2005; Strong et al., 1998). Despite the 
serendipitous gain of some cancer-selectivity through the parallel natural 
evolution of both malignant cells and viruses, this often provided insufficient 
anti-cancer activity, or excessive off-target toxicity, in clinical practice. Thus, the 
field turned to genetic engineering to tip the balance in the oncologist’s favour. 
 
2.3.3 Tropism and engineering 
The whole cancer cell phenotype is aberrant. Intriguingly, a number of the 
characteristics which comprise this anomalous phenotype, many elegantly 
described by Hanahan and Weinberg as ‘hallmarks of cancer’, are mirrored in 
cells undergoing viral infection (Hanahan and Weinberg, 2011). Of course, 
these two phenotypes can be considered as one and the same in the context of 
cellular transformation induced by a virus with oncogenic potential, such as 
human papillomavirus (HPV). Indeed, these similarities provided the basis for 
the use of viral genes such as the large T antigen of SV40 to study 
transformation (Sullivan et al., 2000).  
However, leaving aside multicellular processes such as metastatic ‘behaviour’, 
malignant traits at the single-cell level have correlates in cells infected with 
replicative, non-oncogenic viruses as well, even though the factors underlying 
these two phenotypes are so different (Seymour and Fisher, 2016). For 
instance, a resistance to cell death (particularly via apoptosis) is a cancer 
hallmark that is common to virus-infected cells (Thomson, 2001). The vested 
interest that viruses have in avoiding immune detection means that infected 
cells display characteristics of immune evasion like those of cancer cells 
(Iannello et al., 2006). Viruses can also subvert the cell cycle machinery so 
critical to neoplastic growth in order to facilitate replication (Bagga and 
Bouchard, 2014). These and other similarities between the two phenotypes 




A number of viruses do have a natural suitability or tropism for certain types of 
cell, some of them malignant. For instance, the tropism of human 
immunodeficiency virus (HIV) for T cell subpopulations, on account of CD4 
being its major receptor, has provoked its use in targeting T cell leukaemias 
(Jeeninga et al., 2006). In the era before genetic manipulation, our mode of ‘re-
engineering’ a virus was primitive, being limited to adapting a viral strain to a 
particular cell type, typically by repeated passaging. This concept of 
‘evolutionary engineering’ appeared to hold value: in Moore’s translational work, 
passaging the encephalitis virus through sarcoma cells endowed it with greater 
lytic ability (Moore, 1952). However, clinical use of these early OV was plagued 
by an inability to limit toxicity, particularly of neurotropic viruses to the brain; the 
status of live OV as the causative agents of potentially severe pathology was 
not to be forgotten. 
It took all of three decades since genetic engineering was proposed as a 
solution to this trade-off (Southam, 1960) for the technology to reach its advent 
in the 1990s. Molecular advances enabled the modification of OV in order to 
enhance their safety and efficacy profiles, creating ‘second-generation’ viruses. 
The main change has involved better selectivity through attenuation; that is, 
deleting genes in order to limit activity in healthy cells, but not to the extent of 
crippling replication in malignant cells. The parallels between the attributes of 
virus-infected and cancer cells, and our increasing ability to tailor the virus 
genome, provided the opportunity to create more tumour-specific viruses. By 
engineering viruses without the ability to induce typical ‘virus-infected’ cell 
hallmarks, such agents rely on the presence of these traits in cancer cells alone 
– a strategy named phenotypic complementation. 
The first effective example of this novel process saw Martuza successfully treat 
human glioma xenografts by intracranial injection of HSV bearing a deleted 
thymidine kinase (TK) gene (Martuza et al., 1991). The virus demonstrated 
cancer-selective activity without inducing encephalitis, based on the enhanced 
TK activity seen in cancer cells versus non-transformed cells (Hengstschläger 
et al., 1994). The same paradigm was exploited in the design of the adenovirus 
Onyx-015, the first OV in phase I trials in 1996. Onyx-015 harbours an ablation 
in the gene which otherwise permits the inactivation of cellular p53, leaving the 
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virus reliant on the inactive p53 often present in cancer cells (Heise et al., 
1997). Although the mechanism of selectivity was subsequently questioned 
(Kirn, 2001), Onyx-015 demonstrated good tumour selectivity and formed the 
basis for the adenovirus termed H101, which was the first virus to be licensed 
as a modern cancer therapy upon its approval alongside chemotherapy for 
head and neck cancer in China (Lu et al., 2004; Xia et al., 2004). 
A variety of strategies have been employed in trying to reap maximal benefit 
from our ever-improving ability to genetically modify OV. As with Onyx-015 and 
H101, adenovirus backbones provide the typical OV constructs (Alemany, 
2007). The re-engineered adenovirus CV706 was designed to replicate under 
the control of a promoter driven by prostate-specific antigen (PSA), most highly 
secreted by prostate cancer cells, yielding a tissue-specific OV which has 
reached clinical trial (DeWeese et al., 2001; Hardcastle et al., 2007). A similar 
strategy involves the use of an OV promoter responsive to conditions common 
among tumours, such as hypoxia (Post et al., 2007). Newer constructs target 
the expression of OV based on specific microRNA (miRNA) which are 
dysregulated in cancer cells or their often immunosuppressive stromal 
neighbours (Kumar et al., 2007; V. Jennings, personal communication). 
Moving ‘backwards’ a step out of the cell interior, other viruses generated to 
date have been targeted towards specific cancer types by equipping them with 
the capacity to bind certain receptors, such as CD46 (Takagi-Kimura et al., 
2013), or receptor families such as αvβ integrins (Dmitriev et al., 1998; Lal and 
Raffel, 2017), overexpressed on tumour cells themselves or its vascular 
endothelium. They can even be targeted towards other viral antigens, such as 
proteins of the HPV virus implicated in the aetiology of head and neck cancer 
(LaRocca et al., 2016). Other investigators have adopted translational 
approaches for viruses already in clinical testing, by encoding imaging markers 
within OV to track spread and persistence (Dispenzieri et al., 2017). 
A natural extension of these strategies involves ‘arming’ OV by encoding pro-
therapeutic proteins that are only expressed during productive infection of the 
viral target cell. The possibilities are enormous: immune modulators such as 
miRNA, immunostimulatory cytokines including the pro-apoptotic tumour 
necrosis factor (TNF), and even checkpoint inhibitor antibodies (Dias et al., 
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2012; Hirvinen et al., 2015). To further their stimulation of the tumour-specific 
response, OV have also been engineered with pre-defined TAA or entire cDNA 
libraries (Kottke et al., 2011b; Pulido et al., 2012). 
Some ‘third-generation’ OV, providing combination therapy within one agent, 
have already breached the clinical market. The most clinically successful agent 
to date is talimogene laherparepvec (T-VEC), a modified type-1 HSV construct. 
T-VEC bears the genetic deletion of ICP34.5, which minimises neurovirulence 
by limiting antagonism of PKR, and deletion of ICP47, which enhances antigen 
presentation to T cells via MHC. T-VEC is also armed with a human GM-CSF 
cassette in order to promote the anti-tumour activity of local APC, acting as an 
in situ tumour vaccine (Liu et al., 2003; Senzer et al., 2009). 
 
Molecular engineering is indeed a powerful tool for the translational 
virotherapist. However, it would be wise to remember the inherent traits of OV 
that have brought the field to this point. The safety profiles of unmodified OV are 
truly remarkable, and represent a product of the prolonged co-existence of virus 
and host. Compared to this stable relationship, the introduction of a genetically 
modified agent offers risk. Even with extensive precautions, there remains the 
potential for rapid evolution or recombination, as well as unforeseen immune 
interactions (Lehrman, 1999), with engineered viral vectors. Even in the 
absence of modification, many viruses – reovirus included – display powerful 
natural oncolytic properties which have been essential to bringing the field to its 
current state. To paraphrase a popular 1990s hit – for oncolytic virologists, it is 
surely advisable to never forget where you’ve come here from. 
 
2.3.4 Mechanisms of OV activity 
The mechanisms by which OV generate anti-cancer effects in vivo remain far 
from comprehensively understood. In part, this is due to the sheer diversity of 
tumour types targeted and viruses used, plus our evolving ability to manipulate 
the viral genome to optimise its activity.  
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Historically, OV were considered therapeutic agents by virtue of their intrinsic 
ability to lyse infected cells; hence their ‘oncolytic’ tag. Changes to cellular 
morphology prior to and during lytic death underlie the characteristic cytopathic 
effect and monolayer destruction observed due to OV infection in vitro. The lytic 
potential of an OV in commandeering the cell as a virus factory is dependent 
primarily on entry, via cell surface receptors, and replication, via the viral 
replication machinery and its interface with host cell antiviral responses. Many 
viruses contain components which modulate the timing or execution of cell 
death; a well-understood example is the delay of apoptosis by adenovirus, 
vaccinia, and other viruses, to facilitate generation of viral progeny (Dobbelstein 
and Shenk, 1996; Han et al., 1996). The subsequently released viral load is 
able to infect neighbouring cells, a process ideally repeated in order to consume 
the whole tumour mass. 
While the process of lysis or ‘bursting’ would appear likely to be indiscriminate 
and uniform among viruses, modes of OV-induced cell death are many and 
varied. Some OV stimulate the somewhat controlled process of apoptosis, and 
some trigger necroptosis, necrosis or autophagic cell death (reviewed in De 
Munck et al., 2017). Although one often predominates, the profound impact that 
OV have upon multiple aspects of cellular physiology means that they seldom 
inflict only one mode of death (reviewed in Guo et al., 2014). Every virus is 
different, and the type of death – if it occurs – is reliant on host, virus and cell 
type.  
While progeny virus is ostensibly the main element released from an OV-
infected cell upon death, a degree of the intracellular material is also exposed to 
nearby cells, by its ectopic display on the cell membrane or its egress into the 
extracellular milieu. As far as the immune system is concerned, the relevant 
components are cytokines, DAMP, PAMP, and TAA. In the ‘classical’, non-
immunogenic version of apoptosis, cellular integrity is maintained, limiting the 
spread of these components. By contrast, in necrosis and pyroptosis this is 
commonly compromised, allowing DAMP, PAMP and TAA release. 
Immunogenic modes of apoptosis also permit DAMP release and their exposure 
on the cell surface. Such characteristics have earned these three latter modes 
the collective term of immunogenic cell death (ICD). In the field of oncolytic 
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virotherapy, this terminology reflects a realisation that rather than being an end 
in itself, the death of virus-infected cells may be merely one step towards the 
ultimate clearance of a tumour. 
OV are a particularly attractive modality for overturning the chronic 
immunosuppressive state found in the TME. During infection and OV-induced 
death, cells release a characteristic array of pro-inflammatory cytokines and 
chemokines – commonly TNF, CCL5/RANTES, IL-12, CCL3/4 (MIP-1α/β), 
numerous IFN molecules, and others – which can influence both innate and 
adaptive immunity. DAMP, typically heat-shock proteins (HSP), calreticulin, uric 
acid and ATP, also have this capacity. Specifically, these encourage the 
recruitment and maturation of APC, and consequently facilitate the activation 
and expansion of antigen-specific T cell clones. This process is aided by the 
release of antigens from dying cells, whether they be tumour-associated (TAA) 
or viral, both of which can prime T cells to elicit adaptive responses upon 
subsequent exposure in the context of infected, live tumour cells potentially 
expressing both types of antigen. Indeed, increases in both virus- and tumour 
antigen-specific T cells have been noted following virotherapy (Diaz et al., 2007; 
Li et al., 2017; Zamarin et al., 2014). Cytokine-activated T cells within the TME 
are also capable of eliminating uninfected or antigen-poor ‘bystander’ tumour 
cells via the release of cytolytic granules (Spiotto et al., 2004).  
Alongside these effects on adaptive effectors, it should be noted that OV are 
potent stimulators of innate immunity. While DC are the prototypical APC, they 
also modulate innate cells, being able to communicate bidirectionally with and 
activate NK cells against tumour targets following reovirus infection (Errington et 
al., 2008a; Prestwich et al., 2009a). The capacity to stimulate NK-mediated 
tumour cell killing appears to be an attribute shared by a diverse range of OV 
(Bhat and Rommelaere, 2013; Ogbomo et al., 2013). This is supported by the 
broad ability of OV to trigger the influx of immune cells to tumour sites via 
PAMP and cytokines, contributing towards turning an immunologically ‘cold’ 
tumour ‘hot’ (Benencia et al., 2005; Diaz et al., 2007). Indeed, in the context of 
systemic GM-CSF administration, the efficacy of reovirus appears highly reliant 
upon two innate immune effectors: monocytes and NK cells (Ilett et al., 2014). 
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The process of replicative cell death formed the presumed mechanism of action 
for the clinical efficacy of OV and underpinned the rationale for their use. 
However, it emerged through the transition from cell culture assays to in vivo 
studies that the ‘oncolytic’ label is restrictive. The mechanism of action is not 
limited to OV replication, but includes – and in many cases may even be reliant 
on – engagement of the immune system and the initiation of a broader anti-
tumour immune response. Hints that this is the case have emerged from the 
lack of efficacy observed in immunodeficient mice, when compared to 
immunocompetent animals (Kirn and Thorne, 2009; Miller and Fraser, 2000; 
Qiao et al., 2008b). The ability of OV to mediate regression of oncolysis-
resistant tumour types in vivo provides further corroborative evidence 
(Prestwich et al., 2009b). Thus the contribution of the – particularly adaptive – 
immune response towards OV therapy was soon clear (Melcher et al., 2011; 
Prestwich et al., 2009b; Sobol et al., 2011).  
The importance of the pro-inflammatory, ‘immune adjuvant’ activity of OV has 
since been proven throughout their collective clinical trajectory (Andtbacka et 
al., 2016; Ribas et al., 2017). This is encapsulated by the popularity of GM-CSF, 
itself an independent clinical agent (Lawson et al., 2010), as a viral transgene 
(Heo et al., 2013; Hu et al., 2006; Kanerva et al., 2013). Arming OV in this way 
aims to augment their intrinsic immunostimulatory ability. The position of the 
GM-CSF-expressing herpes virus T-VEC as the most advanced OV in the 
clinical arena supports the use of engineering to fine-tune our growing arsenal 
of viruses, and provides a validation of the OV as a true immunotherapy agent. 
 
 
2.3.5 Clinical trials 
Driven by the momentum gained by the field after interest was revived in the 
1990s, OV swiftly progressed into formal clinical testing. Not long after 
Martuza’s successful use of an oncolytic HSV-1 derivative against glioma 
xenografts, similar results were obtained with the recombinant adenovirus 
Onyx-015 (Heise et al., 1997) which subsequently entered phase I testing in 
1996. The virus was administered to patients with recurrent, refractory 
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squamous cell carcinoma of the head and neck (HNSCC), with a single 
intratumoural bolus given as monotherapy (Ganly et al., 2000). With the highest 
dose tested of 1011 plaque-forming units (pfu) being well tolerated, Onyx-015 
progressed to phase II evaluation, showing modest anti-tumour activity as 
monotherapy and potentially synergistic efficacy when combined with cytotoxic 
chemotherapy as shown by a response rate of 65% (Khuri et al., 2000; 
Nemunaitis et al., 2001).  
Development of Onyx-015 stalled when, for corporate reasons, its ongoing 
highly-anticipated phase III trial was abandoned: an unfortunate event that 
many – probably wrongly – interpreted as a failure of the agent itself (Jia and 
Kling, 2006). Yet the highly related adenovirus H101 was subsequently tested in 
a randomised phase III trial for nasophayngeal carcinoma, alongside platinum-
based chemotherapy. With the chemotherapy-alone arm yielding responses in 
40% of patients, the combination of H101 plus chemotherapy generated a 79% 
response rate (Xia et al., 2004). This statistically significant improvement 
triggered the approval of H101 in this setting in China (Garber, 2006). 
However, H101 was not the first virus to gain regulatory approval as a 
virotherapeutic for cancer. An unmodified ECHO virus termed Rigvir has held 
approval for the treatment of melanoma in Latvia since 2004, founded on 
dubious activity in the adjuvant setting for resectable disease (Doniņa et al., 
2015). However, without a rigorous level of clinical trial evidence, Rigvir has not 
gained acceptance outside Eastern Europe. Until the recent emergence of T-
VEC, global oncology markets have remained without access to a proven, 
established viral therapy for melanoma. 
As for many immunotherapies, melanoma has represented a major clinical 
‘testing ground’ for prospective OV. This is in part due to its status as an 
immunogenic tumour type, which in the more advanced stages has a 
particularly poor prognosis, leaving a pool of patients standing to gain 
substantially from a novel immunotherapy modality. Alongside carcinoma of the 
head and neck, primary cutaneous melanoma is also an anatomically 
accessible lesion. Tumour access is relevant in that, to date, the majority of OV 
in clinical testing have been administered directly into the tumour bed, rather 
than being given systemically. With early-phase trials in this new field being 
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focused on safety, the intratumoural injection route has proven attractive in 
aiming to limit adverse events. The relative merits of local and systemic therapy 
are the subject of ongoing scrutiny, as will be discussed later. 
The major viral platforms under clinical investigation as oncolytic agents in 
melanoma are as follows. The double-stranded (ds)RNA reovirus type 3 
Dearing and single-stranded (ss)RNA Coxsackievirus serotype A21 – marketed 
as Reolysin® and Cavatak® respectively – have both completed phase II trials in 
advanced melanoma (Andtbacka et al., 2015a; Galanis et al., 2012). These 
non-enveloped viral strains are unmodified, not generally being associated with 
major human disease, and represent the most clinically advanced wild-type OV 
candidates. Other well-known viruses that have required modification include 
OV derived from the dsDNA vaccinia virus by attenuation, such as JX-594 
(Hwang et al., 2011). Similarly, the highly amenable nature of the adenoviral 
dsDNA genome has enabled a band of variously retargeted, armed and 
conditionally replicative oncolytic adenovirus constructs to reach human 
melanoma patients (Larson et al., 2015; Linette et al., 2013). 
As a human pathogen, the dsDNA backbone of type 1 HSV is one that has 
been heavily re-engineered in the 25 years since the pivotal Martuza study. As 
described above, the removal of the TK gene has been superseded by more 
complex attenuation measures to avoid neurotoxicity, and the virus’ natural 
immunogenicity augmented with stimulatory factors such as GM-CSF. 
HSV1716 (Seprehvir®), derived from the 17+ strain with a single attenuating 
deletion in ICP34.5, was one of the first wave of oncolytic HSV to show activity 
in vitro, and subsequently demonstrated safety and signs of efficacy in phase I 
melanoma trial (MacKie et al., 2001). The HF10 virus is derived from a different 
HSV-1 strain and is attenuated by disruption to the protein transport factor 
UL56; this too has more recently progressed from preclinical to clinical 
evaluation, first as monotherapy in phase I and then in combination with 
ipilimumab in phase II trial for melanoma (Andtbacka et al., 2017; Ferris et al., 
2014). 
Between the initial testing of HSV1716 and the recent emergence of HF10, one 
HSV construct has blazed a trail for OV through the clinical landscape. T-VEC is 
a JS1-derived virus with an attenuating deletion in ICP34.5 and the 
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immunostimulatory deletion of ICP47 and addition of human GM-CSF. 
Preclinical data indicated potent lytic efficacy against various cell lines, including 
melanoma, which successfully translated into efficacy in vivo when the virus 
was given intratumourally (Liu et al., 2003). T-VEC, then known as OncoVEXGM-
CSF, therefore entered phase I testing, being administered to patients with 
various malignancies that were amenable to intralesional injection, including 
melanoma (Hu et al., 2006). A regimen in which a low dose of virus was 
administered prior to the larger therapeutic doses as a safety precaution was 
quickly adopted. T-VEC was well tolerated and, although no responses were 
generated according to standard response criteria, demonstrated signs of 
efficacy, including visible flattening of tumours and necrotic areas associated 
with virus by histology. 
In 2005, T-VEC was thus taken forward into phase II trial in a cohort of 50 
melanoma patients with either unresectable local disease or metastases at pre-
specified sites (NCT00289016; Senzer et al., 2009). In this largely pre-treated 
population, the virus was given every three weeks and obtained an objective 
response rate (ORR) of 26%. Particularly promising was that 8 of 13 responders 
gained complete responses (CR), the majority being durable over time, and that 
efficacy was shown in both injected and non-injected (including visceral) 
lesions. 52% of patients were alive beyond 2 years, highly suggestive of a 
benefit to overall survival (OS). 
With a good safety profile and a strong evidence of efficacy, the OPTiM phase 
III study (NCT00769704) opened in 2009. This trial recruited 436 treatment-
naïve or pre-treated patients with stage IIIb-IV melanoma, who were 
randomised 2:1 to receive intratumoural T-VEC or subcutaneous GM-CSF. In 
this larger group, the virus was again well tolerated, with the most common 
high-grade toxicity being cellulitis in only 2.1% of patients. The trial successfully 
met its primary endpoint of durable response rate for T-VEC (16% vs 2%, p < 
0.0001), and similar to phase II, registered an ORR of 26% (CR 11%) versus 
6% (CR 1%) (Andtbacka et al., 2015b; Andtbacka et al., 2016). Responses 
were noted in injected (64%) as well as non-injected (34%) and visceral (15%) 
lesions, suggestive of an abscopal effect sufficient to underpin a degree of 
35 
 
systemic anti-tumour immunity. Median OS in the T-VEC arm was 23.3 months, 
versus 18.9 months for GM-CSF (p = 0.051).  
Despite this statistical miss on extending OS, the first-in-class OV T-VEC was 
approved by the US Food and Drug Administration (FDA) for recurrent 
melanoma in 2015; a landmark regulatory milestone for the field (Greig, 2016). 
It was subsequently approved in Europe in 2016, after an exploratory sub-
analysis of the earlier-stage III/IVM1a population demonstrated its superiority in 
overall (40.5% vs 2.3%) and durable (25.2% vs 1.2%) response rates, and OS 
(median 41.1 vs 21.5 months) (Harrington et al., 2016). A recent phase IIIb 
study confirms that the post-approval use of T-VEC outside of the clinical trial 
setting is safe, despite its extra challenges in handling and administration 
(Chesney et al., 2018; Harrington et al., 2017). 
With the clinical performance of T-VEC noted, it is clear from the multitude of 
earlier-phase trials that, across indications, the ability of OV to induce tumour 
regression and prolong survival when used alone is limited. Response rates in 
metastatic melanoma are typically 25% at best, compared to approaching 40% 
for anti-PD-1 agents. Collectively however, OV safety profiles are very good, 
making them excellent candidates for combination therapy. Further, during 
preclinical development, various OV showed a propensity to synergise with 
other established modalities. Chemo-, radio- and targeted therapies can 
sensitise tumour cells to OV killing, via the upregulation of receptors and the 
enhancement of antigen presentation or apoptosis (Dai et al., 2014; Kaneno et 
al., 2011; Zurakowski and Wodarz, 2007). For instance, reovirus synergises 
with cytotoxic chemotherapy in melanoma and other tumour types (Heinemann 
et al., 2011; Pandha et al., 2009), both in murine models and potentially in 
cancer patients (Karapanagiotou et al., 2012). In a phase I/II trial for advanced 
HNSCC, 82% of patients obtained a response to the combination of T-VEC with 
chemoradiotherapy (Harrington et al., 2010a). 
That OV can combine effectively with traditional modalities has been known for 
some time. The potential for OV to enhance the already impressive efficacy of 
checkpoint inhibitors is an altogether more exciting prospect. OV appear to 
have a shared capacity to promote lymphocyte infiltration into tumours and to 
liberate TAA; this suggests they are ideal agents to partner with checkpoint 
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inhibitors, which are incapable of reversing immune tolerance to tumours 
without the presence of lymphocytes and tumour-reactive antigens (reviewed in 
Robert, 2017; Tumeh et al., 2014). The relatively novel use of dual checkpoint 
inhibitors in melanoma has resulted in unprecedented benefits in response rate 
and survival, but their overlapping toxicity profiles cause tolerability issues. In 
advanced melanoma patients receiving first-line nivolumab and ipilimumab, the 
majority experienced grade 3-4 toxicities (Larkin et al., 2015a) – surely an 
unpalatable rate for routine practice. By contrast, checkpoint inhibitors and OV 
are separate modalities with different modes of action, and thus far appear to be 
far better tolerated. 
T-VEC is in trial with each of the three major checkpoint inhibitors to date. In the 
first of these, the combination of T-VEC plus ipilimumab recently reached its 
phase II primary endpoint in melanoma, more than doubling ORR (39% vs 18%) 
over ipilimumab alone without significantly increasing the incidence of severe 
toxicities (Chesney et al., 2017). Another phase II study, combining T-VEC with 
nivolumab in order to interrogate the OV’s mechanism of action, has recently 
been opened (NCT02978625).  
The third of these is MASTERKEY-265 (NCT02263508), a phase Ib/III trial of T-
VEC plus pembrolizumab in treatment-naïve advanced melanoma patients. 
Results from the phase Ib part have recently been updated, showing a 
confirmed ORR of 62% and CR rate of 33% (Long et al., 2016; Ribas et al., 
2017). These data compare favourably with the published ORR from phase III 
trials of pembrolizumab (42%) or T-VEC (26%) alone (Andtbacka et al., 2015b; 
Robert et al., 2017). It should however be noted that differences in the study 
populations prevent the direct comparison of these trials; in particular the fact 
that the combination trial involved injectable and therefore earlier-stage disease 
compared to the entire advanced melanoma population. Nevertheless, these 
measures of efficacy, allied with an associated IFN-γ signature and T-cell 
infiltration, represent the most promising yet for the OV-checkpoint combination. 
If borne out in the phase III part, such data may enable it to threaten the existing 
combination regimen. 
Even more encouragingly, it is not only T-VEC which is meriting inclusion in 
combination trials, but a wide variety of OV. Alongside ipilimumab, its cousin 
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HF10 has now demonstrated encouraging efficacy in a phase II patient group 
with even more advanced melanoma than in OPTiM (37% stage IV), extending 
median progression-free survival (PFS) to 22 months versus a landmark of 6 
months with ipilimumab alone (Andtbacka et al., 2017). Although the field is 
increasingly comfortable with HSV-derived oncolytics, the candidates do not 
stop there. Adenovirus constructs are currently under investigation with 
nivolumab for carcinoma (Harb et al., 2016) and with pembrolizumab for 
melanoma (NCT03003676). JX-594 is being combined with ipilimumab in phase 
I testing across indications (NCT02977156). 
In addition to these numerous re-engineered OV, a select few naturally 
occurring viruses are quietly progressing into similar trials. CVA21 is the first 
wild-type virus to do so, being combined with ipilimumab in a phase I trial for 









The virus now generically known as reovirus was first isolated from an 
aboriginal Australian child in 1951. It was termed hepato-encephalomyelitis 
virus, on account of the symptoms elicited on its administration to mice (Stanley 
et al., 1953, 1954), and categorised as ECHO (enteric cytopathic human 
orphan) virus 10. This being a time of rapid change in virology, the virus was 
promptly renamed reovirus (respiratory enteric orphan) due to its host cell 
tropism and lack of association with human disease (Sabin, 1959; Stanley, 
1961). 
The isolate currently in testing as a cancer therapeutic is the serotype 3 Dearing 
strain of mammalian orthoreovirus, belonging to the Orthoreovirus genus, and 
to the Reoviridae family, which also includes the more well-known rotavirus. 
Each of the three serotypes of the mammalian orthoreovirus have a prototype 
strain: type 1 Lang, type 2 Jones, and type 3 Dearing (Ramos-Alvarez and 
Sabin, 1954). Reoviruses are found across kingdoms, having found hosts in 
mammals, fish, birds and plants. Among mammals, the mammalian reoviruses 
infect a broad spectrum of host species, and this promiscuity is thought to 
enable some infection events to be zoonotic (Lelli et al., 2016; Steyer et al., 
2013). 
Although there are discrepancies in its effects between human and murine 
systems, the pathogenesis of reovirus in newborn mice has made it a useful 
experimental model of virus-host interaction and spread. Following initial 
infection in the gut mucosa, the virus spreads via the bloodstream and 
lymphatic system to the central nervous system and other organs (Forrest and 
Dermody, 2003). In immunodeficient mice, reovirus infection leads to fatal 
myocarditis (Sherry et al., 1993). 
Consistent with its taxonomy, reovirus type 3 Dearing (hereafter reovirus) is 
typically isolated from the human gastrointestinal and upper respiratory tracts, 
and is found in the faecal material of both healthy and symptomatic individuals 
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(Ramos-Alvarez and Sabin, 1954, 1958). Upon transmission by the faecal-oral 
route, natural infection first involves the attack of epithelial cells in the ileum, 
which can precipitate diarrhoea and vomiting. Similarly, infection of the 
respiratory tract can lead to symptoms of the common cold. However, in most 
individuals, reovirus infection is considered to proceed asymptomatically, in line 
with its historical designation as an orphan virus. The deliberate intranasal 
inoculation of healthy volunteers with reovirus yielded symptoms in only a third 
(Rosen et al., 1963).  
The literature does contain sporadic reports of severe pathology associated with 
reovirus infection, particularly in infants and the immunocompromised. Reovirus 
has been associated with conditions consistent with its main tissue tropism, 
such as gastroenteritis, acute respiratory disease and pneumonia (Chua et al., 
2007; Steyer et al., 2013; Tillotson and Lerner, 1967), others such as 
encephalitis and meningitis which indicate its neurotropic ability (Ouattara et al., 
2011; Tyler et al., 2004), and still others with a less apparent aetiology, 
including hepatitis and biliary atresia (Morecki et al., 1982; Richardson et al., 
1994). For some, although causative roles for reovirus have not been 
exhaustively proven, corroborative evidence is provided by mouse studies 
(Wilson et al., 1994). Most recently, reovirus has been implicated in coeliac 
disease by promoting the TH1 response, an association that bodes well for the 
virus as an immunotherapy (Bouziat et al., 2017). 
Reovirus is ubiquitous in the environment, particularly in stagnant water and raw 
sewage (Matsuura et al., 1988). A multitude of studies, spanning temporal and 
geographical boundaries, have been conducted into reovirus exposure, 
indicating that global seroprevalence for reovirus among adults is commonly 
above 50%, and typically closer to 100% (Lerner et al., 1962; Minuk et al., 1985, 
1987; Pal and Agarwal, 1968; Selb and Weber, 1994; Stanley, 1974). At birth, 
passive immunity stands at around 75% and diminishes quickly in the first few 
years of life. Exposure in childhood is frequent, with around 50% of 5-year-olds 
seropositive (Leers and Rozee, 1966; Tai et al., 2005). Multiple peaks of 
seroprevalence have been observed throughout adulthood, indicative of re-
infection (Berger and Brody, 1967).  
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Serum immunoglobulin G (IgG) is the major class of neutralising antibody, as 
corroborated by the transfer of maternal immunity; in line with mucosal 
exposure, IgA are also elicited, but decay more rapidly (Selb and Weber, 1994). 
The innate immune response to reovirus does not appear to be serotype-
specific, as antiviral antibodies are cross-reactive between serotypes (Virgin 
and Tyler, 1991). However, unlike humoral responses, cell-mediated responses 
to type 1 Lang and type 3 Dearing vary qualitatively, indicating that they bear 
immunologically relevant structural differences. Due to the frequency of 
infection, it not yet clear whether cellular immunity confers protection across 
serotypes (Douville et al., 2008). 
 
2.4.2 Structure and replication 
The identification of the reovirus genome as a dsRNA structure was made in the 
1960s, marking the first description of dsRNA in any biological system 
(Gomatos and Tamm, 1963). It is therefore a Group III virus, with the genome 
comprising 10 segments of dsRNA (Shatkin et al., 1968), which are classified 
as large (L1-3), medium (M1-3) or small (S1-4). These segments give rise to 
viral proteins respectively termed λ, µ and σ. The segmented RNA backbone 
makes reovirus relatively difficult to modify genetically, partly due to its lower 
genetic stability. Recently, a reverse genetics approach has made this possible 
(Mohamed et al., 2015), and small transgenes including reporter constructs 
have been inserted (Kemp et al., 2016; van den Wollenberg et al., 2015), 
suggesting that the oncoytic potency of reovirus could be enhanced in future. 
The 10 gene segments of reovirus encode for 8 structural proteins – λ1-3, µ1-2, 
and σ1-3 – which contribute towards the structure of the mature virion, and the 
non-structural proteins µNS and σNS, which facilitate the intracellular viral 
replication cycle (Chandran et al., 2001). The assembled virion is non-
enveloped, 80 nm in diameter, and is formed of an icosahedral outer capsid and 
inner core. The three reovirus serotypes are defined by their antibody 
neutralisation and haemagglutination activity, and differ in their tropism in vivo. 
There is a high degree of genetic similarity between types 1-3, with 
approximately 90-98% of their identity being conserved (Gaillard and Joklik, 
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1982). The exception is in the highly type-specific S1 gene, encoding the σ1 
attachment protein in the outer capsid, which has undergone significant 
evolutionary divergence (Cashdollar et al., 1985). 
It is via the σ1 protein that reovirus is able to initiate the process of target cell 
entry. This process occurs over multiple steps, with the first being a low-affinity 
‘tethering’ event between the carbohydrate-binding domain of σ1 and cell-
surface sialic acid (Barton et al., 2001a; Chappell et al., 2000). This use of 
surface carbohydrates, a trait shared by many viruses, is important for reovirus 
infection in vivo (Barton et al., 2003; Olofsson and Bergström, 2005). 
Subsequently, σ1 engages JAM-A, the canonical reovirus receptor from the 
immunoglobulin superfamily. This high-affinity interaction is also essential for 
viral spread in vivo (Antar et al., 2009; Barton et al., 2001b). The substantial 
effect on reovirus infectivity and oncolysis mediated by the mutation of σ1 
highlights its critical role in cell binding (Shmulevitz et al., 2012). 
Following sialic acid tethering and JAM-A binding, reovirus gains entry to the 
cell interior by receptor-mediated endocytosis. β1 integrins on the cell surface 
are subverted by the binding of the viral λ2 protein, and trigger internalisation; 
this integrin-binding strategy appears to be highly conserved between reovirus 
and adenovirus (Stehle and Dermody, 2004). Within the endosome, the viral 
particle undergoes acid-dependent proteolysis and well-defined conformational 
changes. The entry intermediate, known as an intermediate (or infectious) 
subviral particle (ISVP), is characterised by the loss of the prominent outer 
capsid protein σ3 and cleavage of µ1 (Ebert et al., 2002).  
This proteolytic uncoating, principally by cathepsins, is critical for the eventual 
penetration of the endosomal membrane by µ1. Indeed, if reovirus uncoating 
occurs extracellularly, ISVP can gain entry independent of surface receptors 
(Borsa et al., 1979). It is considered that acid-dependent proteases in the 
respiratory tract and intestinal environment may facilitate epithelial infection 
through this mechanism (Bass et al., 1990; Golden and Schiff, 2005). 
Immediately prior to endosomal escape, ISVP become ISVP* as a result of 
conformational changes and autocleavage of µ1 into µ1N, triggering pore 
formation in the endocytic membrane (Chandran et al., 2002). This permits the 
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delivery of the transcriptionally active reovirus core, lacking σ1, into the cytosol 
of the host cell (Nibert et al., 2005; Odegard et al., 2004). 
Aside from the very earliest phase of transcription, which occurs while still an 
ISVP, the replication of the reovirus genome is entirely cytoplasmic. The core 
contains the transferases and the catalytic RNA-dependent RNA polymerase 
(RdRp, encoded by λ3) necessary to conduct RNA synthesis. Capped, positive-
sense ssRNA is thus generated and serves both as mRNA for the translation of 
reovirus proteins, and also as the template for the regeneration of nascent 
dsRNA genomes by conservative replication (Li et al., 1980). Transcription and 
translation occur in cytoplasmic inclusions; viral ‘factories’, nucleated by non-
structural proteins, which oversee the two processes (Fields et al., 1971; 
Kobayashi et al., 2006). The assortment and packaging of the segmented 
genome into individual virions is highly accurate and appears to occur 
concomitantly with RNA synthesis, by a presumably sophisticated yet largely 
undefined mechanism (Antczak and Joklik, 1992; McDonald and Patton, 2011). 
Although viral egress can be non-cytolytic in the absence of transformation, 
release of progeny virus is typically lytic, particularly in permissive, transformed 
cell lines (Connolly et al., 2001; Lai et al., 2013). 
 
2.4.3 As an oncolytic agent 
The basis for the success of reovirus as an oncolytic agent has been the 
subject of decades of research, and at times, dispute. It began in the virology 
lab of Patrick Lee, with a series of discoveries that – as is so often the case – 
were serendipitous in their origin (Thagard, 2002). As part of an investigation 
into the role of cell-surface sialic acid in facilitating reovirus binding, an 
association was revealed between a cell’s permissivity to reovirus and its 
epidermal growth factor receptor (EGFR) status (Strong et al., 1993; Tang et al., 
1993). It emerged through transfection with the v-erb oncogene that the critical 
factor was not the receptor itself but the activation of downstream signal 
transduction cascades (Strong and Lee, 1996). Transfection of cells with 
constitutively active elements of the Ras pathway, a group of small GTP-binding 
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proteins regulating cell fate and growth, enabled it to be specifically implicated 
(Strong et al., 1998). 
By showing that reovirus infection can be established by inhibiting the 
phosphorylation of the dsRNA sensor PKR, precluding its ability to inhibit 
protein synthesis, it was determined that Ras activation may promote 
susceptibility via PKR (Strong et al., 1998). The absence of PKR 
phosphorylation in Ras-transformed cells suggested that they, unlike wild-type 
cells, are unable to prevent viral replication by halting the formation of the 
translation initiation complex (de Haro et al., 1996). This is corroborated by 
reports finding no enhancement in viral attachment, entry, or initial transcription 
in Ras-transformed cells (Norman et al., 2004). Indeed, the dysregulation of 
PKR is implicated in malignant transformation, given it can function as a tumour 
suppressor by promoting the apoptosis of aberrant cells via IFN (Barber et al., 
1995; Donzé et al., 1999). The reovirus σ3 protein is capable of stimulating 
translation by binding PKR directly, providing further evidence for its potential 
involvement in susceptibility (Yue and Shatkin, 1997). 
Consequently, what started as a hunt for a reovirus receptor actually 
crystallised a link between corrupted intracellular signalling and reovirus activity. 
However, the potential impact of this series of studies in the context of cancer 
was only realised by Lee in 1995 (Thagard, 2002). This was nearly 20 years 
after the original link was made between reovirus and oncolysis, in the absence 
of a molecular basis. The ability of reovirus to exert cytotoxic effects on 
transformed cell lines, and the predisposition of cells to infection by 
transformation with the viral SV40 T antigen, was first reported in the 1970s 
(Duncan et al., 1978; Hashiro et al., 1977). Further, these findings were 
translated into in vivo models, with reovirus successfully generating anti-tumour 
responses against mouse lung tumours (Theiss et al., 1978). 
Despite these early reports, it was only after the virologist Lee published his 
studies on the underlying mechanism that interest in reovirus as a cancer 
therapeutic began in earnest. In a pivotal 1998 paper, one intratumoural 
injection of the virus was found to induce responses in the majority of 
immunodeficient mice bearing human glioma xenografts, and efficacy was also 
shown in immunocompetent animals (Coffey, 1998). The link between reovirus 
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and cellular Ras status was strengthened by observations that tumour cell 
susceptibility could be influenced by modulating Ras and its downstream 
effectors using short-hairpin (sh)RNA or small-molecule inhibitors (Norman et 
al., 2004; Smakman et al., 2005).  
Across cancer types, Ras mutations are highly prevalent – present in nearly 
20% on average, with a range of 1-63% (Prior et al., 2012) – and this does not 
take into account activating mutations elsewhere in the Ras cascade. 
Consequently there would appear to be a strong rationale to underpin the 
oncolytic capacity of reovirus. This is relevant even in the non-malignant 
context, where it has been suggested that the basal level of Ras activity in the 
highly proliferative ileal epithelium may be sufficient to permit replication 
(Shmulevitz et al., 2005). Cellular permissivity to other viruses, such as HSV, is 
also influenced by activation in the Ras pathway, and specifically its effector 
MEK, which can directly suppress PKR (Farassati et al., 2001; Veerapong et al., 
2007). 
Although the Ras-PKR axis would appear to provide a neat explanation, the 
true molecular mediator of reovirus susceptibility has been the subject of 
debate. Doubt has been cast by the susceptibility of cells with wild-type Ras 
status, and the ability of a minority of tumour cells to survive virus treatment in 
vitro in spite of Ras transformation (Kim et al., 2007; Smakman et al., 2006). 
The absence of a correlation between total or phospho-PKR and either Ras 
expression or cell death contradicts previous studies (Song et al., 2009), and is 
corroborated by a lack of association between oncolysis and EGFR signalling 
(Twigger et al., 2012). Ras may therefore modulate susceptibility via other steps 
in the replication cycle, such as virion uncoating, infectivity of progeny, and 
induction of cell death (Shmulevitz et al., 2009). 
The diverse effects of Ras transformation on multiple elements of cellular 
homeostasis and signalling – and therefore many aspects of the virus-cell 
interaction – have made this issue a complex one. There is a gathering 
acceptance that reovirus susceptibility is multifactorial: dependent on more than 
Ras status alone. It is also increasingly apparent that viral replication and cell 
death are not inextricably linked; Ras activation appears not to underlie 
replication but instead a sensitivity to apoptosis, and apoptosis can occur 
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independently of replication (Connolly et al., 2001; Smakman et al., 2005). 
Thus, a more careful examination of both replication and death appears 
essential to a precise judgement upon the true basis for the cancer-selective 
activity of reovirus. 
Reovirus was originally considered to operate predominantly by apoptosis 
(reviewed in Clarke et al., 2005). The apoptotic signalling often displayed by 
infected cells includes the generation of IFN and acute activation of the NF-κB 
hub, either through detection of cytoplasmic dsRNA by PKR, RIG-I and MDA5, 
or of the σ1 and µ1 proteins upon receptor engagement or membrane 
penetration (Connolly et al., 2001; Deb et al., 2001). A study in which cells were 
transfected with Fc receptors to enable antibody-bound reovirus to enter 
independently of JAM-A and sialic acid demonstrated that the canonical mode 
of entry is not key for apoptosis to occur (Danthi et al., 2006). In response to 
NF-κB and IRF3, inflammatory cytokines such as TRAIL are secreted, bind to 
surface death receptors, and trigger mitochondrial Smac/Bid signalling and pro-
apoptotic activation of caspase-3 and -7 (Clarke et al., 2000; Kominsky et al., 
2002). While IFN are potent promoters of cell death, it appears that IFN may be 
dispensable for reovirus-induced apoptosis, which may explain the ability of 
infected, IFN-deficient tumour cells to undergo apoptosis (Knowlton et al., 2012; 
Kominsky et al., 2002).  
However, blockade of apoptotic caspases does not entirely abrogate reovirus-
induced cell death in vitro, suggesting that other modes of cell death contribute 
(Berger and Danthi, 2013). In particular, necroptotic cell death has been 
observed in reovirus-infected cells. This does appear to be contingent on type I 
IFN, elicited not only by the exogenous dsRNA of the infecting virion, but also 
the subsequent wave of RNA synthesis within the cell (Berger et al., 2017). 
Additionally, like many viruses, reovirus is capable of triggering autophagy as a 
consequence of acute endoplasmic reticulum stress (Thirukkumaran et al., 
2013). While certain types of cell death are broadly common between reovirus 
and other OV, it is increasingly apparent that the molecular intricacies within 
each mode can vary significantly, with novel OV-mediated subtypes of cell 
death now emerging (Weigert et al., 2017). Thus, as for any OV, both the 
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category of reovirus-induced death and its finer details are exquisitely linked to 
the phenotype of the target cell and the attributes of the incoming virus. 
 
2.4.4 Pre-clinical evidence 
Although the mechanism by which reovirus exerts cytotoxic effects has been 
the subject of some debate, the fact that it can reliably do so against malignant 
targets remains largely unquestioned. Following the observations of Hashiro, 
reovirus has demonstrated oncolytic activity in cells derived from the vast 
majority of the major solid tumour types in vitro, including lung, breast, ovarian, 
prostate, colorectal, pancreatic, glioma, melanoma, and head and neck 
carcinoma (Adair et al., 2013; Errington et al., 2008b; Hirasawa et al., 2002; 
Norman et al., 2002; Sei et al., 2009; Thirukkumaran et al., 2010; Twigger et al., 
2012). Reovirus also shows promise in haematological models, such as multiple 
myeloma and both lymphoid and myeloid leukaemias (Hall et al., 2012; Parrish 
et al., 2015; Thirukkumaran et al., 2012). Of these, melanoma models have 
served as perhaps the most common testing ground. 
Despite the evidence for the involvement of PKR dysfunction in cellular 
susceptibility to reovirus, in melanoma cells it does appear that PKR is 
functional in the detection of intracellular virus. Via the degradation of I-κB, 
autophosphorylated PKR is able to stimulate the NF-κB-mediated production of 
the inflammatory cytokines IL-1, -6 and -8, CCL3/4 (MIP-1α/β), CCL5/RANTES, 
and the chemokine CXCL10 (also known as IP-10) (Errington et al., 2008b; 
Steele et al., 2011). These cyto- and chemokines not only serve as 
chemoattractants for immune cells, but also stimulate the priming ability of DC 
and bystander killing by lytic NK cells in vitro. APC such as DC are also 
activated by direct infection with reovirus via PRR, whereupon they mature and 
secrete soluble factors which elicit innate tumour cell killing by both NK and T 
cells. This is corroborated by the anti-tumour activity shown by human PBMC 
cultured with reovirus (Errington et al., 2008a; Prestwich et al., 2008a). The 
innate immune killing by NK cells in the context of PBMC is highly reliant on 
type I IFN, secreted principally by DC and CD14+ monocytes in response to 
virus (Adair et al., 2013; Parrish et al., 2015). 
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When first used as a cancer therapeutic in vivo, reovirus was delivered directly 
into tumour lesions (Coffey, 1998). Reovirus administered by the intratumoural 
(i.t.) route is able to induce the regression of established subcutaneous B16 
melanoma tumours, and significantly extends survival in immunocompetent 
mice (Qiao et al., 2008a). The virus primes a tumour-specific TH1 response 
mediated by CD8+ T cells (Prestwich et al., 2008a), which along with NK cells 
mediates anti-tumour activity (Rajani et al., 2016). The therapeutic outcome to 
i.t. reovirus is also influenced by other arms of T cell immunity. Locally 
administered reovirus can also promote the accumulation of Treg to the 
detriment of therapy (Clements et al., 2015; Rajani et al., 2016). The induction 
of a melanoma-specific TH17 response, in a dual-OV ‘prime-boost’ regimen, 
augments existing TH1 responses to i.t. reovirus (Ilett et al., 2017). 
As part of a strategy aiming to treat inaccessible and metastatic cancer 
deposits, the systemic delivery of reovirus has been investigated. In the context 
of intravenously (i.v.)-administered reovirus, the contribution of immune cells to 
efficacy is even more critical. Indeed, although administered reovirus gains 
access to tumours, its ability to purge reovirus-resistant B16ova tumour cells in 
vitro and in vivo – but not in immunodeficient animals – demonstrates that, 
unlike immune-mediated killing, oncolysis is not essential for therapy (Prestwich 
et al., 2009b). Given alone, the impact of i.v. reovirus upon tumour growth is 
often somewhat limited in comparison to i.t. injection. As this has long been 
associated with the generation of antiviral antibodies in circulation, i.v. reovirus 
has been combined with cyclophosphamide with a view to maximising the virus 
titre reaching tumour beds (Qiao et al., 2008b). While this approach was 
associated with elevated systemic toxicity, some enhancement of reovirus 
efficacy against subcutaneous B16 melanoma was observed. 
In the past, systemic reovirus has been co-administered with a variety of agents 
in pre-clinical models, such as chemotherapy compounds and inhibitors of 
angiogenesis (Kottke et al., 2010, 2011a). More recently, the virus has been 
combined successfully with immunostimulatory agents, in order to capitalise 
upon its inherent traits as an immune adjuvant. As will be discussed later, 
based on the carriage of virus by circulating lymphocytes, i.v. reovirus therapy 
has been potentiated by pre-conditioning the host with GM-CSF, to expand 
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immune effector populations (Ilett et al., 2014). The efficacy of GM-
CSF/reovirus is reliant on innate populations: monocytes and NK cells. Most 
recently, i.v. reovirus has shown promising efficacy in combination with 
checkpoint inhibitors. Murine models of myeloma, glioma and melanoma 
suggest that the two modalities operate by complementary mechanisms, and 
together induce highly durable tumour responses (Ilett et al., 2017; Kelly et al., 
2018; Samson et al., 2018). 
 
2.4.5 Clinical trials  
Reovirus type 3 Dearing is the subject of one of the largest clinical trial 
programmes in oncolytic virotherapy. Aside from CVA21, it is the only 
unmodified virus in late-phase clinical development, being the first to reach 
phase III trial, and its clinical grade formulation is marketed as Reolysin® 
(generic name pelareorep) by Oncolytics Biotech (Calgary, Canada). The virus 
is listed in 22 trials identified on clinicaltrials.gov, although the number is 
believed to be over 30 based on additional others not listed. As of 2018, 
reovirus holds orphan drug status from the FDA for glioma, ovarian, pancreatic, 
peritoneal and gastric cancers, and from the EMA for ovarian and pancreatic 
cancer. 
The first-in-man phase I study of reovirus as a cancer therapy, REO-001, 
enrolled 19 patients with accessible, advanced malignancies, who were treated 
intralesionally with ascending doses of the virus. No dose-limiting toxicities were 
observed, all being grade 2 or below, with the most common being nausea, 
headache or vomiting in 50-80% of patients (Morris et al., 2013). Tumour 
responses were also apparent in 37%. Based on this, and its promising safety 
profile in animal models, reovirus progressed quickly into trials of systemic 
treatment. Intravenous delivery was first tested in REO-004, in which 18 
patients with advanced solid tumours received virus doses of up to 3 x 1010 
TCID50 without identifying a maximum tolerated dose, or dose-limiting toxicity. In 
fact, only two patients experienced grade 2 events, even when multiple doses 
were given on successive days (Gollamudi et al., 2010). When corroborated by 
other phase I trials (Vidal et al., 2008; White et al., 2008), these results 
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demonstrated that, when delivered by infusion as a very large, non-
physiological bolus, the unmodified reovirus is remarkably well tolerated. 
Reovirus has now undergone further evaluation in phase I and II clinical trials 
across a range of indications. Historically, the tumours most heavily targeted 
within the reovirus programme have been melanoma, myeloma and glioma 
(Forsyth et al., 2008; Galanis et al., 2012; Sborov et al., 2014), although trials 
have also taken place in pancreatic, lung, breast, colorectal, prostate, and head 
and neck cancers (Bernstein et al., 2017; Karnad et al., 2011; Noonan et al., 
2016; Ocean et al., 2013; Samson et al., 2018; Villalona-Calero et al., 2016). 
Initial trials deployed reovirus as a monotherapy, with the majority of these by 
i.v. administration. With safety largely established in the almost total absence of 
serious adverse events (Gong et al., 2016), a small number of phase II trials 
were conducted, with equivocal outcomes.  
In REO-014, 52 patients with sarcoma lung metastases were treated i.v. with 
five daily doses of 3 x 1010 TCID50 reovirus every four weeks. Depending on the 
data source, disease control was achieved in 34-43% of patients, and in some 
for as long as 22 months (Gong et al., 2016; Mita et al., 2009). The first phase II 
study of reovirus in melanoma employed the same dosing schedule. None of 
the 21 patients registered responses by pre-defined criteria, precluding a 
positive conclusion or expansion of the trial. 29% of patients did however exhibit 
stabilisation of disease, and reovirus was detected in 2/13 metastasis biopsies, 
with one patient experiencing extensive necrosis in two lesions (Galanis et al., 
2012). The low degree of efficacy may have been linked to the paucity of BRAF 
mutations in the trial cohort (2 of 13 tested), and the presence of prior systemic 
therapy in the vast majority. 
As a result of the generally disappointing outcomes from such phase II trials, 
the virus is no longer under active investigation as a monotherapy. No 
monotherapy trials of reovirus are currently open on clinicaltrials.gov, and 
Oncolytics Biotech is instead developing the virus along three combination 
programmes (www.oncolyticsbiotech.com). Indeed, reovirus has been 
combined with a wide variety of agents over the past decade. Based on its 
ability to synergise with ionising radiation in culture and in murine models 
(Twigger et al., 2008), the combination of reovirus with radiotherapy has been 
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tested further, demonstrating tolerability in phase I and a promising disease 
control rate of 93% in a small phase II trial (Harrington et al., 2010b; Saunders 
et al., 2009).  
By far the more extensive line of enquiry has been the combination of reovirus 
with standard chemotherapy agents, including platinum-based compounds, 
taxanes, gemcitabine and cyclophosphamide. Similar to the effects observed 
with radiotherapy, reovirus readily synergises with chemotherapy in vitro and in 
murine models of melanoma and prostate cancer (Heinemann et al., 2011; 
Pandha et al., 2009). Minimal exacerbation of the side effects of chemotherapy 
was noted in phase I combination testing (Comins et al., 2010; Karapanagiotou 
et al., 2012; Lolkema et al., 2011). The addition of reovirus to dual 
paclitaxel/carboplatin (P/C) chemotherapy has been the most heavily studied 
combination. In REO-020, reovirus plus P/C provided signs of efficacy in 
melanoma, with responses observed in 21% (Mahalingam et al., 2017a). Two 
phase II trials for non-small cell lung cancer have tested this combination, 
identifying objective responses in 48% of patients with squamous cell 
carcinomas (Mita et al., 2013) and 31% of patients with Ras-activated 
carcinomas (Villalona-Calero et al., 2016) in REO-021 and REO-016 
respectively. Allied with a median OS of 13.1 months, this compares favourably 
to a historical rate of approximately 20% with P/C alone (O’Byrne et al., 2011). 
The inclusion of randomised control groups in these trials would have enabled a 
formal comparison to be made.  
A subsequent, larger phase II trial of reovirus plus pemetrexed or docetaxel in 
lung cancer (IND-211) did include comparator arms, and although exploratory 
analyses hinted at potential benefit for patients with mutations in EGFR or p53, 
the addition of reovirus failed to improve PFS or OS (Morris et al., 2016). 
Similarly, the addition of reovirus to paclitaxel failed to improve therapy in 
gynaecological cancer patients (Cohn et al., 2017). Thus, even in combination, 
the results of efficacy-based trials with reovirus have not been universally 
positive. The only phase III trial conducted to date, REO-018, was a 
randomised, double-blind trial of P/C with or without reovirus in HNSCC. The 
virus was given by i.v. infusion at a dose of 3 x 1010 TCID50 on days 1-5 every 
four weeks, alongside standard-of-care P/C. As reported on the Oncolytics 
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Biotech website (but not published), the interim trial results were positive: in 118 
evaluable patients with locoregional disease, reovirus extended median PFS 
from 48 to 95 days, and significantly enhanced OS, using censoring for 
subsequent therapies. In fact, the study was curtailed, converted from a phase 
III to a large phase II trial, and no analysis of the pre-defined endpoints 
published, leaving the results unconvincing. 
These mixed results have made the therapeutic potential of reovirus a topic of 
debate. It is accurate to state that i.v. reovirus has often shown very modest 
activity, particularly as monotherapy (Galanis et al., 2012). However, it has also 
demonstrated promising efficacy, sometimes in much the same patient 
population, and reliably gains access to tumour lesions when given systemically 
(Adair et al., 2012; Samson et al., 2018). It is important to note that, like many 
immunotherapies, reovirus shows potential to extend overall survival in the 
presence of limited PFS benefit; this phenomenon has been observed in IND-
213, a recent phase II trial involving combination with paclitaxel in metastatic 
breast cancer, which will likely spawn the next phase III study (Bernstein et al., 
2017). 
With the virtues of chemotherapy combinations accepted, it is trials adding 
reovirus (and its fellow OV) to other immunotherapies that appear destined for 
the most success. Somewhat similar to T-VEC, combining reovirus with anti-
PD-1 inhibitors elicits powerful anti-tumour responses in animal models (Rajani 
et al., 2016; Samson et al., 2018) and is currently under investigation for 
pancreatic cancer in the REO-024 trial (Mahalingam et al., 2017b). Another trial 
with translational support that has been planned, REO Melanoma GM-CSF 
(NCT03282188), is designed to mobilise not only cellular effectors but also 
humoral immunity in the cause of tumour clearance. It is surely by innovating, 
and maximising our ability to harness the immune system, that the best 





2.5 Oncolytic viruses and the immune system 
 
2.5.1 The delivery conundrum 
Outside the therapeutic setting, a natural viral infection typically involves small-
scale virus exposure, either by venous puncture or (as for reovirus) contact at 
the mucous membranes of the gut and respiratory tract. The administration of a 
large OV bolus differs primarily in scale – the number of virus particles involved 
– but also in the compartments exposed to virus, meaning that virotherapy must 
operate under a very different set of pharmacokinetic considerations. It is 
currently unclear how best to administer an OV to obtain the optimal therapeutic 
response while prioritising patient safety. The route designed to maximise 
efficacy based on the historical rationale in which oncolysis is paramount may 
vary from that designed to facilitate immune-mediated tumour clearance. 
The only robustly approved OV as of 2018, T-VEC and to a lesser extent H101, 
are administered by direct injection into the lesion (i.t.). Intuitively, delivery of 
virus directly into tumour beds would appear to be the most capable of 
maximising virus titre in tumour tissue, while circumventing off-target toxicity in 
normal cells. It does not appear that i.t. T-VEC injection leads to substantial 
viraemia, although it remains possible that a delayed viraemia may occur 
secondary to explosive amplification within the tumour (Ott and Hodi, 2016). OV 
administered i.t., including T-VEC and JX-594, can elicit regression of non-
injected lesions in the absence of viraemia, indicative of abscopal effects 
mediated by the immune system (Andtbacka et al., 2016; Park et al., 2008). 
However, the degree of systemic anti-tumour immunity generated by i.t. OV 
may be sub-maximal. Responses to T-VEC were observed in 15% of visceral 
metastases, compared to 64% of injected lesions (Andtbacka et al., 2015b). 
Further, and perhaps more important, the use of i.t. administration immediately 
restricts the range of tumour types and anatomical sites that can be targeted to 
those that are readily accessible through the skin, or can be safely targeted 
using ultrasound guidance (Chang et al., 2012). A range of other administration 
routes have been tested for OV delivery: ovarian cancer has been targeted with 
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intraperitoneal measles virus (Galanis et al., 2010), mesothelioma by 
intrapleural HSV1716 (Danson et al., 2017), and bladder cancer by intravesical 
adenovirus (Burke et al., 2012). Although they may prove marginally more 
practical than i.t. delivery, these modes of administration are utilised against 
local or regionally disseminated disease, limited to specific cancer types, and 
are anatomy-dependent. 
Compared to local delivery, the systemic administration of virus into the 
bloodstream would appear to have the greatest potential to access 
disseminated tumour cells within the vascular system or distant organs. This is 
of clinical importance given that metastasis is estimated to be the cause of 90% 
of cancer-related deaths (Mehlen and Puisieux, 2006). Oral intake, by far the 
most commonly used and convenient route of systemic drug administration, 
appears the least suited to OV therapy given the need for virus to gain tumour 
access, and the ability of the gastrointestinal system to inactivate virus. 
Vascular injection is therefore the preferred method of systemic delivery, being 
only mildly more impractical and invasive than taking a pill, and far less so than 
most locoregional administration routes which demand significant clinical 
support.  
An exploration of the course taken by an i.v.-administered OV reveals the 
numerous anatomical challenges required for the virus to persist and generate 
therapy. Once dumped in the bloodstream, the OV bolus is immediately diluted. 
Complement and any antiviral antibodies rapidly opsonise the virus, while the 
virus also interacts with the cellular components of blood. Virions that remain 
free must evade the reticulo-endothelial system in the liver and spleen. To 
access tumour cells outside the vasculature, free or cell-associated virus must 
take advantage of the high permeability of tumour capillaries (Fang et al., 2011) 
to extravasate, and subsequently negotiate the aberrant tumour matrix to reach 
its target population. Therefore circulatory pharmacokinetics, virus clearance, 
and practical barriers to viral egress must all be considered. Tailoring the dosing 
and scheduling of i.v. delivery over time has allowed us to maximise circulating 
levels of virus and mitigate against the occasionally significant flu-like side 
effects (Calvo et al., 2014; Small et al., 2006).  
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Critically, recent translational studies reliably demonstrate that the nucleic acid 
and proteins of OV (such as reovirus) can be identified in patient tumour 
samples after i.v. administration (Adair et al., 2012; Samson et al., 2018), and 
that systemic therapy is capable of generating the long-lasting remission of 
widespread disease (Russell et al., 2014). 
 
2.5.2 Anti-tumour or antiviral immunity? 
The viraemic state established immediately after i.v. delivery allows an OV to 
provoke inflammatory effects upon cells in peripheral blood. These agents are 
immune adjuvants; recognition of viral motifs by PRR engages functional 
antiviral signalling within immune cells, characterised by IRF3/7 and NF-κB 
activation and synthesis of pro-inflammatory cytokines and IFN, which are 
consistently upregulated in the serum of reovirus-treated patients (Samson et 
al., 2018; White et al., 2008). These soluble factors are known for their ability to 
promote the maturation of APC, and the activation of NK and T cells, as 
evidenced by the upregulation of CD69 on patient NK cells (El-Sherbiny et al., 
2015). 
These initial inflammatory processes are classical innate responses to a viral 
pathogen, and in the absence of a subsequent adaptive component are not 
inherently classified as ‘anti-tumour’ or ‘antiviral’. They become so as a result of 
adaptive events. This is particularly well demonstrated in the humoral response 
to virus, characterised by massive production of virus-binding immunoglobulins. 
The key event is the recognition of virus-specific epitopes by immature B 
lymphocytes, triggering their maturation into antibody-secreting plasma cells. 
The process is reinforced by activated helper T cell signalling (Mari et al., 2013) 
and the direct influence of type I IFN (Braun et al., 2002), both of which are 
induced by virus. The corresponding process on the side of cellular immunity is 
the generation of virus-specific CTL, designed to identify and kill infected cells. 
While such ‘antiviral’ responses are evolutionarily designed as strategies to 
combat the invading pathogen alone, it is increasingly clear that they are 
fundamental to the efficacy of OV because of their overlap with ‘anti-tumour’ 
processes. The activation and recruitment of immune cells out of the 
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vasculature is normally involved in the resolution of infection in the lymphatic 
system. Lymphocyte extravasation is also routinely observed following 
administration of OV (Ribas et al., 2017). In a recent phase I study of i.v. 
reovirus, 48-72 hours after infusion there was an increase in transcripts of the 
pro-recruitment chemokines CCL3/4 (MIP-1α/β) in tumour RNA, and in the 
expression of the adhesion molecule ICAM-1 by T cells (Samson et al., 2018). 
Along with CD68+ myeloid cells, tumours of reovirus-treated versus control 
patients appeared to contain a higher number of CD8+ T cells, whose presence 
is strongly associated with superior outcomes (Gooden et al., 2011). 
Collectively the evidence suggests that, as immune adjuvants, OV promote 
leukocyte infiltration into tumours and thus support tumour immune surveillance. 
Immune responses to virus that have anti-tumour effects are also elicited by OV 
within the tumour itself. For instance, it is not just cytotoxic T cells reactive to 
tumour antigen (liberated by oncolysis) that may kill other tumour cells. CD8+ T 
cells specific for virus antigen may also be able to recognise and kill infected 
cells that express such antigens, even before oncolysis can take place. 
Similarly, the recognition of virus-infected tumour cells by CD4+ T cells promotes 
their activation of DC by secretion of IFN-γ, or of CD8+ T cells via secretion of 
IL-2 or ligation of CD40. As both malignant transformation and viral infection 
promote downregulation of MHC molecules, an OV-infected tumour cell may 
have sufficiently low MHC-I to evade T cell recognition and killing. However, as 
a result, this increases the risk of NK cell-mediated cytolysis. Consequently, 
even if an OV does not itself induce cell death, it may subvert antiviral 
responses to deliver anti-tumour effects. 
Compared to the cell-mediated response to OV, humoral immunity would 
appear less well suited to being harnessed against a tumour. Because of the 
size of the typical therapeutic OV infusion (109-1010 pfu), B cell mobilisation and 
antibody production occurs rapidly and on an enormous scale. From a not-
insubstantial baseline, anti-reovirus antibody titre following infusion commonly 
increases ~1,000-fold (Adair et al., 2012). Antibody generation is greater in 
response to i.v. than i.t. injection, and is dose-dependent (White et al., 2008). In 
the context of natural reovirus infection, systemic antibody generation is 
fundamentally protective (Sherry et al., 1993). Virus clearance is normal in mice 
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lacking CD8+ T cells, but is significantly delayed in B cell-deficient mice (Barkon 
et al., 1996). Protection is predominantly attributed to the ability of neutralising 
antibodies (NAb), mainly IgG, to impair viral binding and entry into target cells.  
 
2.5.3 Modulation of antiviral immunity  
Correspondingly, in the context of virotherapy, there is evidence from studies 
using reovirus (Qiao et al., 2008b) and other OV (Chen et al., 2000; Tsai et al., 
2004) that circulating antiviral antibodies can impair viral persistence and 
spread to tumours. This is relevant even for seronegative individuals as, unless 
therapy can be obtained by a ‘one-shot cure’ (Russell et al., 2014), NAb arise 
prior to subsequent cycles of OV. Regardless, most individuals are seropositive 
for reovirus, making NAb an unavoidable factor in i.v. therapy.  
Consequently, with the view that NAb are universally detrimental to OV, various 
strategies have been adopted to suppress the influence of antiviral immunity. 
Perhaps the simplest is the use of animal pathogens such as Newcastle 
disease virus (NDV) and vesicular stomatitis virus (VSV), which combine the 
ability to replicate in human tumour cells with low seroprevalence. The use of 
multiple virus serotypes or even entirely different viruses should in theory allow 
the virus delivered second to evade the antibody response to the first. This 
approach is particularly applicable to adenovirus, given that over 50 serotypes 
that infect humans are available (Bangari and Mittal, 2006). As measles virus 
only has one serotype, a variation on the ‘serotype switching’ strategy has been 
devised by creating chimaeric viruses with mutated or homotypic envelope 
glycoproteins, which permit evasion of NAb (Lech et al., 2014; Miest et al., 
2011). 
For reovirus, the range of NAb evasion strategies is more limited. Within the 
mammalian Orthoreoviridae, only three distinct serotypes exist, and NAb 
appear cross-reactive between the three (Virgin and Tyler, 1991). Interestingly, 
the possibility of using avian reoviruses as OV has recently been raised as a 
solution (Kozak et al., 2017). Similarly, although mutations in surface proteins 
can be made (Shmulevitz et al., 2012), the limited pliability of the reovirus 
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genome has largely prevented the generation of variants capable of evading 
antibody detection. 
As a result, efforts to circumvent humoral immunity in aid of reovirus have 
centred around the use of immunosuppressive chemotherapy, particularly 
cyclophosphamide (CPA). CPA is an alkylating agent which at low doses can 
deplete Treg and at higher doses can kill or profoundly suppress the effector 
functions of all lymphocytes, including the production of antibody by B cells 
(Hurd and Giuliano, 1975; Varkila and Hurme, 1983). In preclinical models, CPA 
successfully curtails the antibody response and facilitates the persistence and 
delivery of OV including reovirus, measles virus and HSV (Ikeda et al., 1999; 
Peng et al., 2013; Qiao et al., 2008b). CPA and other chemotherapy agents 
have been used alongside i.v. reovirus in clinical trials; some focusing on the 
antineoplastic effects of both (Comins et al., 2010), and others explicitly using 
chemotherapy as a modulator of anti-OV NAb. These trials were able to show 
attenuation of anti-reovirus NAb by chemotherapy (Karapanagiotou et al., 2012; 
Lolkema et al., 2011), with the exception of one phase I trial employing CPA as 
a bolus (Roulstone et al., 2015). 
It is difficult to draw solid conclusions from these trials as to the potential 
therapeutic benefit of NAb suppression for reovirus therapy, due to their small 
scale and lack of comparator groups, and the fact that chemotherapy may 
contribute to anti-tumour efficacy aside from its effect on NAb levels. In fact, 
across OV, pre-clinical and clinical evidence that circulating NAb entirely 
precludes viral efficacy is weak. After i.v. infusion of adenovirus, which also has 
a high seropositivity rate, tumour antigen-specific immune responses were 
generated regardless of patient NAb status (Morse et al., 2013). Similarly, the 
efficacy of oncolytic HSV is not lost in NAb-bearing animals, and NAb titre does 
not appear to predict response in patients (Markert et al., 2014). 
Early pre-clinical studies of the in vivo potential of reovirus indicated no 
difference in tumour regression between reovirus-naïve and -immune mice 
(Coffey, 1998). Indeed, the enhancement of reovirus therapy by chemotherapy 
in murine melanoma was shown to be independent of NAb titre (Pandha et al., 
2009). In patients, reovirus persists in the bloodstream of seropositive 
individuals after i.v. infusion, often in association with immune cells (Adair et al., 
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2012; Roulstone et al., 2015). Moreover, in spite of NAb, reovirus gains access 
to tumour beds. In the recent REO-013 Brain trial, after a single viral infusion, 
evidence of reovirus was found in 6 of 9 brain tumours by IHC and 9 of 9 
tumours by electron microscopy (Samson et al., 2018). In its predecessor REO-
013, reovirus protein was found in 9 of 10 colorectal liver metastases by IHC 
(Adair et al., 2012). In REO-020, it was in patients exhibiting some of the 
highest NAb titres that reovirus was successfully detected (Galanis et al., 2012). 
Thus it would seem that the elimination of circulating NAb is not essential for 
effective viral delivery. NAb also play an important role in controlling toxicity. In 
mice with NAb ablated by CPA, reovirus replication in the heart and other 
organs results in lethality, mirroring observations in B cell-deficient mice (Qiao 
et al., 2008b). Although not severe, the identification of occasional hepatic and 
cardiac toxicities in trials combining reovirus with chemotherapy emphasise the 
importance of NAb in systemic virotherapy (Lolkema et al., 2011). It is also 
important to note that immunosuppressive agents such as CPA dampen cell-
mediated immunity (Varkila and Hurme, 1983), and may therefore compromise 
the development of anti-tumour immunity which is critical to long-term 
therapeutic benefit (Prestwich et al., 2009b). 
 
2.5.4 The monocyte as a Trojan horse 
Of the cell types in peripheral blood, the monocyte population is key in the 
context of viral infection. Monocytes represent a cell subset that originate from 
myeloid precursors in the bone marrow during haematopoiesis (Hettinger et al., 
2013). They enter the bloodstream where they comprise roughly 10% of the 
nucleated cells, and undergo constant turnover, with a short half-life of 1-5 days 
(Haller Hasskamp et al., 2005). Three sub-populations have recently been 
defined, based on expression of the lipopolysaccharide receptor and classical 
monocyte marker CD14, and the Fc receptor CD16 / FcγR III (Wong et al., 
2011). Along with CD14 itself which is activated by bacterial motifs, monocytes 
express a variety of PRR, including RLR and a number of TLR, consistent with 
their remit as mediators of innate pathogen surveillance. Circulating monocytes 
act as a reservoir: upon receiving the appropriate (often inflammatory) signals, 
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they begin the process of differentiation towards the myeloid-derived DC or 
macrophage lineage, and extravasate in order to traffic to lymph nodes 
(typically DC) or to become tissue-resident macrophages. Broadly, while the 
macrophage is characterised by its phagocytic capacity and the DC by antigen 
presentation, their precursor monocyte retains both abilities (Cros et al., 2010; 
Kim and Braciale, 2009). 
Among human PBMC, the monocyte is the primary cell type targeted by many 
viruses, both oncolytic and otherwise (Esolen et al., 1993; Hou et al., 2012; Kou 
et al., 2008). Ex vivo, adenovirus associates rapidly with blood monocytes 
(Lyons et al., 2006). Using a representative panel including VSV, influenza and 
vaccinia viruses, between 50-100% of monocytes were infected in vitro, versus 
0-25% in all other major PBMC subsets (Hou et al., 2012). In this study, viral 
infection of monocytes provided a potent stimulus for differentiation to DC, 
which were then able to prime an antiviral T cell response. VSV exerts similar 
phenotypic effects (Tomczyk et al., 2018). Thus it has been proposed that the 
readily infectable nature of the myeloid phagocytes in blood represents an 
evolutionary strategy, in that by allowing cellular entry and often abortive or 
limited viral replication, they promote inflammatory signalling and differentiation 
that actually facilitates the immune response (Yewdell and Brooke, 2012). 
Evidence suggests that the interaction between human blood monocytes and 
reovirus may be similarly dynamic. Monocytes are major producers of IFN-α on 
recognition of viral motifs, as evidenced by their vigorous response to the 
dsRNA analogue poly(I:C) (Hansmann et al., 2008). A significant elevation in 
IFN-α is observed in patient serum obtained two days after a single i.v. infusion 
of reovirus (Samson et al., 2018). Further, reovirus-induced monocyte 
production of IFN-α is vital in driving killing of tumour cell targets by patient-
derived NK cells (Adair et al., 2013; El-Sherbiny et al., 2015; Parrish et al., 
2015). However, in mice, i.v. administration of reovirus has also been implicated 
in the accumulation of suppressive myeloid cells in tumours, suggesting that the 
interaction of the myeloid compartment as a whole may be more complex than 
anticipated (Clements et al., 2015). 
Like other cells of the innate immune system, monocytes are endowed with Fc 
receptors – proteins typically at the cell surface which, among other functions, 
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enable their interaction with and response to opsonised pathogens. Fc 
receptors bind to the Fc domain of their corresponding immunogloblin 
subclasses: FcαR for IgA, FcεR for IgE, and multiple FcγR for IgG. In doing so, 
Fc receptors link humoral and cellular immunity, by enabling cells to respond to 
antibody-tagged material. For instance, the degranulation of mast cells and 
basophils in the allergic response is mediated by the ligation of FcεR by IgE-
opsonised allergen (Rivera et al., 2008). Specific FcγR isoforms allow NK cells 
to recognise IgG-opsonised cells prior to killing by ADCC (Srivastava et al., 
2013).  
There are multiple FcγR isoforms in humans, encoded by FCGR1 (CD64, FcγR 
I), FCGR2A-C (CD32, FcγR IIa-c) and FCGR3A/B (CD16, FcγR IIIa-b) 
respectively (Guilliams et al., 2014). The neonatal Fc receptor (FcRn) is an 
additional molecule responsible for recycling IgG. Most FcγR have activatory 
functions, such as the NK cell-expressed FcγR IIIa, while the FcγR IIb present 
on B cells and most other leukocytes acts as an important inhibitory checkpoint 
(Nimmerjahn and Ravetch, 2008). FcγR signalling is triggered by their spatial 
clustering upon binding of aggregated IgG, which signals opsonised material or 
‘immune complexes’; the exception being FcγR I, whose higher binding affinity 
allows it to be stimulated by monomeric IgG. Activating motifs in the FcγR-
associated γ-chain instigate intracellular phosphorylation cascades, and these 
elicit effector functions which are cell type-specific. The response of myeloid 
cells is characterised by inflammatory cytokine release and phagocytosis of the 
immune complex, ostensibly leading to its degradation and the presentation of 
antigen (Amigorena and Bonnerot, 1999). 
This same process designed to facilitate pathogen clearance is simultaneously 
implicated in a phenomenon that promotes virus persistence, termed antibody-
dependent enhancement (ADE). Viewed from a viral perspective, if it can evade 
subsequent degradation, antibody binding and uptake via Fc receptors (or 
complement receptors) theoretically provides an increased number of host cells 
in which to propagate. The ability of monocytes to permit ADE was first 
identified in the context of dengue virus infection, which has become a 
prototypical example. During acute dengue infection either ex vivo or in the in 
vivo scenario, human monocytes are principal viral targets and display an 
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activated phenotype (Durbin et al., 2008; Kou et al., 2008). The presence of 
anti-dengue antibodies at a defined titre actively promotes the infection of 
monocytes, which amplify the virus and precipitate more severe disease (Sun et 
al., 2011; Tsai et al., 2014). Recently FcγR IIIa (FCGR3A) was specifically 
identified as the causative Fc receptor (Wang et al., 2017). Far from being an in 
vitro process, epidemiological studies demonstrate that this paradoxical 
phenomenon is one of real clinical relevance (Katzelnick et al., 2017) and even 
questions the safety of antiviral vaccines which elevate antibody levels 
(Ferguson et al., 2016). 
ADE has clinically significant consequences in the context of a natural viral 
infection, begging the question: wouldn’t the influence of ADE be 
proportionately greater on the outcome of a massive, non-physiological infusion 
of virus? There appears no fundamental reason why ADE should not be 
applicable to a virotherapy scenario. In addition to dengue, the relevance of 
ADE has been demonstrated in diverse virus types, from the highly pathogenic 
blood-borne Ebola to seasonal respiratory viruses (reviewed in Taylor et al., 
2015). This includes viruses with oncolytic properties, such as Coxsackievirus 
(Hober et al., 2001). Indeed, by conjugation to a non-neutralising anti-VSV 
antibody, the ability of oncolytic VSV to infect myeloid cells and extend the 
survival of tumour-bearing mice when given i.v. can be increased (Eisenstein et 
al., 2013). The amenability of reovirus to antibody-dependent cell entry outside 
the oncolytic context has been assessed in two studies, which have shown that 
the virus is capable of infecting Fc receptor-transfected cells (Danthi et al., 
2006) and mouse macrophages (Burstin et al., 1983) via the binding of 
antibody. This raises the possibility that human monocytes may remain able to 
be infected even in the presence of anti-reovirus antibody. 
 
2.5.5 Cell carriers 
Concern over the detrimental effect of antibodies and complement on the 
persistence of OV in the bloodstream spawned the concept of using cellular 
chaperones to deliver virus to tumours. This is regarded as a natural strategy, 
which is well matched to the aim of delivering viruses systemically to gain 
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maximum therapeutic benefit. The overarching rationale is that these so-called 
‘cell carriers’ will shield the viral payload from antiviral effectors, and will home 
to tumour beds in order to deliver it. The ability of the carrier to amplify virus on 
the way to the tumour, and to exert its own anti-tumour effects once there, are 
viewed as a potential bonus. A wide repertoire of immune and non-immune cell 
types have been shown to be capable of OV carriage. Tumour cells themselves 
have been courted as carriers, on the basis that they may be best able to 
amplify virus and to stimulate anti-tumour immunity (Guo et al., 2010; Liu et al., 
2010; Power et al., 2007). The tumour-homing ability of progenitor cells, 
particularly neural and mesenchymal stem cells, is a particularly attractive 
property that appears to facilitate the delivery of their adenovirus cargo to brain 
tumours (García-Castro et al., 2010; Tyler et al., 2009). 
Immune cells are another population with excellent tumour trafficking potential, 
and offer the potential advantage of generating anti-tumour effects once there: 
two traits that OV carriage may itself promote. A plethora of immune 
populations have been tested as carriers. These are typically autologous cells 
that are loaded with virus ex vivo prior to i.v. infusion. T cells represent an 
attractive option given their ability to become tumour-specific and contribute to 
therapy. VSV has been successfully delivered to murine melanoma metastases 
by association with T cells, providing therapy that was superior to either 
unloaded T cells or VSV alone (Qiao et al., 2008a; Qiao et al., 2008c). Similarly, 
cytokine-induced killer cells, a heterogenous NK/T cell population, have been 
used as carriers to deliver both adenovirus (Yang et al., 2012) and vaccinia 
virus (Thorne et al., 2006) and yield tumour regression in mice. 
These effector cell populations are poorly phagocytic, if at all, and typically allow 
virus to ride on, rather than within, the carrier cell. By contrast, myeloid cells are 
far more amenable to internalisation, which may offer increased viral protection. 
They are also capable of ‘regurgitating’ internalised antigen intact, on demand 
(Le Roux et al., 2012). Myeloid cells evaluated as OV carriers include MDSC, 
which deliver VSV cargo to tumours following systemic administration and 
simultaneously acquire a more ‘M1’ phenotype which promotes tumour killing 
(Eisenstein et al., 2013). Similarly, human monocyte-derived macrophages 
serve as hosts for vaccinia virus dissemination (Byrd et al., 2014), and are 
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capable of conveying adenovirus to inhibit the growth of murine prostate 
tumours (Muthana et al., 2011, 2013). Human monocytes themselves have 
been used for the carriage of measles virus to human ovarian and myeloma 
xenografts, which prolongs mouse survival (Iankov et al., 2007; Peng et al., 
2009). With the exception of vaccinia (Byrd et al., 2014), this group of cells 
appears to resist large-scale amplification of their OV cargo – in contrast to 
murine myeloid DC and monocytes (Ilett et al., 2014, 2009) – although abortive 
or low-level replication is commonly observed. 
When administered i.v., reovirus associates with a number of immune cell 
populations in blood. In patient blood sampled during a single therapeutic 
infusion, reovirus RNA was detected on monocytes, NK cells, B cells and 
granulocytes (Samson et al., 2018). Indeed, replication-competent reovirus 
associates with PBMC in patients known to be seropositive for the virus (Adair 
et al., 2012; Roulstone et al., 2015). These observations have given rise to 
strategies aiming to use PBMC as reovirus carriers, based on the hypothesis 
that they may allow the virus to evade neutralisation. Human PBMC were found 
to be capable of reovirus ‘hitch-hiking’, and its subsequent delivery to kill 
colorectal tumour targets in vitro, in the presence of neutralising serum, 
supplemented by their ability to trigger tumour cell lysis by patient-derived NK 
cells (Adair et al., 2013). A subsequent study used a heterogenous population 
of lymphokine-activated killer cells and DC to demonstrate similar results 
against ovarian targets (Jennings et al., 2014). 
Having found that ex vivo-loaded murine DC are able to deliver reovirus for the 
clearance of disseminated melanoma (Ilett et al., 2009), it was demonstrated 
that, in the presence of neutralising serum, human monocyte-derived DC 
internalise the virus and deliver it to kill melanoma targets (Ilett et al., 2011). As 
the therapeutic use of cells virus-loaded ex vivo is expensive and requires 
complex regulatory oversight, a new approach of ‘in vivo loading’ was 
developed, predicated on the use of circulating monocytes as potential carriers. 
In mice with previous exposure to reovirus – like most human adults – i.v. 
reovirus associates predominantly with the myeloid (CD11b+) fraction, 
consistent with a role for monocytes as primary viral targets (Ilett et al., 2014). 
Hence a treatment schedule was designed in which intraperitoneal GM-CSF 
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was administered in order to mobilise this pool in circulation, prior to i.v. reovirus 
infusion. GM-CSF pre-conditioning successfully increased both myeloid cell 
trafficking and viral delivery to B16 melanoma tumours (Ilett et al., 2014). The 
resulting regression of tumours and extension of survival was shown to be 
dependent on both the myeloid and NK cell fractions. 
Most significantly, the therapeutic value of the GM-CSF/reovirus combination 
was only observed in mice pre-immunised to the virus, but not in reovirus-naïve 
mice. There also appeared to be a role for Fc receptors, given that Fc receptor 
blockade abrogated the killing of melanoma targets in vitro (Ilett et al., 2014). 
Viewed together, and in light of the capacity of monocytes to take up immune 
complexes, these data suggested a model in which systemically administered 
reovirus is rapidly bound by antibody and via Fc receptors gains access to 
circulating monocytes, which deliver the virus to tumour sites and initiate 
oncolytic and/or immune-mediated killing. 
If proven, this hypothesis represents a highly novel way in which antiviral 
immunity may potentiate anti-tumour efficacy of OV. It is consistent with 
burgeoning data using other OV, where pre-immunity to NDV enhances therapy 
in mice (Ricca et al., 2016), and has prompted the prospective evaluation of 
reovirus pre-immunisation as a therapeutic element, alongside the GM-
CSF/reovirus regimen, in clinical trial for melanoma (NCT03282188). It is not 




2.6 Aims of the project 
This study aimed to investigate the hypothesis that primary human monocytes 
can permit the carriage of antibody-neutralised reovirus, and ultimately generate 
melanoma cell killing in vitro and in vivo. 
The specific elements of this multi-faceted ‘hitch-hiking’ process to be examined 
were: 
i. The formation of reovirus-antibody (reo-NAb) complexes within patient-
derived, reovirus-treated serum 
ii. The ability of monocytes to carry and deliver reo-NAb for melanoma cell 
oncolysis in a novel in vitro assay 
iii. The molecular mediators enabling monocytes to interact with reo-NAb 
cargo 
iv. The impact of reo-NAb carriage upon monocyte phenotype 
v. The capacity of reo-NAb to generate immune-mediated tumour cell killing 




 Materials & methods 
3.1 Cell culture 
3.1.1 Method 
Cell cultures were maintained in a Sanyo CO2 incubator (Sanyo, Loughborough, 
UK) at 37°C in a humidified atmosphere of 5% CO2 in air. Cells were 
manipulated under aseptic conditions using Nuaire (Plymouth, UK) Class II 
biological safety cabinets, Pipetman pipettes (Gilson; from Anachem, 
Bedfordshire, UK) and Pipetboy pipette guns (Integra, Berkshire, UK). Cabinets 
were cleaned before and after use with 2% (w/v) Virkon (Thermo Fisher, 
Loughborough, UK) and 70% (v/v) ethanol (Sigma, Dorset, UK). Cells were 
cultured in vented plastic tissue culture flasks (25, 75 or 150 cm2) or well plates 
(Corning, High Wycombe, UK). Adherent cell lines were passaged near 
confluence twice per week, first by washing with phosphate-buffered saline 
(PBS) (Sigma), then adding a 1X solution of trypsin-EDTA (Sigma) in Hanks’ 
balanced salt solution (HBSS) (Sigma) to detach. Cells were centrifuged in an 
Eppendorf 5810R centrifuge (Eppendorf, Leicestershire, UK), at 400 g for 5 
minutes at room temperature (RT), unless stated otherwise. Cells were 
harvested and washed using 15 ml or 50 ml sterile plastic Falcon tubes 
(Corning) or 25 ml plastic universal tubes (SLS, Nottingham, UK). A Nikon 
Eclipse TS100 microscope (Nikon, Kingston upon Thames, UK) was used to 
view cells, which were counted using a Neubauer chamber (Marienfeld, 
supplied by Thermo Fisher) following staining with 0.2% (v/v) trypan blue 
(Thermo). Light microscopy images were obtained using a Nikon DS-Fi1 
camera. Cells were regularly tested for the presence of mycoplasma using 
Mycoalert (Lonza, Slough, UK) and were confirmed to be free from 
contamination. 
 
3.1.2 Cell lines and media 
Cell lines and primary cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) or Roswell Park Memorial Institute (RPMI)-1640 (Sigma); this 
was supplemented with 10% (v/v) foetal calf serum (FCS) (Life Technologies, 
Thermo Fisher) which had been heat-inactivated at 56°C for 30 minutes. The 




Cells were suspended in freezing medium (FCS + 10% (v/v) dimethyl 
sulphoxide (DMSO) (Merck, Nottingham, UK)) and 1 ml aliquots added to 
cryovials (Nunc, Thermo Fisher) which were frozen at −80°C prior to transfer to 
liquid nitrogen storage the following day. Cells were recovered by rapid thawing 
of aliquots at 37°C, addition of excess fresh medium, centrifugation and transfer 
into tissue culture flasks in further fresh medium. 
 
3.1.4 Preparation of PBMC by density gradient separation 
Human peripheral blood leukapheresis products (cones) were collected from 
healthy blood donors, who were all recruited locally through the NHS Blood and 
Transplant Service in Leeds (NHSBT). Cones were rested overnight, then 
diluted in an equal volume of HBSS and layered gently on to Lymphoprep (Axis-
Shield, Dundee, UK) in a 50 ml tube at a 2:1 ratio. Tubes were centrifuged at 
800 g for 25 minutes at RT, and the mononuclear cell (PBMC) layer harvested 
with a Pasteur pipette. PBMC were washed with 50 ml HBSS, centrifuged (400 
g, 10 minutes), then washed again and centrifuged (300 g, 5 minutes). Cells 




3.2.1 Use and storage 
All virus stocks were stored in PBS at 4°C (for up to 3 weeks) or at −80°C (for 
long-term storage). Virus stock sources, titres, and susceptible cell lines for 
plaque assay and neutralisation assay are shown in Table 2. 
 
3.2.2 UV inactivation of virus 
To render virions incompetent of replication, 100 µl aliquots of virus in a 96-well 
plate were irradiated with UV-C (λ = 254 nm) for 2 minutes, using a Stratalinker 
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UV 1800 (Stratagene, Cambridge, UK) to give a 500 mJ dose. Virus was 
confirmed to be non-replicative by plaque assay (section 3.7). 
 
3.3 Sources of antiviral antibody 
3.3.1 Use and storage 
Serum was obtained with ethical approval and consent from patients enrolled in 
clinical trials: for reovirus, the REO-013 Brain trial (ISRCTN70443973); for 
CVA21, the STORM trial (NCT02043665). For REO-013 Brain, ethical approval 
was obtained through NHS REC, via NRES Committee Yorkshire & The 
Humber – Leeds East (reference number 12/YH/0402). The REC granted an 
extension to ethical approval for the study of patient samples (reference number 
18/LO/0080). 
Blood was taken one to six weeks following the final intravenous (i.v.) infusion 
of virus and allowed to clot in red-topped Vacutainer tubes (BD, Berkshire, UK). 
Serum was obtained by centrifugation (800 g, 10 minutes) and stored at −80°C 
until use. For this study, ten serum samples were available from six individual 
REO-013 Brain trial patients, and five serum samples from four individual 
STORM trial patients. Serum was limited, with approximately 5 ml of each 
sample available. 
Pleural fluid from patients treated with repeat intrapleural HSV1716 (trial 
NCT01721018) was provided by Joe Conner (Virttu Biologics) with whom a 
Material Transfer Agreement is in place. Pleural fluid was collected one to six 
weeks following the virus infusion, passed through a 0.22 µm filter (Merck) and 
stored at −80°C until use. Three pleural fluid samples (approximately 3 ml each) 
were available for use. 
Serum (for reovirus and CVA21) and pleural fluid (for HSV1716) were used as 
shown in Table 3.  
 
3.3.2 Neutralisation assay 
The neutralising capacity of the three antibody sources listed in Table 3 was 
tested on virus-susceptible cell lines by a modified neutralisation assay protocol 
(Yang et al., 2004). Halving dilutions of serum or pleural fluid were made in 
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DMEM-10 and 100 µl added to sub-confluent monolayers of susceptible cells 
(see Table 2) in a 96-well plate. Virus was diluted in serum-free DMEM to 
achieve MOI 0.05 (reovirus and CVA21) or MOI 1 (HSV1716), unless stated, in 
a final volume of 200 µl per well. Control wells without virus were included for all 
plates to exclude the possibility that the sera or pleural fluid were cytotoxic. 
After 72 hours, 20 µl of the tetrazolium dye MTT was added to each well. After a 
further 4 hours, the medium was removed and replaced with 150 µl DMSO to 
solubilise formazan crystals (5 minutes), after which a Multiskan EX microplate 
reader (Thermo Fisher) was used to assess optical density at λ = 540 nm. 
Readings were used to infer metabolic activity and thus viability of the treated 
cell population. Cell viability was calculated by normalising values to wells free 
from virus or serum/pleural fluid in each case. 
To assess the involvement of heat-labile factors in serum neutralisation of 
reovirus, patient sera were incubated in a 56°C water bath for 30 minutes in 
order to inactivate complement. Inactivated and non-inactivated sera were 
immediately assayed for neutralising capacity as above. 
 
3.3.3 Depletion of antibody isotypes from anti-reovirus serum 
To determine the contribution of specific immunoglobulin classes to reovirus 
neutralisation, individual classes were depleted using agarose bead-conjugated 
antibodies specifically targeting the human γ- or α-chain (Sigma). Serum from 
reovirus-treated patients was diluted 1:1 in PBS and incubated with bead-
conjugated antibodies for 90 minutes at RT, on an SRT9 tube roller (Stuart, 
Staffordshire, UK). Depleted samples were obtained by centrifuging to remove 
beads (3,000 g, 15 seconds) and harvesting the supernatant. Antibody 
depletion was confirmed by enzyme-linked immunosorbent assay (ELISA) using 
human IgG/IgA ELISA kits (Mabtech, via 2B Scientific, Oxfordshire, UK) 
(section 3.9.2) and the effect of depletion assessed by neutralisation assay 
(section 3.3.2).  
 
3.3.4 Immunoprecipitation of reovirus 
3.3.4.1 Detection of anti-reovirus antibodies in serum 
Reovirus was added to anti-reovirus patient serum at a 1:5 (v/v) ratio, i.e. 1 µl 
serum per 106 pfu, and incubated at 37°C for 3 hours. Screw-cap 1.5 ml 
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Eppendorf tubes were first blocked with 3% (w/v) bovine serum albumin (BSA) 
for 1 hour at 4°C, prior to the addition of reovirus-antibody samples. Pre-washed 
protein A resin beads (GenScript, via 2B Scientific) in excess were mixed with 
samples and allowed to bind for 2 hours at 4°C on an SB3 rotator (Stuart). 
Samples were centrifuged (400 g, 2 minutes) and washed four times in 0.1% 
(v/v) Triton-X in PBS, then boiled (95°C, 5 minutes) in loading buffer (Table 7) to 
dissociate IgG from beads, and centrifuged (13,200 g, 2 minutes) using an 
Eppendorf 5415D microcentrifuge to yield supernatant for analysis.  
 
3.3.4.2 Detection of endogenous reo-NAb complexes in serum 
Serum samples, taken 24 hours following i.v. virus infusion, were directly 
combined with protein A beads, and centrifuged, washed, boiled and purified 
antibodies harvested as above. 
 
 
3.4 In vitro hand-off assay 
3.4.1 Standard protocol 
3.4.1.1 Preparation of target cells 
Confluent flasks of target cells (as stated) were trypsinised (section 3.1.1) and 
counted. Cell density was adjusted to 1.5 x 105 cells/ml in DMEM-10, and 2 ml 
added to each well of a 6-well plate. After 24 hours, any floating cells were 
removed by replacing medium with fresh DMEM-10, and treatments added as 
below. 
 
3.4.1.2 Formation of reovirus-antibody complexes 
To form reovirus-antibody complexes (reo-NAb), reovirus was combined with 
patient serum at a ratio known to be neutralising by neutralisation assay on 
L929 cells (section 3.3.2) and by the absence of cell death in target cells treated 
directly with reo-NAb, by flow cytometry (section 3.6.2). Neutralisation was also 
confirmed for complexes formed by CVA21 and HSV1716 (Table 3). In all 
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cases, virus was incubated with serum/pleural fluid for 2-3 hours at 37°C prior to 
loading on to carrier cells. 
 
3.4.1.3 Selection of carrier cells 
PBMC were isolated from leukapheresis cones (section 3.1.4). CD14+ 
monocytes were isolated from PBMC by positive selection with anti-CD14 
microbeads (Miltenyi, Surrey, UK): PBMC were re-suspended in 20 µl MACS 
buffer (Table 7) per 107 cells, and incubated with 5 µl anti-CD14 microbeads per 
107 cells at 4°C for 15 minutes. Cells were washed in excess cold MACS buffer 
and pelleted (300 g, 5 minutes), then re-suspended in 40 µl MACS buffer per 
107 cells and added to pre-rinsed LS columns within a QuadroMACS separator 
(Miltenyi). Columns were washed three times with 3 ml cold MACS buffer, and 
CD14+ cells eluted in 5 ml MACS buffer per column. These were counted and 
washed in excess cold HBSS, then 2 x 106 (in 500 µl, unless otherwise stated) 
transferred to individual universal tubes. Purity of positively-selected monocytes 
was confirmed by flow cytometry (section 3.6.1). 
 
3.4.1.4 Carrier cell loading and co-culture 
Treatments (virus, NAb or the combination) were added to monocytes as 
described, mixed, and tubes returned to 4°C for 2-3 hours to permit adsorption. 
Cells were then washed in 10 ml PBS and pelleted three times (300 g, 5 
minutes). Cell pellets were re-suspended first by flicking, and then gently 
triturating in 500-750 µl RPMI-10. If to be analysed by plaque assay, a set 
volume of monocyte cell suspension was routinely set aside from all conditions 
and stored at −80°C. The remaining cell suspension was then added to wells 
containing pre-seeded target cells (section 3.4.1.1) and co-cultured at 37°C for 
72 hours, unless stated otherwise. Target cell viability was subsequently 





3.4.2 Adaptations of the hand-off assay 
3.4.2.1 Negative selection of monocytes for electron microscopy 
Due to interference from uptake of anti-CD14 microbeads in electron 
microscopy (EM) images, monocyte cells for EM analysis were negatively 
selected using the Human Pan Monocyte Isolation Kit (Miltenyi) as per the 
manufacturer’s instructions. Briefly, after isolation of PBMC (section 3.1.4), cells 
were suspended with 40 µl MACS buffer, 10 µl FcR blocking reagent, and 10 µl 
Biotin-Antibody Cocktail per 107 cells respectively, and incubated at 4°C for 5 
minutes. Subsequently, anti-biotin microbeads (20 µl per 107 cells) and MACS 
buffer (30 µl per 107 cells) were added, and cells further incubated at 4°C for 10 
minutes. 
Labelled non-monocytes were then depleted from PBMC by magnetic 
separation. Cell suspension was added to pre-rinsed LS columns and washed 
three times with 3 ml MACS buffer, the flow-through (enriched monocytes) 
being collected. Purity of the enriched fraction was confirmed by flow cytometry 
(section 3.6.4). 
 
3.4.2.2 Selection of CD16+ and CD16− populations 
Isolation of monocyte subsets from PBMC according to differential CD16 
expression was performed based on a previously described method 
(Frankenberger et al., 2012). 
CD16+ monocytes were isolated from 4 x 108 PBMC per donor using the CD16+ 
Monocyte Isolation Kit (Miltenyi). To deplete CD16+ non-monocytes, PBMC 
were first incubated with 400 µl of FcR Blocking Reagent and Non-Monocyte 
Depletion Cocktail (Miltenyi) respectively in 1.2 ml MACS buffer (hereafter 
‘buffer’) at 4°C for 15 minutes. Cells were washed in excess buffer and 
centrifuged (300 g, 5 minutes). The pellet was re-suspended in 3 ml buffer and 
added to pre-rinsed LS columns. Columns were washed twice with 2 ml buffer, 
retaining the flow-through. Subsequently, CD16+ monocytes were positively 
selected from the enriched PBMC. Cells were pelleted, re-suspended in 2 ml 
buffer, and incubated with 400 µl anti-CD16 microbeads at 4°C for 15 minutes. 
After washing in excess buffer and centrifuging (300 g, 5 minutes), cells were 
re-suspended in 3 ml buffer and added to fresh pre-rinsed LS columns. Three 3 
ml washes were performed with buffer, and positively selected CD16+ 
73 
 
monocytes eluted in 5 ml buffer per column. These were counted and rested 
overnight at 2 x 106 per ml in RPMI-10 to allow beads to dissociate from the 
receptor. Cells were gently mechanically re-suspended in medium using cell 
scrapers (Falcon, Thermo Fisher), washed in HBSS and re-counted prior to 
virus loading as described. 
CD16− monocytes were isolated from 1 x 108 PBMC per donor. First, CD16+ 
cells were depleted using anti-CD16 microbeads: PBMC were incubated with 
200 µl anti-CD16 microbeads in 1 ml buffer (4°C, 15 minutes), then washed in 
excess buffer, centrifuged (300 g, 5 minutes), re-suspended in 1.5 ml buffer and 
added to pre-rinsed LS columns. Columns were washed three times with 2 ml 
buffer, and flow-through retained. These CD16− enriched PBMC were pelleted 
(300 g, 5 minutes), re-suspended in 1 ml buffer and incubated with 200 µl anti-
CD14 microbeads (4°C, 15 minutes). After washing with excess buffer and 
centrifuging (300 g, 5 minutes) cells were transferred to LS columns in 1.5 ml 
buffer. Three 2 ml washes were performed prior to elution of magnetically 
labelled CD14+ monocytes. As for the CD16+ population, cells were rested 
overnight at 2 x 106 cells per ml in RPMI-10, then re-suspended, washed in 
HBSS and re-counted prior to virus loading. 
 
3.4.2.3 Blockade of monocyte virus entry 
For assays in which specific monocyte receptors were targeted, carrier cells in a 
total volume of 150 µl were pre-treated with blocking agents at 10 or 100 µg/ml 
as stated at 4°C for 45 minutes. These blocking agents (Table 4) remained 
present during subsequent incubation with virus/antibody cargo. Washing and 
co-culture with targets was then performed as described (section 3.4.1.4). 
 
3.4.2.4 Target cell killing by monocyte conditioned medium 
After loading with reovirus or reo-NAb at MOI 10 and washing, monocytes were 
either directly added to Mel-624 target cells, or resuspended at 1 x 106 per ml in 
RPMI-10 and cultured in 6-well plate format for 48 hours. The resulting medium 
was aspirated and centrifuged to remove cells (400 g, 5 minutes) to yield 
conditioned medium (CM). Filtered CM (FCM) was generated by passing CM 
through OptiScale-25 Viresolve NFP filters (Merck). Flow cytometry was then 
used as described (section 3.6.2) to analyse the killing of Mel-624 cells after 72 
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hours, by either loaded monocytes, or CM or FCM derived from an equivalent 
number of loaded monocytes. 
 
3.4.2.5 Blockade of virus transmission by monocytes 
To assess the involvement of JAM-A, the JAM-A-expressing Mel-624 line was 
used, being seeded the day before treatment at 1.5 x 105 cells per well (12-well 
plate format). Prior to the addition of loaded monocytes, targets were incubated 
with an azide-free preparation of the J10.4 antibody against JAM-A (Santa 
Cruz), or isotype, at 10 µg per well in DMEM-10. After a 30-minute incubation at 
37°C, loaded and washed carrier cells (section 3.4.1.4) were added for 90 hours 
and co-cultures processed as described (section 3.6.2). 
To assess the involvement of cell-cell contact, a 24-well transwell system was 
used (Corning). Mel-624 cells were seeded in the well base the day before 
treatment at 0.6 x 105 cells per well. Monocytes loaded at MOI 5 (or reovirus or 
reo-NAb alone) were added to the well insert in a volume of 150 µl RPMI-10. 
For ‘no transwell’ conditions, a standard 24-well plate was used. After a 90-hour 
incubation, co-cultures were processed as described (section 3.6.2). 
 
3.4.2.6 Virus loading of monocytes in whole blood 
Blood was taken from healthy donors by venepuncture, and collected in purple-
topped Vacutainer tubes containing EDTA (BD). 9 ml blood was supplemented 
with 500 µl patient-derived serum prior to the addition of 90 x 106 pfu reovirus 
(MOI 10 based on 1 x 106 PBMC per ml blood). Tubes were incubated at 37°C 
for 30 minutes with occasional agitation. Density gradient separation with 
Lymphoprep was then used to obtain PBMC. Myeloid cells were selected as 
before using anti-CD14 microbeads. Both the CD14-selected and -depleted 
fractions were collected, washed in HBSS and analysed by plaque assay on 






3.5 Immune cell stimulation assays 
3.5.1 Co-culture of immune cell populations 
3.5.1.1 Virus-loaded monocytes and whole PBMC 
To broadly assess the influence of virus-loaded monocytes on other human 
PBMC, monocytes were first selected and loaded with antibody, virus or reo-
NAb complexes at MOI 10 for 3 hours at 4°C as described above (section 
3.4.1.4). After washing with PBS, monocytes were re-suspended in RPMI-10 
and counted. 2.5 x 106 cells were either cultured alone in 3 ml RPMI-10 in 6-
well plates, or added to 12.5 x 106 autologous CD14− PBMC (i.e. at a 
physiological 1:5 ratio) in a total of 15 ml RPMI-10 in 75cm2 flasks. Cells were 
cultured for 40 hours at 37°C.  
Medium was then aspirated and centrifuged (300 g, 5 minutes) to obtain cell-
free supernatants, which were stored at −20°C prior to cytokine analysis. 
Plates/flasks were scraped and flushed with PBS to harvest adherent cells, 
which were combined with pelleted cells from suspension. Cells were 
centrifuged again, re-suspended in FACS buffer (Table 7) and 2 x 105 cells 
added to each FACS tube; the cells were stained with antibodies as below 
(Table 8). 
 
3.5.1.2 Virus-loaded monocytes and NK cells 
3.5.1.2.1 Stimulation of monocytes by NK cells 
Monocytes were first positively selected from PBMC according to CD14 
expression (section 3.4.1.3), and the depleted fraction then used for the 
negative selection of NK cells using the human NK cell isolation kit (Miltenyi).  
After loading with NAb, reovirus or reo-NAb (MOI 10), monocytes were washed 
with PBS and cultured at a 2:1 monocyte:NK ratio in RPMI-10 for 48 hours. 
Cells were then harvested and stained with PE-conjugated antibodies against 
activation markers as indicated, in addition to FITC CD11b (Biolegend, London, 





3.5.1.2.2 Stimulation of NK cells by monocytes 
To assess NK cell activation and the specific monocyte-generated factors 
involved, monocytes loaded with reovirus or reo-NAb at MOI 5 (section 3.4.1.4) 
were cultured overnight (16 hours) at 2 x 106 cells/ml in RPMI-10. Cells were 
collected by scraping and flushing with medium, then centrifuged (300 g, 5 
minutes) to obtain conditioned medium (CM). CM was passed through 
OptiScale-25 Viresolve NFP filters (Merck) to generate filtered CM (FCM).  
Prior to the addition of CM/FCM, 1.5 x 106 autologous PBMC were added to 
each well of a 12-well plate in 1 ml RPMI-10. Receptor blocking antibodies 
(Table 4) were added to target PBMC at stated concentrations. After 30 minutes 
at 37°C, CM or FCM was added to wells at a 1:2 (v/v) ratio, and incubated for 
48 hours. Cells were harvested, washed in FACS buffer, and NK cell activation 
quantified by PerCP CD69 staining on the PE CD3−, FITC CD56+ population 
(section 3.6). 
 
3.5.1.2.3 NK cell cytotoxicity 
To assess the ability of virus-loaded monocytes to stimulate NK cell-mediated 
killing of tumour cell targets, monocytes were first loaded with patient serum, 
reovirus or reo-NAb at MOI 10 (section 3.4.1.4). Autologous NK cells were 
obtained from PBMC using a negative isolation kit (Miltenyi) according to the 
manufacturer’s instructions. 2.5 x 106 NK cells were then cultured with or 
without 1 x 106 loaded monocytes in 2 ml RPMI-10. Alternatively, NK cells were 
treated directly with the same agents used to treat monocytes, at the same 
dose. After 40 hours at 37°C, cells were harvested for analysis of NK cell 
cytotoxicity by chromium assay (section 3.5.2) and expression of CD107 as a 
degranulation marker (section 3.6.5). 
 
3.5.2 Chromium release assay 
Cell line targets were trypsinised, and 1 x 106 cells transferred to 50 ml Falcon 
tubes and centrifuged (300 g, 5 minutes). The supernatant was discarded and 
100 µCi of 51Cr (Amersham Biosciences, Buckinghamshire, UK) added. Cells 
were labelled for 1 hour at 37°C, and subsequently washed three times with 
excess PBS to remove unbound 51Cr. Labelled tumour cell targets were re-
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suspended in RPMI-10 and 5,000 added to each well of a round-bottom 96-well 
plate. 
Treated effector NK cells (section 3.5.1.2.3) were harvested from culture, 
counted and added to target cells at effector:target (E:T) ratios ranging from 
20:1 (1 x 105 NK cells) to 2.5:1 (1.25 x 104 NK cells) in a total of 200 µl fresh 
RPMI-10. For each target, spontaneous 51Cr release was determined from wells 
containing 5,000 target cells alone, and maximum release from wells containing 
5,000 targets in RPMI-10 plus 1% (v/v) Triton X-100. E:T co-cultures were 
incubated at 37°C for 4 hours to allow NK cell cytotoxicity to proceed, after 
which the cells were pelleted (300 g, 5 minutes). 50 µl supernatant was 
transferred to 96-well scintillant LumaPlates (Perkin Elmer, Buckinghamshire, 
UK) and allowed to dry overnight. Chromium release as counts per minute 
(cpm) was detected using the Wallac 1450 MicroBeta TriLux scintillation 
counter. The degree of target cell killing was assessed by the formula 
% killing = 100 ∗  
test cpm − spont. cpm




3.6 Flow cytometry 
3.6.1 Default antibody staining protocol 
For routine analysis, cells from culture were transferred to FACS tubes 
(Corning), washed once in 2 ml FACS buffer, centrifuged (300 g, 5 minutes) and 
the supernatant discarded. Tubes were flicked to re-suspend cells in the 
residual volume, and antibodies added (Table 8) and incubated for 30 minutes 
at 4°C in the dark. Cells were then washed in FACS buffer, centrifuged and the 
supernatant removed prior to fixing cells in 300 µl PBS + 1% (w/v) 
paraformaldehyde (PFA) (hereafter 1% PFA/PBS). These were stored wrapped 
in foil at 4°C for up to 3 days, until data were acquired and analysed using the 
Attune® Acoustic Focusing flow cytometer and Attune software (v. 2.1.0) (Life 
Technologies).  
Where antibody staining was used to assess expression of surface markers, the 
median fluorescence intensity (MFI) of the protein of interest was subtracted 
from that of the appropriate isotype control antibody as standard. In all cases, at 




3.6.2 Live-dead viability assay 
All cells (both adherent and non-adherent) were harvested from culture plates, 
transferred to numbered plastic FACS tubes (Falcon) and washed with 2 ml 
PBS. After centrifuging (400 g, 5 minutes) and discarding supernatant, the cell 
pellet was washed once in 2 ml PBS and centrifuged. The supernatant was 
discarded, and tubes gently flicked to re-suspend cells in the residual volume. 
To assess viability, cells were then stained using the LIVE/DEAD® Fixable Red 
Dead Cell Stain (Thermo) at 1 µl stain in 1 ml PBS per tube (4°C, 30 minutes, in 
the dark). Tubes were then centrifuged, washed in 2 ml PBS and centrifuged 
again, prior to fixing cells with 300 µl of 1% PFA/PBS.  
For the default use of the Mel-624 cell line in hand-off assays, the smaller 
monocyte and larger Mel-624 populations - both alive and dead - could be 
readily discriminated by size and granularity, necessitating no further gating 
strategy. Where other cell lines were used as targets, a gate was drawn around 
the entire cell population; myeloid carrier cell number was quantified by staining 
with CD11b FITC antibody (Biolegend) and this subtracted from the total ‘live’ 
population in order to generate a target cell-specific assessment of viability. 
 
3.6.3 Detection of reovirus binding 
Freshly isolated monocytes were pulsed with patient serum, virus or reo-NAb 
(MOI 50) as above (section 3.4.1.4), then washed twice with PBS and once with 
FACS buffer. Cells were distributed between FACS tubes and stained with 1 µg 
of primary antibody against reovirus σ3 (Developmental Studies Hybridoma 
Bank (DSHB), Iowa, USA) or human IgG (Thermo) for 30 minutes at 4°C. After 
washing with FACS buffer, 0.2 µg of fluorophore-conjugated secondary 
antibody against mouse or rabbit IgG was added (30 minutes, 4°C). Cells were 
subsequently washed and fixed with 300 µl of 1% PFA/PBS, prior to acquisition. 
 
3.6.4 Analysis of monocyte phenotype 
Freshly isolated monocytes were pulsed with patient serum, virus or reo-NAb 
(MOI 10), then washed three times with excess PBS. Cells were resuspended 
in RPMI-10 at 1 x 106 per ml and cultured in 6-well plate format for 48 hours. 
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Wells were scraped to ensure that suspended and adherent cells were 
harvested into FACS tubes. Cells were washed in FACS buffer, stained with 
antibodies as indicated, and fixed in 1% PFA/PBS prior to acquisition. 
 
3.6.4.1 Monocyte migration 
To assess the ability of reovirus to stimulate monocyte migration, monocytes 
were first loaded with reovirus or reo-NAb (MOI 5) and cultured overnight (16 
hours) at 2 x 106 cells/ml in RPMI-10. Cells were collected by scraping and 
flushing with medium, and 2 x 105 cells added to the upper ‘insert’ of a 24-well 
transwell system with 5 µm pore size (Corning). The lower chamber of the well 
contained either fresh RPMI-10 medium or 1 x 105 Mel-624 cells which had 
already been in situ for 48 hours in order to create a chemoattractant gradient. 
Transwell plates were returned to 37°C for 5 hours to permit monocyte 
migration. The lower face of the transwell membrane was then flushed twice 
with medium from the chamber. This medium was collected and stained with 2 
µl CD11b FITC antibody to detect the number of monocytes present in the lower 
chamber by flow cytometry. 
 
3.6.5 Degranulation assay 
Alongside the 51Cr killing assay, CD107 expression was employed as a 
complementary marker for NK cell degranulation. To co-cultures of NK cells and 
treated monocytes (section 3.5.1.2.3), 2 x 105 target cells were added and 
incubated for 1 hour at 37°C in lidded FACS tubes (Falcon). Cells were then 
stained by incubation with 100 µl RPMI containing 2.5 µg brefeldin A 
(Biolegend), PerCP CD3, PE CD56, and FITC CD107a and CD107b antibodies 
(4 hours, 37°C). After washing with 2 ml FACS buffer, cells were centrifuged, 
the supernatant removed, and cells fixed in 1% PFA/PBS. The degree of NK 
cell degranulation was determined by the proportion of CD56+ cells staining 





3.7 Plaque assay 
The same general protocol was employed for the titration of virus stocks and 
the quantification of viral load in cell culture samples. For the determination of 
reovirus stock titre, the new batch was thawed and small aliquots made and 
returned to −80°C; one aliquot was thawed and used to calculate the titre for 
that batch. 
For the quantification of viral load in infected cells, cell suspension samples at 
−80°C were rapidly thawed in a 37°C water bath and subjected to two further 
rounds of freeze-thaw (5 minutes each) using a methanol-dry ice bath, to lyse 
cells. After the third thaw, samples were vortexed vigorously for 10 seconds to 
liberate virus, and cell debris removed by centrifugation (500 g, 2 minutes). 




Reovirus-susceptible L929 cells were seeded in 6-well plates at 5 x 105 cells 
per well in 2 ml DMEM-10. These were allowed to adhere for 24 hours. Serial 
dilutions of the reovirus stock or virus-containing samples from culture were 
created in serum-free DMEM in a 96-well plate. Medium was removed from 
near-confluent L929 cells, and 100 µl of serially diluted reovirus added drop-
wise directly on to the monolayer in each well, followed by 500 µl of serum-free 
DMEM. Plates were tilted to mix, and incubated at 37°C for 2.5 hours to allow 
virus adsorption. The inoculum was subsequently removed and cells covered 
with 2 ml of overlay solution, which was made from two parts DMEM-10 to one 
part 1.6% (w/v) carboxy-methylcellulose (CMC). Plates were returned to 37°C 
incubators for 72-96 hours to permit plaque formation. The overlay was then 
tipped away, and the cells rinsed with 2 ml PBS and fixed with 500 µl of 1% 
PFA/PBS for 10 minutes at RT. PFA was tipped away and replaced by 750 µl of 
stain solution, containing 1% (w/v) methylene blue (Sigma) in 50% (v/v) ethanol. 
After 3 minutes, the stain solution was washed away with running water and 
plates dried prior to manually counting plaques. The mean plaque number was 
obtained from duplicate wells, and titre was calculated by the formula 
pfu/ml =
# plaques






3.8 Western blotting 
3.8.1 Preparation of samples 
3.8.1.1 Reovirus-infected cell line lysates 
In order to probe for antibodies against reovirus, lysates were made from 
reovirus-infected Mel-624 and L929 cell lines. First, these cells were seeded 
from culture into 10 cm2 tissue culture dishes (Corning) at 2 x 106 cells per dish 
in 12 ml DMEM-10. After 24 hours, cells were treated with either reovirus (MOI 
10) or PBS as a control. After a further 24 hours, medium was removed, and 
cells harvested by scraping in 1 ml cold PBS. These were pelleted in a 1.5 ml 
Eppendorf tube (400 g, 5 minutes) and the pellet re-suspended in 200 µl cold 
Giordano lysis buffer (GLB) (Table 7) (van den Wollenberg et al., 2008) 
supplemented with 5 µl Complete protease inhibitors (Roche, Welwyn Garden 
City, UK). Samples were left on ice for 15 minutes, then centrifuged (14,000 g, 
4°C, 15 minutes). The lysed cell supernatant was harvested and stored at 
−80°C. 
 
3.8.1.2 Monocyte lysates 
1 x 107 CD14-selected monocytes (section 3.4.1.3) were pulsed with stated 
treatments (MOI 10) for 2-3 hours at 4°C. Following two washes in 10 ml PBS, 
cells were transferred into 5 ml RPMI-10 and cultured in T25 flasks at 37°C. 
After 24 hours, attached cells were gently released by scraping, and cells 
pelleted (400 g, 5 minutes) and washed in excess cold PBS. The resulting pellet 
was repeatedly triturated in 200 µl radioimmmunoprecipitation assay (RIPA) 
buffer (Table 7) supplemented with protease inhibitors as above, on ice for 30 
minutes. Cell debris was removed by centrifugation (14,000 g, 4°C, 15 minutes) 
and the supernatant aspirated for analysis. Protein levels were subsequently 





3.8.2 DC assay 
The protein concentration in lysates was determined by the colorimetric DC 
Protein Assay (Bio-Rad, Hertfordshire, UK) according to manufacturer’s 
instructions. Briefly, samples (diluted 1:1) were dispensed into triplicate wells of 
a 96-well plate, and mixed with 25 µl of solution A’ and 200 µl of solution B. 
After incubation for 15 minutes at RT, protein concentration was quantified 
according to optical density at λ = 620 nm using a Multiskan EX plate reader 
(Thermo). Sample concentrations were subsequently equalised by the addition 
of further GLB or RIPA buffer as appropriate, supplemented with protease 
inhibitors. 
 
3.8.3 Electrophoresis and blotting 
100 µl of lysate was added to 100 µl of 2X SDS-PAGE loading buffer (Table 7). 
Immediately prior to loading, the reducing agent dithiothreitol (DTT) was added 
to a final concentration of 2 mM, and samples boiled in a heat block (95°C, 5 
minutes). 
Samples (15-20 µg protein per lane) were loaded on to standard 10% SDS-
polyacrylamide gels alongside the PageRuler Plus molecular weight marker 
(Thermo). In some blots, as a control for antibody specificity, ChromPure 
human IgG (Jackson Immunoresearch, Cambridgeshire, UK) was prepared in 
loading buffer as above and used at 1 µg per lane. Gels were run at 120 V in 
running buffer (Table 7) for 2 hours to separate proteins by size. Proteins were 
then transferred to nitrocellulose membrane (Bio-Rad) in transfer buffer (Table 
7) at 25 V for 2.5 hours. Membranes were blocked for 1 hour in PBS + 0.1% 
(v/v) Tween-20 (Sigma) (PBST), supplemented with 5% (w/v) non-fat skim milk 
powder (Sigma). Membranes were then probed, using primary antibody or 
serum as described (Table 5) in 5% milk/PBST (overnight incubation at 4°C). 
After three 5-minute washes in PBST, membranes were incubated with an 
HRP-conjugated secondary antibody, diluted as described (Table 8) in 5% 
milk/PBST (1 hour, RT). After a further three washes, blots were visualised with 
the chemiluminescent SuperSignal West Pico substrate (Thermo) on a Gel Doc 
XR system using Image Lab software (Bio-Rad). ImageJ software (NIH) was 




3.8.3.1 IP of patient-derived serum for reovirus 
After immunoprecipitation of patient antibodies using protein A beads (section 
3.3.4), the protein concentration of samples was determined and adjusted, and 
gels run, as above. After transfer to nitrocellulose and blocking, membranes 
were incubated overnight with the 4F2 antibody against reovirus σ3 (DSHB) at 
1:200 in 1% (w/v) milk/PBST. Three PBST washes were performed prior to a 1-
hour incubation with an HRP-conjugated secondary antibody against mouse 
IgG (Sigma) at 1:5,000 in 0.1% (w/v) milk/PBST. After a further three washes, 
antibody binding was assessed as above by chemiluminescence. 
 
3.9 Cytokine analysis 
3.9.1 Luminex 
The secreted factors in cell culture were broadly analysed using a magnetic 
bead-based kit. Cells and debris were removed from supernatants by 
centrifugation (400 g, 5 minutes) and stored at −20°C. 
Multiple analytes were investigated from the same samples using the Bio-Plex 
Pro human cytokine 21-plex and 27-plex immunoassay kits (Bio-Rad) according 
to manufacturer’s instructions. Fluorescence intensity values were obtained 
using the Bio-Plex 100 machine (Bio-Rad), corrected for background signal and 
converted to cytokine concentrations (pg/ml). Values above the standard range 
were either extrapolated from the standard curve or assigned the maximal 
standard value, as appropriate. For the purposes of calculating fold-change 
over mock-treated samples, readings below 5 pg/ml were assigned a value of 5 
pg/ml to mark the lower limit of detection. 
 
3.9.2 ELISA 
Culture medium was rendered cell-free by centrifugation (400 g, 5 minutes) and 
the supernatant stored at −20°C prior to analysis by enzyme-linked 
immunosorbent assay (ELISA).   
Flat-bottomed 96-well Maxisorp plates (Nunc) were first coated with capture 
antibodies against specific protein targets – at optimised concentrations in 100 
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µl PBS or coating buffer (Table 7) as stated (Table 9) – overnight at 4°C. Plates 
were washed three times with 200 µl per well PBST (PBS + 0.05% (v/v) Tween-
20) using a Skanwasher 300 machine, and 200 µl of ELISA blocking solution 
(PBS + 10% (v/v) FCS) added for 2 hours at RT. After three further washes in 
PBST, 100 µl of supernatant (or standard as per Table 10, diluted in RPMI-10) 
was added to triplicate wells, and incubated overnight at 4°C. Wells were 
washed six times in PBST, and 100 µl of biotinylated detection antibodies 
(Table 9), diluted in blocking solution, added for 2 hours at RT. After a further 
six washes in PBST, 100 µl of Extravidin alkaline phosphatase conjugate 
(Sigma) was added to each well, diluted at 1:5,000 in PBST, and left at RT for 1 
hour. Plates were then washed three times in PBST and three times in double-
distilled water (ddH2O). Sigmafast pNPP substrate solution (Sigma) was pre-
prepared in water according to manufacturer’s instructions, and added at 100 µl 
per well. Plates were incubated at RT in the dark for up to one hour to permit 
the development of signal, prior to reading optical density at λ = 405 nm with the 
Multiskan EX plate reader. 
 
3.10 Transcriptional analysis 
3.10.1 RNA analysis by qPCR 
3.10.1.1 Virus treatment 
PBMC were isolated from fresh leukocyte cones (section 3.1.4) and monocytes 
selected (section 3.4.1.3) exactly as described for the hand-off assay, for three 
healthy donors. After washing in HBSS, 3 x 107 monocytes were added to 
universal tubes, and treated with MOI 3 (9 x 107 pfu) reovirus or reo-NAb 
(section 3.4.1.2) with or without prior UV inactivation of virus (section 3.2.2). 
Cells were incubated (4°C, 2-3 h) and washed as in the hand-off assay (section 
3.4.1.4). The washed cell pellet was thoroughly re-suspended in 15 ml RPMI-
10, and 5 ml of cell suspension added to each of three T25 flasks, which were 
left in 37°C incubators for the stated time. 
To harvest cells, flasks were gently scraped and medium flushed to re-suspend 
both adherent and floating cells. The cell suspension was transferred to 15 ml 
falcon tubes and cells pelleted (400 g, 5 minutes); the supernatant was saved at 
−20°C for analysis by ELISA. Cells were subsequently re-suspended in 1 ml 
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PBS, transferred to Eppendorf tubes, and centrifuged (400 g, 5 minutes). After 
aspirating the PBS, the resulting pellet was stored at −80°C prior to processing. 
 
3.10.1.2 RNA processing 
RNA was extracted from treated cells using the RNeasy mini kit (Qiagen, 
Manchester, UK) according to manufacturer’s instructions. Briefly, frozen cell 
pellets were first thawed and immediately re-suspended in buffer RLT. Cells 
were lysed and homogenised using QIAshredder spin columns (Qiagen). RNA 
was purified using RNeasy spin columns by sequential ethanol precipitation, 
column binding, washing, and RNA elution in nuclease-free water (Ambion, 
Thermo Fisher). A Nanodrop ND-1000 spectrophotometer (Thermo Fisher) was 
used to quantify RNA concentration and quality. A total of 0.5 µg RNA was 
taken forward for cDNA synthesis using the SuperScript IV first-strand system 
(Thermo Fisher). cDNA was generated according to manufacturer’s instructions, 
using random hexamer primers (50 ng per reaction) in a reaction volume of 20 
µl. Controls without reverse transcriptase (−RT) controls were included in all 
experiments to control for the presence of genomic DNA in cDNA preparations. 
 
3.10.1.3 qPCR analysis 
The expression of specific RNA sequences was determined by interrogating 
cDNA with gene-specific primers via SYBR Green chemistry. Primers (Table 6) 
were designed using Primer BLAST (NCBI) according to the following criteria: 
must span exon-exon junction1; primer length 18-30 bases; GC content 35-
65%; preferred amplicon size 70-150 bases; range of F/R primer melting 
temperatures (Tm) < 3°C. Specificity for the target gene and absence of self-
complementarity and secondary structure were confirmed. Primers were 
ordered from IDT and on arrival, were re-suspended at 100 µM in nuclease-free 
water and stored at −20°C until use. 
For each gene, a master mix was made, containing 2X SYBR Green master mix 
(Applied Biosystems, Thermo Fisher), and gene-specific forward and reverse 
primers at a final concentration of 0.5 µM each. 18 µl of the master mix was 
transferred into each well of a MicroAmp Optical 96-well reaction plate (Applied 
                                            
1 The IFNA1 mRNA is monocistronic, therefore exon junctions could not be considered 




Biosystems, Thermo Fisher). 10% (i.e. 2 µl) of the final cDNA product was then 
added to triplicate wells. In all experiments, water was also used in place of 
cDNA to act as a ‘no template’ control (NTC). Plates were briefly centrifuged to 
ensure that the entire volume was combined, and then sealed using Optical 
adhesive film (Applied Biosystems). 
Analysis was conducted using the ABI 7500 real-time system (Applied 
Biosystems, Thermo Fisher). 35 cycles were performed, with denaturation step 
at 95°C (15 seconds) and annealing/extension at 2°C below the lowest primer 
Tm. The Tm selected for multiple-gene plates was the lowest of the range, and 
genes to be compared were always included on the same plate. Quantification 
was subsequently performed using the ΔΔCT method against a housekeeping 
gene. For human monocytes, reovirus S4 (for σ3 protein) (Adair et al., 2012) 
was compared to the β-actin gene ACTB, and cytokines compared to the 
YWHAZ (14-3-3 ζ δ) gene (Vandesompele et al., 2002). In murine tumours, the 
mouse GAPDH gene was used as a comparator for reovirus S4 copies. 
 
3.10.2 RNA analysis by RNAseq 
3.10.2.1 Virus treatment 
PBMC isolation (section 3.1.4) and monocyte selection (section 3.4.1.3) were 
performed as previously described, from three healthy donors. After washing in 
HBSS, 5 x 106 monocytes were added to universal tubes, and treated with MOI 
10 (5 x 107 pfu) reovirus or reo-NAb. After adsorption (4°C, 2-3 hours), cells 
were washed three times in PBS and re-suspended in 5 ml RPMI-10, then 
transferred to T25 flasks to incubate (37°C, 24 hours). Flasks were scraped and 
cells flushed in medium and transferred to 15 ml falcon tubes. After 
centrifugation (400 g, 5 minutes), pellets were stored at −80°C. 
 
3.10.2.2 RNAseq methodology 
RNA was extracted from the cell pellets as described above for qPCR analysis 
(section 3.10.1.2) and stored at −80°C. RNA was then transported on dry ice to 
the Tumour Profiling Unit staff at the Institute for Cancer Research (ICR) in 
London. Here, samples were subject to DNase I clean-up prior to quality control 
with Qubit (Thermo Fisher) and Bioanalyzer (Agilent, Shropshire, UK) platforms. 
mRNA libraries were prepared from each sample using the NEBNext Ultra 
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Directional RNA library prep kit (New England BioLabs, Hitchin, UK). Libraries 
were subsequently sequenced using the HiSeq 2500 system (Illumina, Essex, 
UK) with single-end 50 base pair (SE50) reads, to generate 20-25 million total 
reads. Fastq files were subsequently analysed in R using the DEseq2 package 
(Bioconductor). Here, raw count data between groups were normalised to 
correct for library size and RNA composition bias, then interrogated to generate 
differential gene expression data. DE genes were identified by statistical 
significance based on padj < 0.1, i.e. Wald test p value with adjustment for 
multiple comparisons (Benjamini and Hochberg, 1995). 
Significant assistance with transcriptomic profiling and analysis was provided by 
Nik Matthews, Ritika Chauhan and James Campbell at the ICR. 
 
3.11 Imaging 
3.11.1 Electron microscopy 
Imaging of virus or virus-loaded cells was performed by individuals in the group 
of Prof. Rob Hoeben, and Electron Microscopy staff at the Leiden University 
Medical Center, including Diana van den Wollenberg, Carolina Jost and Aat 
Mulder. 
 
3.11.1.1 Visualisation of reo-NAb complexes by EM 
Reovirus stock was added drop-wise to Veco 100-mesh copper grids (Electron 
Microscopy Sciences, Hatfield, PA, USA) and allowed to attach (RT, 5 minutes). 
Grids were washed four times in PBS (2 minutes each), prior to incubation with 
patient serum or control serum, diluted 1:10 in PBS (RT, 90 minutes). After four 
further washes in PBS, grids were incubated with protein A-conjugated 10 nm 
gold particles (1:300 in PBS + 1% v/v BSA) (in-house) for 30 minutes at RT. 
Further washes in PBS (4 x 2 minutes) and ddH2O (4 x 1 minute) were 
performed. Grids were then fixed for 1 hour with 1.5% (v/v) glutaraldehyde (GA) 
in 0.1 M sodium cacodylate. After further washes in ddH2O (4 x 1 minute), grids 
were negatively stained with 1% (w/v) phosphotungstic acid (PTA) for 30 
seconds, then blotted and air-dried. Grids were then visualised using an FEI 




3.11.1.2 Visualisation of virus-loaded monocytes by EM 
Negatively selected monocytes (section 3.4.2.1) were pulsed with virus as 
described (section 3.4.1.4) at MOI 50 (4°C, 3 hours). Monocytes were 
subsequently washed twice with 15 ml ice-cold PBS and centrifuged (400 g, 5 
minutes). 700 µl RPMI-10 was added, and cells allowed to rest at RT for 10 
minutes to permit internalisation, prior to addition of 700 µl double-strength 
fixative – giving final concentrations of 2% (v/v) PFA and 0.2% (v/v) GA in 0.1 M 
PHEM buffer (Table 7). After centrifuging (300 g, 3 minutes), the supernatant 
was aspirated and pellets gently re-suspended in 1 ml storage buffer (0.5% w/v 
PFA in 0.1 M PHEM) and kept at 4°C prior to processing. 
For morphological analysis, cell pellets were rinsed in 0.1 M sodium cacodylate 
buffer (Table 7), then post-fixed with osmium tetroxide solution (1% (w/v) in 0.1 
M cacodylate buffer) on ice for 1 hour. Cells were rinsed again and 
resuspended in 2% (w/v) agar. After solidification, 0.5 – 1 mm3 blocks were cut 
and dehydrated using an ascending ethanol series. Blocks were then 
transferred from 100% ethanol to propylene oxide, and subsequently infiltrated 
with ascending ratios of LX-112 Epon resin (Ladd Industries, Kettering, OH, 
USA) to propylene oxide (1 hour each). After 1 hour in pure Epon, fresh Epon 
was added and polymerised at 70°C for 48 hours. 80 nm sections were made 
on an Ultracut S microtome (Leica) and visualised with an FEI Tecnai TWIN 
microscope at 120 kV. 
For immunogold labelling, cell pellets were first embedded in 12% (w/v) gelatin 
in PBS, and 0.5 mm3 cubes infiltrated with 2.3 M sucrose in PBS for 30 minutes. 
Cells were then plunge-frozen in liquid nitrogen. 70 nm sections were made 
using a diamond knife and the Ultracut/FCS machine (Leica, Milton Keynes, 
UK) at −110°C. Sections were collected on mesh-100 grids and washed with 
PBS (3 x 4 minutes) and 50 mM glycine in PBS (3 x 4 minutes) to block 
aldehyde groups. Primary antibody (DSHB mouse anti-σ3 4F2, or isotype 
control) was added as stated in BSA-PBS (1% w/v) for 1 hour, and grids 
washed in PBS-glycine (3 x 4 minutes). Anti-mouse secondary antibody was 
added at 1:200 in BSA-PBS for 1 hour, and grids washed (3 x 4 minutes). 
Protein A-conjugated 10 nm gold particles were then added at 1:300 in BSA-
PBS for 30 minutes. Finally grids were washed with PBS and then ddH2O prior 
to contrasting with uranyl acetate (0.3% (w/v) in 2% (w/v) methylcellulose) on 
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ice for 5 minutes. Grids were dried in air, prior to visualisation with an FEI 
Tecnai TWIN microscope (Thermo Fisher) at 120 kV. 
 
3.11.2 Confocal microscopy 
Monocytes were harvested from fresh PBMC (section 3.4.1.3) and seeded on 
sterile poly-D-lysine coated coverslips in 24-well plates (Corning) at 6.5 x 104 
cells per well in 0.5 ml RPMI-10. Cells were allowed to adhere overnight, then 
chilled and pulsed with reovirus (MOI 2,000) in serum-free RPMI. Virus was 
allowed to adsorb for 1 hour at 4°C, followed by 2 hours at 37°C; the inoculum 
was then removed and cells washed once with excess PBS. Fresh RPMI-10 
was added, and cells incubated at 37°C as stated prior to washing with PBS 
and fixing with 4% (w/v) PFA (20 minutes, RT). Fixative was quenched with 0.1 
M glycine in PBS, and cells washed three times with PBS. Cells were 
permeabilised with 0.5% (v/v) Triton X-100 in PBS for 5 minutes, and blocked 
for 10 minutes with PBS-BGT (0.5% w/v BSA, 0.1% w/v glycine, 0.05% v/v 
Tween-20). 
To stain for reovirus, cells were incubated in the dark with the mouse 4F2 
antibody against σ3 (1:200 in PBS-BGT) for 1 hour at RT. After three washes 
with PBS-BGT, a cocktail of secondary antibodies was added in PBS-BGT: anti-
mouse Alexa Fluor 488 (1:500), phalloidin-Alexa Fluor 647 (1:100) and DAPI 
(1:10,000) (all Thermo Fisher). After a further hour at RT, three PBS-BGT 
washes were performed and coverslips mounted on slides using 10 µl Mowiol 
(Sigma). Labelled cells were visualised using the A1R confocal laser 
microscope (Nikon). 
 
3.12 In vivo work 
All animal experiments carried out at the University of Leeds were approved by 
the local Animal Welfare and Ethical Review Body and under appropriate Home 
Office licence (project licence PFD4C5062); those conducted at the Mayo Clinic 
were approved by the Institutional Animal Care and Use Committee. 
Reo-NAb complexes to be employed in vivo were formulated using serum 
obtained from reovirus-immunised mice. These mice (female C57BL/6, 6-12 
weeks of age) were given two intraperitoneal (i.p.) doses of reovirus at 2 x 107 
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pfu in 100 µl PBS, one week apart. One week after the second dose, mice were 
sacrificed under terminal anaesthesia and blood obtained by cardiac puncture. 
After clotting, blood was centrifuged at 800 g for 10 minutes, and serum 
collected. The neutralising capacity of serum was established as detailed above 
(section 3.3.2) and neutralising ratios of serum to virus determined. Ex vivo-
formed complexes were then generated by incubating serum with virus for at 
least 3 hours (37°C) prior to administration as below. 
In a follow-up experiment, a comparison was made between reo-NAb 
complexes formed using serum from immune mice, and those formed artificially 
using monoclonal antibodies against reovirus epitopes (DSHB). All complexes 
used were confirmed as neutralised by standard L929 neutralisation assays. 
The NAb used for comparison were either G5 alone, or a mAb ‘combo’ of G5, 
10F6, 8H6, 10C1 and 10G10 (directed against epitopes on either σ1, µ1 or σ3), 
all at equal µg doses. 
 
3.12.1 Delivery of reovirus to tumours 
Female C57BL/6 mice at 6-8 weeks of age (reovirus-naïve) were obtained from 
Charles River Laboratories. Flank tumours were seeded by sub-cutaneous 
(s.c.) injection of 2 x 105 or 5 x 105 B16-F10 melanoma cells, suspended in 100 
µl PBS. After seven days, mice (3-4 per group) were given three consecutive 
daily doses of 300 ng recombinant mouse GM-CSF (Peprotech) or PBS by i.p. 
injection. Subsequently on days 10 and 11, reo-NAb complexes (or PBS) were 
administered i.v. at a dose of 2 x 107 or 5 x 107 pfu in a total of 100 µl PBS. All 
mice were sacrificed by cervical dislocation three days after the second 
infusion, and tumours harvested immediately. 
Tumour virus burden was analysed by both plaque assay and qPCR. For 
plaque assay, tumours were mechanically homogenised in PBS, and the cells in 
suspension lysed by three freeze-thaw cycles. The functional reovirus titre in 
these samples was analysed by standard plaque assay on L929 cells (section 
3.7). Separately, for RNA analysis, tumour explants were mechanically 
homogenised in buffer RLT (Qiagen) supplemented with β-mercaptoethanol (to 
denature RNases). Samples were further homogenised using QIAshredder 
columns, and RNA extracted from lysates using the RNeasy kit. 1 µg total RNA 
was used for cDNA synthesis and qPCR analysis as described above (section 
3.10.1). The number of reovirus S4 gene copies was compared to mouse 




3.12.2 Analysis of therapeutic benefit 
The reovirus-sensitive murine B16tk model was used to maximise detection of 
therapeutic benefit, and for consistency with a substantiated model (Rajani et 
al., 2016). Mice were not formally randomised according to tumour burden since 
tumours were too small to be easily seen prior to therapy. Blinding was not 
performed as insufficient personnel were available to conduct the process. 
Based on detecting an effect size observed in a similar prior experiment with 
90% power (at α = 0.05), a group size of 8 mice was selected using the 
G*power programme (http://www.gpower.hhu.de/en.html). Female C57BL/6 
mice at 8-10 weeks of age were first pre-immunised with 2 x 107 pfu UV-
inactivated reovirus (‘immune’) or PBS (‘naïve’). After 11 days, mice were 
subjected to s.c. flank implantation with 5 x 105 B16tk melanoma cells, in 50 µl 
PBS.  
After three days, mice were given three daily i.p. doses of 300 ng recombinant 
mouse GM-CSF (Peprotech, London, UK). On the following two days, PBS, free 
reovirus or reo-NAb complexes (made using serum) were administered i.v. at a 
dose of 1.5 x 107 pfu in a total of 100 µl. Tumours were measured manually 
three times per week, and mice euthanised when tumour diameter reached 1.5 




3.13 Statistical analysis 
Data were analysed using GraphPad Prism software. Significance was 
evaluated using Student’s t-test, one-way or two-way ANOVA as appropriate, 
with p < 0.05 considered significant. Kaplan-Meier curves were assessed by 
Log-rank test. Where multiple comparisons were performed, corrections were 
made to adjust for type 1 error; typically using the Holm-Šídák method (t-test) or 








Cell type Origin Medium Source 
Mel-624 human melanoma DMEM  
+ 10% (v/v) FCS 
(DMEM-10) 
CRUK 
SKmel-28 human melanoma DMEM-10 CRUK 
HCT116 human colorectal 
carcinoma 
DMEM-10 CRUK 
Panc-1 human pancreatic 
carcinoma 
DMEM-10 n/a 
SU.8686 human pancreatic ductal 
carcinoma (metastasis) 
DMEM-10 ATCC 
SKOV3 human ovarian 
adenocarcinoma 
DMEM-10 CRUK 








L929 mouse fibrosarcoma DMEM-10 ATCC 
Vero African green monkey 
kidney 
DMEM-10 ATCC 
B16tk mouse melanoma DMEM-10 Richard Vile,  
Mayo Clinic 




healthy donor PBMC  RPMI-10 leukocyte cones 
(NHSBT) 


















type 3 Dearing 









type A 21 




virus type I  
(ICP34.5 null) 
1 x 109 Virttu 
Biologics 
Vero 







Reovirus Serum In-house 
(REO-013 Brain trial  
ISRCTN70443973) 
i.v. reovirus  
- 1 dose of 1010 
TCID50* 
2-6 weeks 
CVA21 Serum In-house 
(STORM trial  
NCT02043665) 
i.v. CVA21 
- 3 ascending 
doses, 1 x 108 










- 4 doses of  
1 x 107 IU 
2-6 weeks 
Table 3: Sources of antiviral antibody 













107.3 mouse IgG1 whole 
antibody 
1 mg/ml BD 
CD64  
(FcγR I) 
10.1 mouse IgG1 F(ab’)2 
fragment 
1 mg/ml Ancell 
CD32 
(FcγR II) 
7.3 mouse IgG1 F(ab’)2 
fragment 
1 mg/ml Ancell 
CD16 
(FcγR III) 
3G8 mouse IgG1 F(ab’)2 
fragment 
1 mg/ml Ancell 
CD89 
(FcαR) 








MOPC-21 mouse IgG1 whole 
antibody 
1 mg/ml Biolegend 
JAM-A J10.4 mouse IgG1 whole 
antibody 
2 mg/ml Santa Cruz 
CXCR3 G025H7 mouse IgG1 whole 
antibody 
1 mg/ml Biolegend 
IFNAR2 MMHAR-2 mouse IgG2a whole 
antibody 
0.5 mg/ml PBL 








Target Clone Host Concentration Supplier 
reovirus σ3 4F2 mouse 1:200 DSHB 
GAPDH 14C10 rabbit 1:1,000 CST 
NF-κB p50 H-119 rabbit 1:200 Santa Cruz 
RIG-I D14G6 rabbit 1:500 CST 
PKR 13/PKR mouse 1:200 BD 
anti-human  
IgG / IgA / IgM 
(HRP) 
(secondary) goat 1:5,000 Thermo 
anti-mouse 
IgG (HRP) 
(secondary) sheep 1:5,000 Sigma 
anti-rabbit IgG 
(HRP) 
(secondary) goat 1:1,000 CST 
















F GGGCTGCACATTACCACTGA 59.3 300 
R CTCCTCGCAATACAACTCGT 56.0 
CXCL10 F TCCAGTCTCAGCACCATGAA 56.0 84 
R AGGTACTCCTTGAATGCCACT 55.8 
IFNA1* 
(monocistr.) 
F AGGAGGAAGGAATAACATCTGGT 55.3 106 
R GCAGGGGTGAGAGTCTTTGA 56.8 
MCP-1 
CCL2 
F GATGCAATCAATGCCCCAGT 56.1 114 
R AGCTTCTTTGGGACACTTGC 55.8 
IL-8 
CXCL8 
F CACCGGAAGGAACCATCTCA 56.8 109 
R GGCAAAACTGCACCTTCACA 56.5 
EF1A 
EEF1A1 
F GATTACAGGGACATCCTAGGCTG 57.0 195 
 R TATCTCTCCTGGCTGTAGGGTGG 57.7 
YWHAZ F CCTTGCTTCTAGGAGATAAAAAGAA 52.7 134 
R CTCCTTGCTCAGTTACAGACTTC 55.0 
GAPDH 
(mouse) 
F ACTGAGCAAGAGAGGCCCTA 57.7 80 
R TATGGGGGTCTGGGATGGAA 57.7 
Table 6: Primers used for qPCR 
Human, unless stated otherwise. 
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MACS buffer PBS  
+ FCS (1% v/v)  
+ EDTA (20 mM) 
FACS buffer PBS  
+ FCS (1% v/v)  
+ sodium azide (0.1% w/v) 
RIPA buffer Tris (50 mM, pH 8.0) 
+ sodium chloride (150 mM) 
+ EDTA (5 mM) 
+ Triton X-100 (1% v/v) 
+ sodium deoxycholate (0.5% w/v) 
+ SDS (0.1% w/v) 
Giordano lysis buffer (GLB) Tris (50 mM, pH 7.4) 
+ sodium chloride (250 mM) 
+ EDTA (5 mM) 
+ Triton X-100 (0.1% w/v) 
SDS-PAGE loading buffer (2x) Tris (100 mM, pH 6.8)  
+ SDS (4% w/v)  
+ bromophenol blue (0.2% w/v)  
+ glycerol (20% v/v) 
DTT added to samples before use,  
to final concentration of 100 mM 
SDS-PAGE running buffer (1x) Tris (25 mM) 
+ glycine (250 mM) 
+ SDS (0.1% w/v) 
SDS-PAGE transfer buffer (1x) Tris (12 mM) 
+ glycine (96 mM) 
ELISA coating buffer (1x) NaHCO3 (100 mM) - pH 8.2 
PHEM buffer (0.1 M) PIPES (60 mM) 
+ HEPES (25 mM) 
+ MgCl2 (2 mM) 
+ EGTA (10 mM) - pH 7.4 
Table 7: Buffers used for magnetic selection, flow cytometry, western 








PE MOPC-21 mouse IgG1 5 µl BD 
PE G155-178 mouse IgG2a 5 µl BD 
PE MPC-11 mouse IgG2b 5 µl BD 
PerCP MOPC-31C mouse IgG1 5 µl BD 
APC 11711 mouse IgG1 5 µl R&D 
CD3 
 
PE HIT3a mouse IgG2a 5 µl BD 
PerCP SK7 mouse IgG1 5 µl BD 
CD4 FITC RPA-T4 mouse IgG1 5 µl BD 
CD8 FITC RPA-T8 mouse IgG1 5 µl BD 
CD11b FITC ICRF44 mouse IgG1 3 µl Biolegend 
CD14 PE M5E2 mouse IgG2a 5 µl BD 
CD16 FITC B73.1 mouse IgG1 5 µl BD 
CD32 PE 2E1 mouse IgG2a 5 µl Miltenyi 
CD54 PE LB-2 mouse IgG2b 5 µl BD 
CD55 PE IA10 mouse IgG2a 5 µl BD 
CD56 
 
FITC NCAM16.2 mouse IgG2b 3 µl BD 
PE AF12-7H3 mouse IgG1 5 µl Miltenyi 
CD64 FITC 10.1.1 mouse IgG1 5 µl Miltenyi 
CD69 
 
PE FN50 mouse IgG1 5 µl BD 
PerCP L78 mouse IgG1 5 µl BD 
CD80 PE L307.4 mouse IgG1 5 µl BD 
CD86 PE FUN-1 mouse IgG1 5 µl BD 
CD89 unconjugated REA234 recombinant 
human IgG1 
5 µl Miltenyi 
CD107a FITC H4A3 mouse IgG1 5 µl BD 
CD107b FITC H4B4 mouse IgG1 5 µl BD 
CD111 PE R1.302 mouse IgG1 5 µl Miltenyi 
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CD112 PE R2.525 mouse IgG1 5 µl BD 
CD317 PE 26F8 mouse IgG1 5 µl Thermo 
HLA-ABC PE G46-2.6 mouse IgG1 5 µl BD 
HLA-DR PE G46-6 mouse IgG2a 5 µl BD 
HVEM APC 94801 mouse IgG1 5 µl R&D 
JAM-A PE 1H2A9 mouse IgG2b 5 µl Santa Cruz 
reovirus 
σ3 
unconjugated 4F2 mouse  50 µl DSHB 
human 
IgG (H&L) 
unconjugated - rabbit polyclonal 5 µl Thermo 
mouse 
IgG 
FITC - goat polyclonal 0.5 µl BD 
rabbit IgG 
(H&L) 
AF-594 - goat polyclonal - 
F(ab’)2 
0.1 µl Thermo 
human 
IgG 
PE - goat polyclonal 5 µl Bio-Rad 








Target Antibody Dilution Diluent Host Supplier 
CXCL10 capture 1:180 PBS 
 
mouse R&D Systems 
detection 1:180 goat 
IL-29 capture 1:180 PBS 
 
mouse R&D Systems 




capture 1:250 coating 
buffer 
mouse R&D Systems 
 detection 1:500 goat 
TRAIL 
 
capture 1:180 PBS mouse R&D Systems 
 detection 1:180 goat 
IFN-α capture 1:250 PBS 
 
mouse Mabtech 
detection 1:1,000 mouse 
TNF 
 
capture 1:1,000 coating 
buffer 
mouse BD 
 detection 1:1,000 mouse 
Table 9: Antibodies used for ELISA 
Target Standard range Supplier 
CXCL10 2,000 – 15.6 pg/ml R&D Systems 
IL-29 4,000 – 31.3 pg/ml R&D Systems 
CCL5/RANTES 1,000 – 7.8 pg/ml R&D Systems 
TRAIL 1,500 – 11.7 pg/ml R&D Systems 
IFN-α 5,000 – 39.1 pg/ml Peprotech 
TNF 2,000 – 15.6 pg/ml R&D Systems 
Table 10: Protein standards used for ELISA 
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 Formation of reovirus-antibody complexes 
4.1 Introduction 
Independent of the use of the type 3 Dearing strain as a clinical agent, reovirus 
types 1-3 are ubiquitous, naturally-occurring strains in the environment (Lee and 
Jeong, 2004; Spinner and Di Giovanni, 2001). Further, while it has only 
sporadic association with significant clinical disease, humans are routinely 
exposed to the virus at the mucosal interface of the gastrointestinal and 
respiratory tracts. Consequently, seropositivity for reovirus in the general 
population is considerable. Infection commonly occurs in childhood, with 
approximately half of five-year-olds showing seroconversion (Leers and Rozee, 
1966; Pal and Agarwal, 1968; Selb and Weber, 1994; Tai et al., 2005). 
Exposure increases with age, with 60-100% of older adults showing serological 
evidence (Lerner et al., 1962; Minuk et al., 1987, 1985; Selb and Weber, 1994). 
A number of early-phase clinical trials have involved the administration of OV as 
a large intravenous (i.v.) bolus. Seen in the context of a pre-existing low-level 
immunity to the virus, these therapeutic infusions represent a re-exposure to 
abundant viral antigens and result in a large-scale anamnestic response. This is 
characterised by the rapid generation of antiviral antibodies in circulation at very 
high titre (Vidal et al., 2008; White et al., 2008). 
Antibodies are considered a key component of the evolutionarily conserved 
humoral response, which cannot discriminate therapeutic from pathogenic 
viruses. Antibody production arises upon the presentation of viral antigen to B 
cells via specific immunoglobulin receptors. The synthesised antibodies function 
principally by binding directly to pathogens and – in the case of viruses – 
frustrating their binding, uptake and/or uncoating during the infection process. 
The resulting reduction in viral infectivity is termed neutralisation. Separately, 
although some antibodies may be non-neutralising based on direct infectivity, 
they may retain other protective functions; opsonising antibodies may be able to 
trigger more complex immune effector functions such as antibody-dependent 





4.2 Reovirus neutralisation by patient-derived serum 
Prior to assessing any immunomodulatory effects of anti-reovirus antibodies, 
the neutralising capacity and class of reovirus-specific antibodies in cancer 
patients was characterised. In order to do this, serum samples were obtained 
from patients enrolled in the REO-013 Brain trial. These patients received i.v. 
reovirus as monotherapy, 3 to 17 days prior to surgical resection of primary 
brain tumours or metastases in the brain (Samson et al., 2018). Reovirus was 
administered as a single dose of 1 x 1010 TCID50 (i.e. 7 x 109 pfu (Davis et al., 
1972)) each, and blood samples taken within two months of the infusion. Some 
were taken around the time of surgery (approximately 1-2 weeks post-infusion), 
while others were taken during the following month. Patient-derived serum 
(hereafter PS) was obtained by allowing the blood sample to clot, followed by 
centrifugation and harvest of the cell-free fraction. 
Initially, the presence of reovirus-binding immunoglobulins (Ig) in PS was 
confirmed. As an in vitro model of i.v. reovirus infusion, PS – or control serum 
(CS) taken from untreated healthy donors – was combined with virus at a ratio 
of 106 pfu per 1 µl serum and incubated at 37°C for 3 hours. The virus-serum 
suspension was subsequently incubated with beads conjugated to protein A, 
which binds to human IgG1, IgG2, IgG4, IgA and IgM, but not IgG3. The beads 
were used in order to immunoprecipitate (IP) antibodies and their binding 
partners, which were subsequently interrogated for reovirus by SDS-PAGE and 
western blot. The presence of virus-binding antibodies in PS was confirmed by 
positive identification of the reovirus σ3 protein in the IP fraction from PS but not 
CS (Figure 4.2.1a). When virus alone (i.e. without serum) was incubated with 
beads, no signal was detected, indicating that reovirus does not bind to the 
beads. 
Following the detection of ex vivo-formed reo-NAb, the possibility of detecting 
reo-NAb in circulation shortly after i.v. administration of virus was assessed. 
Serum obtained from reo-treated patients 24 hours post-infusion (PS-24hpi) 
was not combined with further virus in vitro, but was directly subjected to 
purification with protein A beads. The IP fraction was subjected to SDS-PAGE 
and western blot. While a band corresponding to reovirus σ3 was detected in 
the positive control, such a band was absent in IP samples from PS-24hpi, even 
with lengthy membrane exposure (Figure 4.2.1b). This indicates that reo-NAb 
complexes are either absent or at a level below the limit of detection in patient 
serum one day after i.v. virus administration. 
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Having confirmed the binding of patient serum antibodies to the reovirus 
particle, in order to prove their neutralising capacity a colorimetric viability assay 
was employed (MTT assay) (Mosmann, 1983). Briefly, this involves testing 
halving dilutions of sera for their ability to prevent reovirus infection of L929 
mouse fibroblasts, which are acutely sensitive to reovirus. After a 48-hour 
incubation, viability of the treated cell population can be inferred from their 
metabolic activity.  
First, serum samples from two reovirus-treated patients were compared to 
serum samples from two healthy controls. As shown in Figure 4.2.2, PS 
demonstrated considerably higher neutralising capacity compared to CS – 
evidenced by the right-shift of the neutralisation curve. The ND50 values, an 
illustration of neutralising capacity, indicate that PS exceeds CS by 
approximately 100-fold in this regard. 
Six patient serum samples taken at various times following infusion were then 
compared. Notably, the sera obtained from patients shortly (1-3 weeks) after 
their last virus infusion appeared more neutralising than those obtained after 5 
or 6 weeks (Figure 4.2.3). Indeed, serum 1 & 4 and 2 & 6 respectively were 
actually taken at different time points from the same patient, which illustrates 
the drop-off in anti-reovirus NAb in the weeks following administration.  
Alongside the antibody compartment, the other pivotal component of humoral 
immune surveillance is the complement system. Elements of the complement 
network have various antimicrobial functions: from their ability to directly lyse or 
neutralise viruses (Spear et al., 1993; Sullivan et al., 1998), to their role as a 
‘danger signal’ heralding innate clearance processes such as complement-
dependent cytotoxicity (Terajima et al., 2011). Indeed, in some circumstances, 
complement is crucial in bridging innate and adaptive immunity during the 
antiviral response (Da Costa et al., 1999; Kopf et al., 2002). Further, in the 
context of an oncolytic virus, complement inhibition was recently shown to 
substantially diminish neutralisation of the enveloped vaccinia virus in a range 
of in vitro and animal models (Evgin et al., 2015). 
This paper suggested that complement also plays a significant role in the 
neutralisation of reovirus. Therefore, after confirming the presence of 
complement activity in patient serum samples using a haemolytic CH50 assay 
(data not shown), this concept was investigated; a basic assay was used, 
predicated upon the heat-labile nature of complement, in which patient serum 
was heat-inactivated (HI) at 56°C for 30 minutes prior to analysis by 
neutralisation assay. Figure 4.2.4 shows that HI-serum demonstrated equivalent 
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neutralising capacity to otherwise untreated serum, suggesting that heat-labile 








Figure 4.2.1  Western blot for reovirus σ3 protein from IP fraction of serum 
 
(a) 20 µl of patient (PS) or control serum (CS) was mixed with 20 x 106 pfu 
exogenous reovirus (+ reo), and then antibodies immunoprecipitated (IP) using 
protein A-beads. Equal amounts of protein (20 µg) from IP fractions were then 
subjected to SDS-PAGE, transferred to nitrocellulose, and probed for 
exogenous reovirus σ3. Neat reovirus (no IP), added directly to the gel after 
boiling, was used directly as a positive control (far right lane). 
(b) Two patient sera taken 24 h.p.i. (#1 and #2) or control serum (CS) were 
directly combined with protein A-beads to IP the antibody fraction, prior to SDS-
PAGE, transfer, and blotting as above. Both blots shown are representative of 

































































Figure 4.2.2  Reovirus neutralisation by control or patient-derived sera 
 
100 µl of halving dilutions of control (con) or patient (pt) sera (1/25 - 1/51,200) 
or DMEM-10 (control) were added to 2.5 x 104 L929 target cells in advance of 
the addition of reovirus at MOI 0.05. (a) Cell viability was determined by MTT 
assay after incubating for 48 hours. (b) 50% neutralising dose calculations were 







Figure 4.2.3 Reovirus neutralisation by patient-derived sera 
 
100 µl of halving dilutions of various patient sera (1/50 - 1/102,400) or DMEM-
10 (control) were added to 2.5 x 104 L929 target cells in advance of the addition 
of reovirus at MOI 0.05. Cell viability was determined by MTT assay after 
incubating for 48 hours. The time between patients’ therapeutic dose of virus 
and the time serum was obtained is referred to as days post-infusion (d.p.i.). 
Paired samples (same patient, different time points) are samples 1 & 4 and 2 & 







Figure 4.2.4 Influence of heat-labile factors in reovirus neutralisation 
 
Patient serum was either heat-inactivated at 56°C for 30 minutes (HI-PS) or not 
(PS); halving dilutions were made in DMEM-10 and 100 µl added to wells 
containing 2.5 x 104 L929 target cells. Reovirus was added in a further 100 µl of 
DMEM to an MOI of 0.05. After 48 h incubation at 37°C, cell viability was 







4.3 Characterisation of specific mediators of neutralisation 
The previous data indicated the importance of circulating antiviral antibodies to 
reovirus neutralisation in vitro. Next, further insight into the breadth of the 
humoral response to reovirus in these patients – both in terms of the virus 
proteins detected and the types of antibody involved – was obtained. 
The B-cell antigen receptor (BCR) is a cell-surface immunoglobulin (Ig) which 
confers antigen specificity on B cells. Only antigens which are able to bind the 
BCR with sufficient affinity are capable of stimulating B cell proliferation and 
differentiation, and concomitant antibody production. This tight specificity means 
that the viral proteome recognised by serum Ig can provide an informative guide 
as to the antigens ‘visible’ to circulating immune cells.  
An unorthodox approach was taken to analysing the antibody repertoire present 
in patient-derived serum. First, lysates were made from mock- or reovirus-
infected mouse and human cell lines. After separation of the protein content of 
lysates by electrophoresis and transfer to nitrocellulose membranes, PS was 
employed as a primary antibody to probe the blot. The serum antibodies 
recognising reovirus proteins were then detected using a secondary antibody 
against human IgG. As shown in Figure 4.3.1a, a variety of proteins are 
identified in reovirus-infected – but not uninfected – lysates, indicating that 
these are indeed virus-specific. No proteins were detected when CS was used 
instead, demonstrating the abundance of antiviral antibodies in patient blood 
(data not shown). 
Based on molecular weight, the individual bands match well with individual 
members of the reovirus proteome, with structural proteins of the µ and σ 
families most strongly represented. Although it appears that the µ1/µ1c protein 
attracts the largest antibody response, given that the stoichiometry of proteins in 
the reovirus virion (and thus on the blot) is not equal, it is not possible to draw 
accurate conclusions as to the ‘most immunogenic’ proteins (Coombs, 1998). 
Interestingly it appears that σ3, at 41 kDa the smallest of the 10 proteins in T3D 
and a major element of the capsid, is not detected by PS in this assay, with the 
two bands nearby probably corresponding to σ1 (49 kDa) and σ2 (47 kDa). It 
was confirmed that the protein itself was present on the blot using the specific 
monoclonal antibody 4F2 (Figure 4.3.1b). This raises the intriguing prospect 
that patients do not generate antibodies against σ3. However, perhaps more 
likely is the explanation that this assay was insufficiently sensitive to detect 
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them, or that such antibodies may recognise conformational epitopes on σ3 that 
are eliminated in the context of a denaturing western blot. 
To more accurately identify the specific molecular players in the neutralisation 
process, the involvement of different antibody classes was examined. IgG is the 
predominant class present in serum (~ 80%), with only IgA (~ 15%) also present 
to any significant degree (Gonzalez-Quintela et al., 2008). Although rapidly 
generated, the IgM pentamer is less common (~ 5%) and has a shorter half-life 
than IgG due to constant IgG salvage by the neonatal Fc receptor, FcRn (Kim et 
al., 2007). The monomeric IgG is thought to play the major role in neutralising 
pathogens in circulation, whereas IgA – dimeric in secretions and monomeric in 
blood – is largely secretory and thus typically operates at the mucosa (Delacroix 
et al., 1982). Further, IgG is the main class induced during an anamnestic 
response (Godfrey et al., 1969; McDermott et al., 1990); relevant given that 
patients had likely been previously exposed to reovirus. Consequently it was 
hypothesised that IgG will represent the primary neutralising source over the 
other classes.  
To obtain a qualitative assessment of the presence of antiviral Ig classes in 
patient serum, the existing western blot approach was modified with secondary 
antibodies restricted to human IgG, IgA or IgM. These revealed the presence of 
anti-reovirus IgG and IgA, while IgM was not detected (Figure 4.3.2). Exposure 
times were kept low to avoid potential non-specific background. To confirm 
antibody class specificity, pure human IgG was run on the same blots; only the 
secondary antibody against IgG (and not IgA) reacted in this lane, indicating 
that antiviral IgA are indeed present in PS. 
Following this preliminary assay, a more quantitative measure of class 
contribution to neutralisation was required. This was evaluated by depleting IgG 
and IgA from PS by targeting their class-specific heavy chains. PS was 
incubated with agarose-conjugated antibodies targeting the γ- or α-chain, and 
then centrifuged. Depletion was confirmed by ELISA, with levels of IgG or IgA 
respectively below the detection limit of the assay (data not shown). The 
neutralising capacity of depleted and intact serum samples were compared by 
the MTT assay previously described. As expected, extraction of IgG 
considerably reduces neutralisation, with IgA depletion exerting a more minor 
effect (Figure 4.3.3). Dual IgG/A depletion almost entirely abrogated 
neutralisation. Thus, as expected, reovirus neutralisation is a predominantly 






Figure 4.3.1 The reovirus-binding antibody repertoire of patient serum 
 
Lysates from mock or reovirus-infected L929 or Mel-624 cells were analysed by 
SDS-PAGE and western blot, with protein concentrations equalised.  
(a) Membranes were probed with patient serum (1:200) and a secondary 
antibody against human IgG (1:5,000). The reovirus proteins bound by patient 
serum antibodies are indicated. Blots are representative of four patient sera. 
(b) Membranes were probed with the 4F2 antibody against reovirus σ3 (1:200) 





























Figure 4.3.2 Western blot for serum antibody classes binding to reovirus 
 
Mock or reovirus-infected lysates were interrogated as before, using patient 
serum as a primary antibody (1:200). Blots were then probed with secondary 
antibodies against human IgG, IgA or IgM (1:25,000) as indicated. Blot 
exposures were equal. Human IgG was also included in one lane to confirm the 
specificity of secondary antibodies to Ig classes. Blots shown were produced 









































Figure 4.3.3 Serum antibody classes mediating reovirus neutralisation 
 
IgG or IgA were specifically depleted from patient serum using agarose-
conjugated antibodies against the γ- or α-chain of IgG or IgA respectively, or 
both (dep γ/α). Depleted (or intact) sera were serially diluted and tested for 





4.4 The interaction of virus with anti-reovirus antibody to 
form complexes 
Having demonstrated that Ig in serum was able to bind to and neutralise 
reovirus, a visual representation of this interaction was obtained using electron 
microscopy (EM). Virus was allowed to adhere to EM grids, which were 
incubated with PS or CS and then labelled with protein A-gold. A higher 
proportion of virions were gold-labelled when pre-incubated with PS (76%) as 
opposed to CS (40%) (Figure 4.4.1a). This difference was found to be 
statistically significant at p < 0.01 by χ2 test (χ2 = 92.9, cut-off 6.6 where df = 1). 
This demonstrates the extensive binding of PS neutralising antibodies (NAb) to 
the virion, hereafter termed a reovirus-neutralising antibody (reo-NAb) complex, 
as depicted in the representative micrographs (Figure 4.4.1b). The lower degree 
of labelling with CS present is consistent with the presence of residual NAb in 





Figure 4.4.1 Immunogold labelling of reovirus-bound antibodies from 
serum 
 
Reovirus was bound to copper grids prior to incubation with CS or PS, and 
subsequent labelling with protein A-gold (10 nm). Preparations were fixed and 
negatively stained with PTA, then visualised at 52,000 X magnification by TEM. 
(a) Representative micrographs of labelled virions (large white area), 
demonstrating typical gold labelling patterns (small dark circles). Scale bar = 
100 nm. 
(b) Quantification of the percentage of virions labelled, or the number of gold 
labels on individual virions. n > 340 virions for each condition.  
** indicates significance at p = 0.01 by χ2 test (df = 1). 
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Intravenous delivery of an oncolytic virus represents not only the optimal means 
of accessing disseminated neoplastic tissue, but also likely the most practical 
way of stimulating a systemic response from the immune system. However, this 
route of infusion is often eschewed in favour of more local methods given the 
many ‘hurdles’ to viral persistence present in the vasculature; one prominent 
obstacle being neutralising antibodies (NAb).  
Anti-reovirus antibodies in patient serum are highly neutralising in vitro. Based 
on the highest serum dilution at which 50% of susceptible cells remain viable, 
the neutralising capacity of patient serum is considerably higher than that of a 
representative control sample, and is consistent with the 100- to 1,000-fold 
increase in NAb titre observed in previous reovirus trials (White et al., 2008). 
There was no evidence for the involvement of the complement system in 
reovirus neutralisation, with heat-inactivation of serum generating no overt 
effect. While supporting previous data indicating no role for complement in 
reovirus neutralisation in ascites (Jennings et al., 2014), this contradicts a 
recent study in which an inhibitor of the complement C3 molecule was shown to 
significantly preclude reovirus neutralisation in plasma (Evgin et al., 2015). The 
basis for this disparity is unclear. This study employed a different strategy of 
disabling complement (HI vs inhibitor) and output method (MTT assay vs plaque 
assay), and used serum rather than anticoagulant-treated plasma; all of which 
could interfere with the outcome. 
Comparison of six different serum samples, including two sets of paired 
samples, yields an insight into the temporal variation in patient NAb titre. Peak 
titre appears to occur within 1-3 weeks of infusion, with NAb levels diminishing 
somewhat beyond five weeks. This reflects the findings of existing trials, 
wherein maximal titres are reached within two weeks (Gollamudi et al., 2010; 
White et al., 2008). Although no pre-treatment samples were available, this 
rapid generation of NAb upon infusion resembles a secondary response, 
supporting the notion that these specific patients had experienced prior 
exposure to the virus. 
The anamnestic response is dominated by high-affinity IgG, and it was 
hypothesised that this antibody class would form the chief defence against the 
virus. Western blot analysis revealed the presence of reovirus-specific IgG and 
IgA in patient serum. IgM was not detected; a more sensitive method such as 
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an indirect ELISA (Selb and Weber, 1994; Tai et al., 2005) would be required to 
conclusively prove its absence. 
As expected, IgG was found to play the most substantial role in neutralisation, 
albeit with a significant auxiliary role for IgA. This is consistent with the 
conclusion inferred from epidemiological studies that reovirus infection 
stimulates a specific IgA response that is not long-lived (Selb and Weber, 
1994). Further, with any prior reovirus exposure in these patients presumably at 
the respiratory or gut mucosa, memory B cells in circulation are more likely to 
be IgA-secreting. These may represent a cell pool primed – upon i.v. reovirus – 
to differentiate into IgA-secreting plasma cells, thus generating a serum 
antibody reaction somewhat polarised towards IgA. Nevertheless this bispecific 
antibody response to the virus is of relevance when considering the ability of 
reo-NAb to interact with certain immune populations. 
As seroprevalence for reovirus is common, in most individuals any i.v.-
administered virus will encounter low-level NAb. This was recapitulated using a 
crude in vitro model, in order to make a visual and functional assessment of the 
proteins binding the virus. It was hypothesised that, in contrast to controls, 
patients treated with a massive, non-physiological dose of virus will develop a 
‘hyper-immune’ NAb response. Electron microscopy demonstrated that patient-
derived serum does indeed boast an enriched quota of virus-binding antibodies. 
The presence of these antibodies is further evidenced by their ability to 
immunoprecipitate reovirus when added exogenously. These assays 
substantiate the concept of a ‘reo-NAb’ immune complex.  
Interestingly, it was not possible to detect endogenous reo-NAb in patient serum 
by the same immunoprecipitation method. While this may be due to insufficient 
assay sensitivity, it appears that levels of free reovirus in serum do decline 
sharply after administration. In the serum of most patients in the REO-013 trial – 
the precursor to REO-013 Brain – the viral genome could not be detected more 
than 24 hours beyond infusion (Adair et al., 2012). Virus can however be 
retrieved from blood mononuclear cells after i.v. infusion in both mice and 
humans (Adair et al., 2012; Ilett et al., 2014), a finding influential to the ‘virus 
hitch-hiking’ tenet discussed later. 
In summary, this chapter confirms the potent neutralising capacity of serum 
from reovirus-treated patients. IgG and IgA readily coat the surface of the virion, 
forming a reo-NAb complex. The influence of these reo-NAb complexes on 
immune and cancer cells is the topic of the following chapters. 
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 Delivery of reovirus for tumour cell oncolysis  
by primary human monocytes 
 
5.1 Introduction 
The field of oncolytic virotherapy is predicated upon the ability of some viruses 
to specifically infect, replicate in and kill malignant cells, whilst leaving other 
cells unharmed. This viral tropism is reliant on exploiting the aberrant pathways 
underpinning the enhanced survival and growth of a cancer cell. 
The selectivity of reovirus for transformed cells was first demonstrated four 
decades ago (Duncan et al., 1978; Hashiro et al., 1977), and the virus has 
represented a leading clinical candidate ever since the resurgence of the field in 
the 1990s. Reovirus demonstrates cytopathic activity against a broad array of 
tumour cell types, both in vitro and in pre-clinical animal models. Consequently 
the virus has been deployed in an international clinical development programme 
spanning over ten indications, with one phase III trial conducted 
(www.oncolyticsbiotech.com). 
Initial phase I trials were based on intratumoural delivery of reovirus, but this 
has since been supplanted by intravenous (i.v.) administration as the preferred 
approach to treating disseminated, metastatic disease. Although a highly 
practical approach, systemic delivery does present its own barriers to effective 
virotherapy. Many of these are unique to the vasculature: the humoral immune 
system for example is a highly evolved pathogen surveillance system, 
seemingly at odds with even a ‘benign’ virus. 
Loading virus on to ‘carrier’ immune cells represents one approach to evading 
complement and NAb as defensive mediators (Ilett et al., 2009; Jennings et al., 
2014). For instance, reovirus can be successfully delivered to tumours by 
loading dendritic cells (DC) or T cells ex vivo, even in the context of pre-existing 
antiviral immunity (Ilett et al., 2011, 2009). This is consistent with the findings of 
the translational REO-013 trial, in which systemically delivered virus accessed 
colorectal liver metastases despite NAb at baseline (Adair et al., 2012). 
Reovirus was associated with circulating immune cells but not found in plasma, 
indicating that while virus is swiftly neutralised in serum, a substantial fraction is 
conveyed to tumours by blood cell ‘hitch-hiking’. Reovirus also accessed brain 
tumours following a single i.v. infusion in REO-013 Brain trial patients, from 
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whom reovirus-immune serum was obtained for this study (Samson et al., 
2018). 
Consequently, the potentially costly and impractical ex vivo loading approach 
has been adapted in order to investigate the concept of loading carrier cells with 
virus in vivo. As systemically delivered reovirus in mice associates primarily with 
the myeloid fraction (Ilett et al., 2014), this compartment was targeted for 
expansion using the cytokine granulocyte macrophage colony-stimulating factor 
(GM-CSF). Mobilising the myeloid CD11b+ population prior to i.v. reovirus 
administration translated into effective virotherapy in a B16 melanoma model 
(Ilett et al., 2014). Alongside NK cells, monocytes were essential for therapy. 
Crucially, the efficacy of this pre-conditioning regime was only manifested in 
mice that had been pre-immunised with reovirus and thus carried significant 
antiviral NAb titres, consistent with a pro-therapeutic role for NAb. 
It was intended to translate these findings into the human setting, employing 
patient-derived sera and primary human monocytes to model systemic reovirus 
treatment for melanoma in vitro. 
 
5.2 Susceptibility of melanoma targets to reovirus 
Historically, metastatic melanoma treatments have been of extremely limited 
efficacy and prognoses poor. Conventional chemotherapy is gradually being 
surpassed by targeted and immunotherapy agents giving improved frequency 
and duration of response, with OV an emerging modality. The typical mutation 
status (MAPK pathway activation) of melanoma makes it an excellent target for 
direct lysis by reovirus in particular; its neoepitope burden, and thus 
immunogenicity, render it vulnerable to subsequent elimination by effector T 
cells. 
The potential for lytic elimination of melanoma cells by reovirus was first 
examined. Flow cytometry was used to confirm that JAM-A, the cognate 
receptor for reovirus, is abundantly expressed on the surface of resting 
melanoma cells, using Mel-624 as a representative cell line and the JAM-A 
clone 1H2A9 (Table 8) (Figure 5.2.1). 
The susceptibility of two well-characterised melanoma cell lines to reovirus was 
subsequently evaluated. The virus was added to sub-confluent cultures of Mel-
624 or SKmel-28 melanoma cells at a multiplicity of infection (MOI) ranging from 
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10-5 to 101 plaque-forming units (pfu) per cell. Cytotoxicity was evaluated after 
48 or 72 hours by the MTT viability assay described previously (section 3.3.2). 
Reovirus exhibits similar cytotoxicity profiles against both cell lines tested 
(Figure 5.2.2). After 72 hours, the virus completely eradicates viable cells when 
added at MOI 0.1, and even at MOI 0.001 is able to reduce viability to 





Figure 5.2.1 Surface expression of JAM-A by Mel-624 cells 
 
Mel-624 cell monolayers were harvested and stained with PE-conjugated 
antibodies against the reovirus receptor JAM-A, or a PE-conjugated isotype 
control. Cells were then washed and fixed, and PE staining analysed by flow 











Figure 5.2.2 Susceptibility of melanoma cell lines to reovirus 
 
Subconfluent monolayers of Mel-624 and SKmel-28 cell lines were treated with 
reovirus at stated MOIs for 48 or 72 hours. Cell viability was calculated by MTT 
assay and normalised to untreated controls at 100%. Values were obtained 
from four technical replicate wells for each condition. 
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5.3 In vitro hand-off assay 
Having confirmed its cytotoxic potential against human melanoma cell lines, 
reovirus was further investigated in the context of immune cell carriers. This 
same virus was employed previously to describe the ability of murine myeloid 
cells to convey virus to tumours in the presence of NAb; thus the aim was to 
use the sera from reovirus-treated patients (PS) described previously (section 
4.2) to replicate this in a human model. To this end, an in vitro assay was 
developed in which the ability of human monocytes to convey free or 
neutralised reovirus to tumour cells was investigated. 
As depicted in Figure 5.3.1, reovirus was first combined with PS such that the 
virus would be fully neutralised (reo-NAb). The neutralising ratio of PS to virus 
was determined for each serum by MTT assay (section 3.3.2). Neutralisation 
was allowed to proceed for 2-3 hours at 37°C. Freshly isolated primary human 
monocytes were then pulsed with an equivalent dose of either free virus (reo) or 
PS-neutralised virus (reo-NAb) for 2-3 hours at 4°C, to allow the inoculum to 
adsorb. Monocytes were thoroughly washed in PBS to remove unbound virus, 
then co-cultured with Mel-624 target cells to permit viral hand-off and killing. In 
parallel, reovirus or reo-NAb were added directly to targets, to act as controls 
for viral killing and viral neutralisation respectively. After 72 hours in culture, 
targets were harvested and viability assessed by flow cytometry. 
The primary human monocytes in this assay were obtained from peripheral 
blood mononuclear cells (PBMC) of normal donors, by positive selection. 
Leukapheresis cones from blood donors were rested overnight prior to density 
gradient separation in order to obtain PBMC. Magnetic beads were then used to 
positively select the CD14-expressing monocyte fraction. As shown by 
representative flow cytometry plots using the anti-CD14 clone M5E2 (Table 8), 
the CD14+ population comprising ~ 15-20% of live PBMC is consequently 
enriched to over 90% (Figure 5.3.2a and 5.3.2b). Few monocytes – as identified 
by CD14 expression, or size and granularity – are omitted by selection, with 
only ~ 1% of the depleted fraction staining for CD14 (Figure 5.3.2c). CD14 
selection was found to yield improved purity over CD11b selection (data not 
shown). 
The expression of the reovirus entry receptor JAM-A on the monocyte surface 
was confirmed by flow cytometry staining (Figure 5.3.3). This suggests that 
monocytes may be capable of the binding and internalisation of free reovirus, as 
previously described for human myeloid-derived DC (Ilett et al., 2011). 
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Light microscopy images provide an illustration of the results of the in vitro 
hand-off assay (Figure 5.3.4). In the absence of cell or virus treatment, Mel-624 
cells form a dense adherent monolayer in the base of the well. At an MOI of 10, 
free reovirus obliterates this monolayer, leaving cells detached and ostensibly 
dead after 72 hours. By contrast, cells treated with reo-NAb exhibit no overt 
signs of viral infection or compromised viability. This remains the case even 
after 144 hours (data not shown).  
In co-culture wells containing both targets and non-loaded monocytes, Mel-624 
monolayer integrity appears totally unaffected, indicating that in the absence of 
cargo primary human monocytes do not (either via phagocytosis or soluble 
factors) directly kill human melanoma cell lines. When pulsed with reovirus 
however, monocytes appear very capable of delivering virus to destroy target 
cells. Similarly, although a minority of targets appear to remain, monocytes 
pulsed with reo-NAb also generate extensive killing after 72 hours in co-culture. 
A more quantitative assessment of the relative potency of direct or monocyte-
loaded reovirus or reo-NAb was gained by live-dead staining (Figure 5.3.5). For 
each condition, an equal input dose was used, and ten-fold dilutions of virus 
tested. As expected, direct addition of free virus proves the most cytotoxic 
treatment; at MOI 0.01 (per Mel-624 cell), over half of the target cell population 
are dead after 72 hours, consistent with the susceptibility data (Figure 5.2.1). In 
light of this sensitivity, the total absence of killing by any reo-NAb dose strongly 
indicates that patient serum does indeed abrogate direct infection of tumour cell 
targets by reovirus. 
Co-culture of Mel-624 with reo-loaded monocytes proves only slightly less 
potent than direct reo, with the vast majority of cells eliminated at an input MOI 
1 or above. Crucially, monocytes loaded with reo-NAb can also yield extensive 
target cell killing, albeit at higher virus doses than those required for free virus. 
In order to demonstrate the wider applicability of the neutralised virus hand-off 
paradigm, a range of other epithelial tumour cell lines were selected – one for 
each of four tumour tissue origins – and used in place of Mel-624 cells as 
targets. After a 72-hour incubation, as for Mel-624, all four lines demonstrated 
increased target cell death upon culture with reo-NAb loaded monocytes 
compared to reo-NAb alone (Figure 5.3.6). Although this increase was less 
substantial in the newly tested lines, it reached statistical significance in four of 
the five. The other cell line, Panc-1, exhibited wider variability in viability at 
baseline. This illustrates that the delivery of pre-neutralised reovirus by 





Figure 5.3.1 Hand-off assay schematic 
 
First, as per section 3.4.1.2, reovirus was combined with a neutralising dose of 
patient serum (NAb) and incubated at 37°C for 3 hours to form reo-NAb 
complexes. These, or other types of cargo (NAb or reovirus alone; grey box) 
were then pulsed on to primary human monocytes at 4°C for 3 hours, prior to 
washing and then co-culture of ‘loaded’ monocytes (mono + cargo) with tumour 
cell targets. In separate wells, tumour cells were cultured with the same doses 
of ‘cargo’ directly. Viability of the target cell population was analysed after 72 
hours by flow cytometry.  
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Figure 5.3.2 Selection of monocytes from human healthy donor PBMC 
 
Following isolation from whole blood, human PBMC were incubated with anti-
CD14 microbeads and a magnetic column used to select microbead-bound 
cells. Beads were permitted to dissociate overnight prior to staining with a PE-
conjugated antibody against human CD14, or isotype control, and flow 
cytometry analysis.  
Whole PBMC (a), CD14-selected (b), and CD14-depleted (c) fractions of PBMC 
are shown. Monocytes are readily distinguished from lymphocytes by scatter 
plots (left) as well as CD14 expression (right). The lower threshold of the CD14-














Figure 5.3.3 Monocyte expression of JAM-A 
 
Following CD14 selection, cells were stained with PE-conjugated antibody 
against human JAM-A (blue) or isotype control (grey), washed and fixed with 
PFA. Gating on monocytes by forward/side scatter, marker expression was 









Figure 5.3.4 Representative images of outcomes from the hand-off assay 
 
Prior to flow cytometry analysis after 72 hours, light microscopy images were 
taken of the tumour cell cultures. In this case, the input dose of reovirus used 
was MOI 10 with respect to Mel-624 cell number. This dose of reovirus or reo-
NAb complexes was added either to monocytes (mono) for hand-off, or directly 
to tumour cells. Compromised cell viability can be clearly observed by cell 
rounding and detachment. Images are representative of at least five identical 
experiments in which images were taken. Scale bar = 100 µm. 
  
mock mono 
reo mono (reo) 




Figure 5.3.5 Quantification of tumour cell killing in the hand-off assay 
 
After 72 hours in culture, all cells were harvested from wells and incubated with 
a fluorophore-tagged dead cell stain prior to analysis by flow cytometry. 
Melanoma cells were identified by their greater size and granularity than 
monocytes (a). The proportion of these cells staining positively was determined 
to be the dead cell fraction, which was quantified for each condition (b). 
The ‘input MOI’ of virus was with respect to the starting Mel-624 cell number. 
MOI 0 refers to mock treatment for both the direct treatments (circles) and 
monocyte co-culture conditions (squares) respectively. Data showing the 
absence of killing by direct addition of serum, or untreated or serum-treated 
monocytes, are not shown for brevity. 
Mean values ± SEM from three independent experiments, each using a different 
serum sample and monocyte donor. 








Figure 5.3.6 Application of the hand-off assay to other target cell lines 
 
Target cells were treated with medium (clear bars), reo-NAb complexes (light 
grey bars) or reo-NAb loaded monocytes (dark grey bars), and cell viability 
assessed by flow cytometry after 72 hours. 
Mean values ± SEM are shown from at least three independent experiments. 







5.4 Transferability to other OV platforms 
Having demonstrated its relevance to various solid tumour types, the hand-off 
assay was next extended to other virus agents to assess its applicability in the 
wider OV arena. Two other well-characterised OV in clinical development were 
selected for comparison to reovirus: coxsackievirus A21 (CVA21), a positive-
sense single-stranded RNA virus; and herpes simplex virus 1716 (HSV1716), a 
modified double-stranded DNA virus. 
First, as for reovirus, the capacity of these agents to exert cytotoxic effects upon 
melanoma cells was confirmed. The expression of the cognate viral receptors 
by Mel-624 cells was determined by flow cytometry staining, using fluorophore-
conjugated antibodies (Table 8). As shown in Figure 5.4.1, this representative 
melanoma cell line expresses high levels of surface CD54 / CD55 (for CVA21), 
and high CD111, moderate HVEM, and negligible CD112 (for HSV1716).  
In line with these observations, melanoma cell lines are readily killed upon 
treatment with either CVA21 or, to a lesser degree, with HSV1716. Using the 
same colorimetric assay as above (Figure 5.2.2), Mel-624 or SKmel-28 cells 
were treated with tenfold-diluted CVA21 or HSV1716, and viability assessed 
after 48 or 72 hours following addition of MTT (Figure 5.4.2). After 72 hours, a 
dose of approximately 0.0001 pfu per cell CVA21 is sufficient to reduce viability 
by half. In contrast, although viability is compromised by addition of HSV1716, 
cell death proceeds much more slowly, with over 1 pfu per cell required to 
reduce viability by half after 72 hours. 
These two OV were then compared to reovirus in terms of their efficacy in the 
hand-off assay. As for reo, this required the prior addition of a neutralising dose 
of patient-derived anti-CVA21 serum or anti-HSV1716 pleural fluid to form virus-
antibody complexes. These complexes were either added directly to Mel-624 
targets at MOI 10, or the same dose added to monocytes, prior to co-culture for 
72 hours as before. As shown in Figure 5.4.3, direct addition of complexes 
yielded no Mel-624 cell death over baseline, confirming viral neutralisation in 
each case. When conveyed by monocytes, CVA21 complexes induced 
significant killing comparable to reovirus complexes, yet HSV1716 complexes 
generated no appreciable cell death (reo p = 0.0038, CVA p = 0.0008, HSV p = 
0.292 respectively by Student’s t-test). This remained the case when the co-





Figure 5.4.1 Expression of receptors for other OV by Mel-624 cells 
 
Mel-624 cells were obtained from cell culture and stained with PE- or APC-
conjugated antibodies against (a) the CVA21 receptors CD54 and CD55, or (b) 
the HSV1716 receptors CD111, CD112 and HVEM (red), or matched isotype 


































Figure 5.4.2 Susceptibility of melanoma cell lines to selected OV 
 
Subconfluent monolayers of Mel-624 and SKmel-28 cell lines were treated with 
OV at stated MOI for 48 or 72 hours. Cell viability was calculated by MTT assay 
and normalised to untreated controls at 100%. Values were obtained from four 
technical replicate wells for each condition. 
ED50 = the MOI at which cell viability is 50% after 72 hours in culture. 
 
  
ED50 (72 h): 
7.58 x 10-4 
ED50 (72 h): 
5.04 x 10-5 
ED50 (72 h): 
4.47 





Figure 5.4.3 Application of the hand-off assay to other oncolytic viruses 
 
Virus-neutralising antibody complexes (virus-NAb) were formed using matched 
OV and patient-derived NAb sources (serum or pleural fluid). These were added 
directly to Mel-624 targets (clear bars), or pulsed on to monocytes prior to 
washing and co-culture with targets (grey bars) for 72 hours. Mel-624 viability 
was assessed by flow cytometry. 
Mean values ± SEM are shown from at least three independent experiments. 





5.5 In vivo effects of reo-NAb complexes 
The efficacy of systemic reovirus, partnered by GM-CSF, as a therapy for 
murine melanoma is enhanced by the presence of NAb which bind reovirus in 
circulation (Ilett et al., 2014). It was intended to replicate the formation of these 
in situ-formed complexes ex vivo, prior to administration, in order to formally 
demonstrate their efficacy. 
In order to assess the capacity of neutralised reovirus to access and destroy 
tumour tissue in vivo, it was necessary to generate mouse serum bearing anti-
reovirus antibodies. 6- to 8-week old mice were immunised i.p. with 2 x 107 pfu 
live reovirus on days 0 and 7. On day 14 mice were culled, and serum collected 
from pooled clotted blood as described for patient blood (section 3.3.1).  
As previously, the neutralising capacity of mouse serum against reovirus was 
assessed by MTT viability assay using halving serial dilutions (Figure 5.5.1). As 
illustrated by the gap between the untreated and anti-reovirus curves, the 
increase in reovirus neutralising capacity (by ND50) is 160-fold in this mouse 
cohort. Using this information, specific ratios of serum to virus were tested on 
L929 cells (data not shown), and only those confirmed to be fully neutralised 
used in subsequent in vivo experiments. 
The hypothesis that ex vivo-neutralised virus remains able to access tumours in 
mice was next investigated. This was conducted in C57BL/6 mice using the 
well-characterised and aggressive syngeneic B16-F10 melanoma model. The 
schematic is shown in Figure 5.5.2a. 6- to 8-week old reovirus-naïve mice were 
given a s.c. injection of 2 x 105 B16-F10 cells, and tumours allowed to establish 
over seven days. Three i.p. injections of 300 ng GM-CSF (or PBS as control) 
were administered over three days, to mobilise the myleloid compartment. Mice 
then received two i.v. injections of reo-NAb, at a low dose (containing 2 x 107 
pfu) or a high dose (5 x 107 pfu), and were sacrificed three days later. 
Tumours were harvested immediately and processed for the presence of 
reovirus by two methods: qPCR, to detect viral genomes, and plaque assay, to 
detect functional virions. The accurate quantitation of reovirus RNA in tumour 
tissue required normalisation to mouse GAPDH as a housekeeping gene, using 
the ΔΔCT method. A mean number of copies of the reovirus S4 gene per cell 
(see Adair et al., 2012) was calculated within each group, and standardised to 
the group given a low reovirus dose (without prior GM-CSF).  
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This revealed that, compared to the ‘low reo’ dose, the high dose produced a 
minimal increase in tumour-borne reovirus copies; by contrast, GM-CSF pre-
conditioning appears to substantially boost the number of copies reaching the 
tumour (Figure 5.5.2b). Unfortunately, it was not possible to judge the 
significance of these findings, as it was necessary to generate individual mean 
values for each group at an early stage of data processing. 
The same tumour samples were homogenised and analysed by standard 
plaque assay on L929 targets to determine the access of functional pfu to the 
tumour bed. The number of pfu was corrected according to both the total 
tumour weight and the volume of lysate derived from the sample, in order to 
estimate the total pfu in the tumour (assuming homogeneity). The data suggest 
that in the region of 1 x 105 pfu were present in each tumour (Figure 5.5.2c). 
There appears to be a slight increase in tumour viral load in the high dose and 
the GM-CSF pre-conditioning groups, which is not significant due to high 
variation between mice. 
Having established that neutralised reovirus can access melanoma lesions 
when given systemically, it was aimed to assess to what extent this process is 
influenced by the nature of the NAb present on the virus surface. It was 
hypothesised that using artificial NAb may reproduce the findings observed with 
whole mouse serum. This was investigated using monoclonal antibodies 
against a number of different epitopes on the reovirus σ3, σ1 and µ1 capsid 
proteins. Two different reo-NAb complexes were made with these ‘artificial 
NAb’. Reovirus was combined with either a sole, highly neutralising anti-σ1 
antibody G5, or a mixture comprising a combination of five monoclonal Ab with 
varying neutralising ability, all in equal proportions, termed ‘combo’ (Tyler et al., 
1993). Both of these formulations were confirmed to be neutralised on reovirus-
sensitive L929 targets (data not shown). 
These two artificial reo-NAb complexes were tested against the reo-NAb 
prepared with immune mouse serum, based on the virus load reaching the 
tumour. The schedule is shown in Figure 5.5.3a. Reovirus-naïve mice (3-4 per 
group) bearing seven-day established B16-F10 tumours were given three doses 
of GM-CSF as before (300 ng i.p.) over three days, followed by two daily doses 
of reo-NAb complexes (5 x 107 pfu); the type of reo-NAb administered to each 
mouse group is detailed in Figure 5.5.3b. Mice were sacrificed three days later, 
and tumour viral load assessed by plaque assay. 
In comparison to the group with the highest titre from the previous experiment – 
group C, receiving GM-CSF and reo-NAb complexes containing virus-immune 
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serum – the groups receiving ‘artificial’ reo-NAb complexes appear to show 
higher titres (Figure 5.5.3c). The increase in titre between groups C (serum) and 
E (mAb combo) is statistically significant (p = 0.045 by one-way ANOVA). The 
increase observed in group D (mAb G5) over group C does not reach 
significance (p = 0.218). These results suggest that a more ‘pure’ solution of 
NAb may be more capable of accessing the tumour than serum, which contains 
other factors such as complement that can destroy virus in transit. The trend 
seen between the ‘combo’ and ‘G5’ conditions is indicative of a benefit from the 
polyclonal as opposed to monoclonal opsonisation of virus in circulation, 
although this requires further investigation. 
These studies in virus delivery demonstrate that intravenously administered, 
fully neutralised reovirus can access well-established melanoma lesions in 
mice, at doses that appear sufficient to yield clinical value. In order to assess 
the therapeutic benefit of antibody-neutralised reovirus, a further experiment 
was conducted to measure efficacy in terms of tumour burden and survival. 
Here, the comparison was made between administering reo-NAb complexes 
formed ex vivo (from mouse serum) to virus-naïve mice, and administering free 
reovirus to virus-immune mice, thus forming reo-NAb complexes in situ. It was 
hypothesised that as the free reovirus would be rapidly neutralised in the 
circulation of immune mice, the therapeutic impact in these two groups would 
be similar; any differences might be attributable to the insufficiency of 
exogenous NAb to replicate elements of the virus-immune state. 
A schematic of the experiment is shown (Figure 5.5.4a). Mice (8 per group) 
were either pre-immunised i.v. with 2 x 107 pfu UV-inactivated reovirus 
(‘immune’) or PBS (‘naïve’), and NAb allowed to accumulate for 11 days, 
consistent with the timing of peak NAb titre in mice and patients (Adair et al., 
2012; Ilett et al., 2014). Flank tumour implantation was then performed using 
the reovirus-sensitive B16tk cell line (5 x 105 cells s.c. in 50 µl PBS). Mice 
bearing these three-day established tumours were administered three doses of 
i.p. GM-CSF as above, prior to two 1.5 x 107 pfu ‘live virus’ doses of either free 
reovirus (immune animals) or reo-NAb complexes (naïve animals). 
Data on the progression of tumour growth are displayed in Figure 5.5.4b. The 
curves representing tumour volumes in both virus-treated groups separate early 
from the control group, showing a numerical trend for slower tumour growth. 
However, at no time point do these differences reach statistical significance, as 
determined by unpaired Student’s t-test (values shown in inset), so it cannot be 
judged that these treatments significantly retard tumour growth in this instance. 
138 
 
Notably, the main causal ‘limiting factor’ in this outcome appears to be variation 
in the control group. No significant difference in tumour volumes was observed 
between the two reovirus groups. 
Figure 5.5.4c shows the Kaplan-Meier survival curves for the three groups 
tested. All mice in the control group were sacrificed by day 17 after implantation. 
The virus treatment groups showed no survival benefit over control, as 
assessed by Log-rank test (data not shown). A substantial number of mice 
needed to be sacrificed due to tumour ulceration rather than size, which was 







Figure 5.5.1 Generation of mouse anti-reovirus serum 
 
6- to 8-week old C57BL/6 mice were twice immunised with i.p. reovirus (reo) or 
PBS as control (con), then blood was collected and serum obtained. (a) Serial 
dilutions of serum were tested by neutralisation assay against reovirus (MOI 
0.05) for 48 hours on L929 cells. (b) 50% neutralizing dose values were 








Figure 5.5.2 Delivery of replicating virus to melanoma tumours by i.v. 
administration of reo-NAb complexes formed ex vivo with immune serum 
 
(a) In vivo schematic. Mice (3 per group) with seven-day established B16-F10 
flank tumours were administered GM-CSF or PBS i.p., then ex vivo-formed reo-
NAb at a dose of 2 x 106 pfu (low), or 5 x 106 pfu (high) i.v. prior to sacrifice.  
(b) Tumours were analysed for the presence of reovirus RNA, normalised to 
mouse GAPDH, by qPCR.  
(c) The same tumour samples were analysed for total reovirus pfu by plaque 
assay. Each data point represents one mouse; mean values are indicated.  
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Figure 5.5.3 Delivery of replicating virus using complexes formed of 
reovirus-immune serum or monoclonal antibodies 
 
(a) In vivo schematic. Mice with seven-day established B16-F10 flank tumours 
were administered GM-CSF or PBS i.p., followed by ex vivo-formed reo-NAb* at 
a dose of 5 x 106 pfu i.v. prior to sacrifice.  
(b) Groups tested. The ‘NAb’ used in reo-NAb complexes was either reovirus-
immune mouse serum, or a single (G5) or multiple anti-reovirus monoclonal 
antibodies (‘combo’). 
(c) Quantification of reovirus pfu in tumour tissue by plaque assay. Each data 
point represents one mouse; mean values are indicated. *p < 0.05 between 
selected groups by one-way ANOVA (Tukey’s multiple comparisons test). 
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Figure 5.5.4 Therapeutic benefit of i.v. administration of reo-NAb 
complexes 
 
(a) In vivo schematic. Virus-immune or -naïve mice bearing three-day 
established B16tk flank tumours were administered GM-CSF i.p., followed by 
1.5 x 107 pfu live reovirus or reo-NAb i.v., and monitored for tumour growth. 
(b) Tumour volumes, judged at various time points following implantation. Mean 
values from 8 mice + SEM are shown. Table shows the p values between 
conditions by unpaired Student’s t-test (Holm-Šidák corrected). 
(c) Kaplan-Meier analysis of survival within groups. No significant differences 
were observed by Log-rank test.  
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Although 5-year survival rates for melanoma as a whole exceed 90%, the 
prognosis for patients with advanced metastatic disease has been dismal 
(DeSantis et al., 2014). Prior to the current decade, therapies with the ability to 
improve this outlook have proven elusive. However, the approval of targeted 
drugs such as vemurafenib, and immunotherapy agents including checkpoint 
inhibitors, have fundamentally altered the treatment landscape. Now other 
emerging classes are adding to the weaponry of immunotherapy, led by 
adoptive cell therapy and OV. 
In a limited sense, some OV may be viewed as targeted therapies in that they 
are able to infect not just transformed cells but subsets with specific activating 
mutations – the tropism of reovirus for Ras-transformed cells being one 
example. Melanoma is at least theoretically an attractive target for reovirus 
based on the prevalence of activating mutations in the Ras/MAPK pathway, with 
BRAF mutations in 40-70% and NRAS mutations 15-30% (Dhomen and Marais, 
2009). A constellation of in vitro studies described an association between 
reovirus infection and signalling downstream of EGFR (Strong et al., 1993; 
Strong and Lee, 1996), and more specifically by putative Ras-mediated 
inhibition of protein kinase R (PKR), which is otherwise pivotal in the clearance 
of virus from the cytoplasm (Bischoff and Samuel, 1989; Coffey et al., 1998; 
Imani and Jacobs, 1988; Norman et al., 2004; Strong et al., 1998). The 
targeting of PKR has also been associated with the cancer-selective tropism of 
vaccinia virus and an attenuated herpes simplex virus (Parato et al., 2012; 
Poppers et al., 2000). 
The evidence for a causal connection between the Ras pathway and reovirus 
permissivity has however been questioned by studies demonstrating Ras-
independent oncolysis in a range of cell lines (Song et al., 2009; Twigger et al., 
2012). Nevertheless there remain defined aspects of reovirus permissivity that 
are augmented by Ras-transformation, including virus uncoating and progeny 
infectivity (Shmulevitz et al., 2010). Therefore there remains support for the 
deployment of reovirus against specific tumour types harbouring Ras pathway 
activation such as melanoma. 
Two well-characterised cell lines expressing the common V600E BRAF 
mutation, Mel-624 and SKmel-28, were tested for susceptibility to three 
genetically diverse yet clinically relevant OV: reovirus (dsRNA), CVA21 
(positive-strand ssRNA) and HSV1716 (dsDNA). Both cell lines were highly 
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susceptible to reovirus, as previously described (Errington et al., 2008b). The 
even higher degree of susceptibility to CVA21 was not surprising given the 
known efficacy of this virus in the melanoma setting, both in vitro and in vivo 
(Andtbacka et al., 2015a; Shafren et al., 2004). Equivalent doses of HSV1716 
killed melanoma targets less quickly than other OV; the virus demonstrating 
lower potency than was shown previously against another melanoma cell line 
(Randazzo et al., 1997). 
The presence of cognate receptors for the two most lytic viruses tested was 
confirmed: both JAM-A for reovirus (Maginnis et al., 2006) and CD54 and CD55 
for CVA21 (Shafren et al., 1997) are richly expressed at the Mel-624 cell 
surface. These data provide a likely basis for cell susceptibility and are 
consistent with the tendency for transformed cells to overexpress these 
receptors (Shafren et al., 2004; Zhang et al., 2013). 
The expression of surface receptors for type 1 herpes simplex virus was more 
variable, which may to some extent explain the comparatively limited 
cytotoxicity of HSV1716 towards the melanoma cell lines tested. This may also 
be attributed to other intrinsic differences between HSV1716 and the two RNA 
viruses, such as its larger and more complex genome, which can result in 
slower replication or lower toxicity. 
Using these melanoma cells as targets, the ability of human myeloid cells to 
deliver neutralised reovirus to kill tumour cells in vitro was illustrated. This assay 
provides a human correlate of previous studies in which mouse-derived myeloid 
cells were shown capable of delivering reo-NAb complexes to murine 
melanoma targets. In the reovirus-immune mouse, myeloid cells are a major 
sink for systemically administered virus (Ilett et al., 2014). Human monocytes 
were employed here based on their abundance in blood, and thus provision for 
use as virus carriers (Ginhoux and Jung, 2014). 
Selection of monocytes (at a physiological ratio of 1 in 6 PBMC) was achieved, 
and found to be highly sensitive and specific. In co-culture assays, these are 
difficult to distinguish visually from dead target cells, but can be readily 
discriminated by flow cytometry, enabling killing of tumour cells to be assessed 
specifically. The direct cytotoxicity of reovirus is almost entirely replicated by 
reo-loaded monocytes – suggesting that – if all killing is virus-mediated – 
monocytes are well-suited to reovirus carriage. This is substantiated by their 
expression of JAM-A and sialic acid (Malergue et al., 1998; Stamatos et al., 
2004), and previous evidence of reovirus hand-off to tumour cells by human 
myeloid cells (Ilett et al., 2011). 
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Given that replication-competent virus is retained by PBMC despite the 
presence of NAb in reovirus-treated patients (Adair et al., 2012; Roulstone et 
al., 2015), myeloid cells could represent an important reservoir for virus in 
circulation. In this study, reovirus that is otherwise fully neutralised by antibody 
can be delivered to kill targets by monocytes – indicating that these cells can 
not only bind and release virus in this form, but can also liberate it from antibody 
neutralisation.  
That this mode of virus carriage can also kill targets of other tumour types 
indicates that the ‘hitch-hiking’ paradigm may be a more widely applicable one. 
Similarly, the delivery of serum-neutralised reovirus can be faithfully replicated 
with CVA21, indicating that this phenomenon could prove more broadly relevant 
in the OV field. However, data suggesting that HSV1716 cannot productively 
hitch-hike in the same way suggests that specific aspects of virus physiology 
may determine applicability, such as the influence of a glycoprotein envelope on 
the initial binding of antibody. A further investigation of this finding would also 
need to consider the far inferior cytotoxicity of HSV1716 towards melanoma cell 
lines, as this, rather than a mechanistic, qualitative explanation, may constitute 
the major reason. 
Building on previous evidence for the efficacy of GM-CSF pre-conditioning plus 
reovirus in virus-immune animals (Ilett et al., 2014), it was hypothesised that 
upon the systemic administration of virus, reo-NAb complexes form in situ which 
can be bound by myeloid cells and conveyed to the melanoma tumour bed to 
mediate therapy. The formation of reo-NAb complexes ex vivo prior to i.v. 
infusion into naïve animals represents a correlate of this approach, designed to 
confirm the therapeutic potential of neutralised virus. Serum-neutralised virus 
accessed tumours in all mice tested, as shown convincingly by the presence of 
viral genomes and replicating virus in tumour homogenates. This is a strong 
indication that reovirus is able to escape from the vasculature and reach 
neoplastic sites, despite – or even via – NAb binding. The increase in tumour 
viral load observed upon the substitution of immune serum for a ‘pure’ solution 
of artificial monoclonal antibodies suggests that other factors in serum aside 
from NAb, such as complement, may exert antiviral effects upon reovirus. 
The presence of virus was associated with a non-significant trend towards a 
reduction in tumour volumes in animals pre-conditioned with GM-CSF prior to 
reo-NAb therapy, when compared to the control group. This numerical trend did 
not translate into meaningful clinical benefit, in that no significant improvement 
in survival was detected over mock-treated mice. Thus it was not possible to 
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replicate the therapeutic benefit observed in virus-immune mice, where the 
incoming virus encounters NAb in situ instead of ex vivo (Ilett et al., 2014). 
However, based on this prior evidence and the observed trend in tumour 
growth, it can be speculated that there may be superior efficacy observed upon 
use of reovirus in pre-immune animals as opposed to reo-NAb in immune 
animals. If this proves the case, it is likely underpinned by the global presence 
of NAb able to support anti-tumour processes such as ADCC at the tumour site 
– consistent with a role for both monocytes and NK cells in therapy (Ilett et al., 
2014). 
The human-derived in vitro and murine in vivo data in this chapter substantiate 
the stated model: in pre-immune patients, i.v. reovirus rapidly binds to NAb, and 
is subsequently able to hitch-hike in or on myeloid cells to the tumour site, 






 Interaction of reovirus-antibody complexes with 
monocyte carrier cells 
 
6.1 Introduction 
Along with immune molecules such as antibodies and complement, immune 
cells represent a major arm of the apparent ‘barriers’ to intravenously 
administered virus, being an evolutionarily conserved surveillance system for 
viral and bacterial defence. These cells are equipped with a range of tools for 
interacting with pathogens, ultimately designed to promote recognition and 
clearance. But what if – in the context of a ‘friendly’, oncolytic virus – these cells 
could be exploited in order to promote viral persistence, rather than elimination? 
The concept of using cell carriers to deliver a viral payload to the tumour bed is 
not a novel one in the context of virotherapy. This stems from the observation 
that systemically administered virus does not exist freely in circulation for long 
(Ilett et al., 2014; Willmon et al., 2009) – in patient blood, OV is readily found 
associated with the immune cell fraction (Adair et al., 2012; Roulstone et al., 
2015). Further, in the non-oncolytic context of HIV transmission, the transfer of 
virus between unwitting ‘carrier’ DC and ‘target’ CD4+ T cells in secondary 
lymphoid organs is a well-described phenomenon (Geijtenbeek et al., 2000). 
Early enquiries into the use of cell carriers deployed T cells as vehicles for 
retroviruses and rhabdoviruses, among others (Cole et al., 2005; Kottke et al., 
2008; Qiao et al., 2008c), with the rationale that tumour antigen-specific T cells 
might permit exquisite specificity of OV targeting. In the last decade, a desire to 
optimise viral loading and persistence, tumour homing, immune evasion and 
viral delivery has led to the testing of various candidate carrier cell types, 
including tumour cells themselves (Power et al., 2007), activated T and NK cells 
(Jennings et al., 2014; Yang et al., 2012), and stem cells (Ahmed et al., 2011; 
Mader et al., 2009). 
More recently, antigen-presenting cell types (APC) have been examined as 
putative carriers. These typically share the ability to bind and internalise virus, 
and to traffic to lymph nodes and tumour sites, offering the possibility of 
engendering a broader anti-tumour response once there via co-operation with 
infiltrating T cells. The fact that APC are unusually prone to viral infection (Hou 
et al., 2012) and, simultaneously, commonly well poised to direct antiviral 
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immune responses is surely no coincidence (Yewdell and Brooke, 2012). More 
likely is that viruses evolve to infect these cell types – or perhaps the other way 
around – in a high-stakes game of bluff. By becoming a willing host at the 
cellular level, the APC can ultimately succeed by co-ordinating forces against 
the virus on a broader scale. In the context of OV however, it is hoped that the 
antiviral response is either sufficiently delayed to deliver a viral payload, or is 
outweighed by a gathering inflammatory response against tumour antigens.  
To date, various myeloid cells, predominantly DC and macrophages, have been 
deployed as vehicles for OV including reovirus, measles virus, vaccinia virus 
and adenovirus (Byrd et al., 2014; Iankov et al., 2007; Ilett et al., 2011; Jennings 
et al., 2014; Muthana et al., 2013; Peng et al., 2009). As their common 
precursor, the blood monocyte therefore represents a cell abundant in the 
circulation which may be readily targeted by OV. While the original cell carriage 
paradigm sought to sequester virus and evade NAb, this chapter aims to 
examine the mechanism by which human monocytes can interact with, 
internalise, and deliver infectious virus following its neutralisation by patient-
derived antibody. 
 
6.2 Imaging reovirus-treated monocytes 
The initial binding, and (in many cases) uptake of an OV by a cell is a 
prerequisite for cell carriage. In keeping with their remit as pathogen sensors, 
lymphocytes express a wide repertoire of virus receptor molecules. Human 
PBMC such as monocytes express high levels of surface JAM-A; this commonly 
operates in extravasation, but in this context functions as the cognate receptor 
for reovirus, readily enabling the virus to bind (Adair et al., 2013). Both T cells 
and DC are capable of reovirus carriage; while T cells permit ‘surface’ carriage, 
DC allow internalisation of the virus, which can ‘shield’ it from antibody 
neutralisation (Ilett et al., 2011, 2009). 
Further to their ability to convey otherwise neutralised reovirus to kill melanoma 
cell targets in vitro, primary human monocytes were assessed by a variety of 
methods to better comprehend their interaction with both free reovirus and reo-
NAb complexes. Immunofluorescence (IF) microscopy has the capacity to 
visually localise sub-cellular components with sensitivity and precision, and has 
become a powerful tool for virus quantification and trafficking. Thus, 
149 
 
confirmation of the binding of virus to the monocyte surface using IF was first 
sought. 
Monocytes on glass coverslips were pulsed with reovirus (MOI 2,000) at 4°C for 
1 hour, then incubated at 37°C for 2 hours to allow the internalisation process to 
begin. The cells were then fixed using PFA, washed, and permeabilised with 
Triton X-100 prior to IF staining. Cells were stained for the reovirus σ3 protein 
(clone 4F2, Alexa Fluor 488), the F-actin cytoskeleton (phalloidin Alexa Fluor 
647) and the nucleus (DAPI), and visualised on a confocal laser scanning 
microscope. 
Figure 6.2.1 provides an illustration of the immunofluorescence images 
obtained. Although as phagocytic cells monocytes are known to be cytoplasm-
rich, in these artificial conditions there is limited cytoplasm visible around the 
nucleus, as represented by diffuse F-actin staining. Using actin to delineate the 
outer margin of the cell, abundant green signal indicates the binding of a 
substantial number of reovirus particles to the cell membrane (Figure 6.2.1a). 
Further, by using Z-stacks to interrogate multiple planes within the same cell, 
individual reovirus-positive ‘pockets’, likely inbound endosomal compartments, 
can be identified (Figure 6.2.1b). 
However, the reliance of IF on antibody labelling means that reo-NAb, in which 
the virus capsid is coated in antibody, is rendered undetectable by this method. 
Consequently, alternative methods of assessing the binding of both reovirus 
and reo-NAb were pursued. 
While IF can provide reasonable spatial resolution on individual cells, other 
methods such as flow cytometry are capable of providing quantitative 
information on a much larger cell population by virtue of its high throughput. 
Monocytes were thus treated with reo-NAb, or an equivalent dose of either NAb 
or reovirus alone (MOI 50), prior to staining for the reovirus σ3 protein (FITC) or 
for human IgG (Alexa Fluor 594). Cells were then washed, fixed in PFA and 
analysed by flow cytometry. As shown in Figure 6.2.2a, only monocytes treated 
with free reovirus demonstrated positive staining for reovirus σ3 (28.09% of the 
viable cell population). The viral component of reo-NAb could not be detected 
by σ3 staining. However, while no human IgG was detected on monocytes 
when treated with NAb alone, over 10% of monocytes stained exhibited a signal 
for human IgG following treatment with reo-NAb (Figure 6.2.2b). 
With this evidence of direct adhesion of reo-NAb to the monocyte surface, a 
more detailed insight into this binding event at the ultrastructural level was 
sought using electron microscopy (EM). Initial attempts to assess the interaction 
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of virus with monocytes obtained by positive selection of CD14+ cells were 
compromised by cellular uptake of the magnetic beads used for their isolation – 
consistent with their phagocytic nature – which interfered with the identification 
of virus particles (data not shown). Consequently, cells used for EM were 
obtained by negative selection from PBMC, generating a cell population of 
91.5% purity for the pan-myeloid marker CD11b (data not shown). 
After selection, as for flow cytometry, these cells were treated with reo-NAb 
(MOI 50) or an equivalent dose of NAb or reovirus alone. After washing, cells 
were rested at RT for 5 minutes to allow internalisation, then fixed with PFA and 
GA. Cells were pelleted, positively stained using osmium tetroxide, embedded, 
and ultra-thin sections (80 nm) cut for transmission electron microscopy. 
Representative images of monocytes treated with reovirus (a,b) or reo-NAb 
(c,d) are shown in Figure 6.2.3. 
Evidence of reovirus entry was found with both treatments. Intact viral particles 
were identifiable by the electron-dense staining of the genome within the viral 
core (Figure 6.2.3b, arrows); a substantial proportion of empty capsids were 
also seen (arrowheads). In reovirus-treated cells, viral structures were observed 
in large endosome-like inclusions, with considerable virus still present at the cell 
surface. In cells treated with reo-NAb, similar viral inclusions were noted, with 
the number of viruses found within cells appearing markedly lower (not 
quantified). In contrast to the sharply delineated borders of free reovirus 
particles (Figure 6.2.3b), evidence of the presence of NAb upon the viral capsid 
within inclusions could be observed as a furry ring around its perimeter (Figure 
6.2.3d). 
To confirm that the structures found were indeed reovirus particles, cells were 
treated as before and processed using an immunogold labelling protocol, with 
70 nm sections cut. Cells were stained using a mouse primary antibody against 
reovirus σ3 (or isotype control), followed by an anti-mouse secondary antibody, 
then 10 nm gold particles conjugated to protein A, and finally contrasted with 
uranyl acetate. In mock-treated cells, no gold labelling was observed, 
demonstrating the specificity of labelling (Figure 6.2.4a). By comparison to 
reovirus-treated, isotype-stained cells (Figure 6.2.4b), gold particles can be 
found in reovirus-treated, σ3-stained cells (Figure 6.2.4c). Gold labelling is also 
observed in reo-NAb treated, σ3-stained cells (Figure 6.2.4d). The degree of 
labelling in reo-NAb treated cells appears substantially lower than with the free 
virus, even taking into account the higher viral load with reovirus. 
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Having demonstrated the ability of free and antibody-neutralised reovirus to 
bind and enter monocytes using various modes of imaging, subsequent assays 
were performed in order to investigate the mechanisms by which reo-NAb 






Figure 6.2.1 Immunofluorescence analysis of reovirus-treated monocytes 
 
Following CD14-selection, monocytes were plated on coverslips and treated 
with reovirus (MOI 2,000, 4°C for 1 hour) and incubated for 2 hours at 37°C, 
then washed and fixed. Cells were then permeabilised, and stained with DAPI 
(blue), Alexa Fluor 647 phalloidin (red) or mouse anti-reovirus σ3 antibody (4F2) 
and Alexa Fluor 488 anti-mouse secondary antibody (green) prior to confocal 
microscopy analysis. Representative single channel (a) and merged (b) images 
are shown.  Arrows indicate apparent ‘pockets’ of possibly internalised virus. 
Scale bars = 10 µm. 
  



























Figure 6.2.2 Flow cytometry analysis of binding of reovirus or reo-NAb to 
monocytes 
 
Healthy donor monocytes were treated with NAb, reovirus (MOI 50) or reo-NAb, 
washed, and stained for (a) reovirus σ3 protein (FITC) or (b) human IgG (Alexa 
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Figure 6.2.3 Positive staining of reovirus or reo-NAb treated monocytes 
 
Healthy donor monocytes were treated with reovirus (a,b) or reo-NAb (c,d) 
(MOI 50) and washed. Virus was allowed to internalise at RT for 10 min. prior to 
fixation and pelleting. Samples were post-fixed with osmium tetroxide, 
dehydrated, and infiltrated with resin. Sections were cut and visualised by TEM. 
Representative low-resolution (a,c) and high-resolution (b,d) images are shown. 












Figure 6.2.4 Immunogold labelling of reovirus or reo-NAb treated 
monocytes for σ3 protein 
 
Healthy donor monocytes were untreated, or treated with reovirus or reo-NAb 
(MOI 50), and washed. Virus was allowed to internalise at RT for 10 min. prior 
to fixation, pelleting and sectioning. Sections were stained with primary antibody 
against reovirus σ3 (4F2) or isotype control, followed by mouse secondary 
antibody, then protein A-conjugated 10 nm gold. Samples were contrasted with 
uranyl acetate prior to transmission electron microscopy. Scale bars = 1 µm 
(a,b) or 300 nm (c,d). 
 
Representative images are shown: 
(a) – mock; σ3 staining 
(b) – reovirus; isotype control 
(c) – reovirus; σ3 staining 







6.3 Mechanism of reo-NAb entry 
Two cell surface molecules are key in the classical mechanism of reovirus 
entry. First, low-affinity interactions occur between sialic acid and the virus σ1 
protein; these are followed by high-affinity viral attachment to the 
aforementioned JAM-A protein (Barton et al., 2001). Both molecules are central 
to viral persistence in vivo (Antar et al., 2009; Barton et al., 2003). In the context 
of human leukocytes, the role of sialic acid appears to predominate in virus 
attachment in vitro (Ilett et al., 2011).  
A fully opsonised pathogen presents a subtly different challenge to one that is 
untouched by humoral effectors. Antibody binding not only limits the free 
interaction of viral mediators of attachment and fusion to the target cell, but also 
provides a route by which opsonised virus can be cleared, termed antibody-
dependent cellular phagocytosis (ADCP). ADCP is reliant on the recognition of 
pathogen-bound antibody Fc regions by Fc receptors on phagocytes, leading to 
uptake and ultimately degradation. 
It is perhaps unsurprising, given the continual arms race between pathogen and 
host, that viruses can co-opt this clearance pathway for their benefit – in limited 
circumstances. The role that antibodies can play in promoting infection at the 
cellular level – ADE – is a paradoxical one. The enhancing effect of antibodies 
in ADE operates at the point of entry to a phagocytic cell, whereby receptors for 
virus-bound antibody or complement can facilitate infection and/or subsequent 
virus amplification – leading to more severe disease in vivo (Halstead et al., 
1973). Following its initial description in the context of dengue virus, this 
phenomenon has been extended to other viruses, both oncolytic and non-
oncolytic (reviewed in Taylor et al., 2015). 
Circulating human monocytes are principal targets of viral infection, in both the 
classical setting and in the context of ADE (Hou et al., 2012; Kou et al., 2008; 
Sun et al., 2011; Tsai et al., 2014; Wang et al., 2010). Reovirus, which infects 
and replicates in human monocytic cells (Thirukkumaran et al., 2003), has been 
the subject of two studies in which antiviral antibodies have been employed to 
promote infection. Virus-immune sera were found to enhance infection of 
mouse macrophages (Burstin et al., 1983). More recently, the artificial 
endowment of otherwise non-permissive cells with the expression of Fc 
receptors was sufficient to permit reovirus infection in the presence of 
neutralising antibodies (Danthi et al., 2006). 
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Before investigating the function of specific receptors, the theory that the 
presence of neutralising antibodies could promote reovirus infection of myeloid 
cells was addressed. Whole blood was taken from healthy donors in anti-
coagulant tubes, and supplemented or not with patient-derived serum as a 
source of NAb. Reovirus was then added at an approximate MOI of 10 with 
respect to PBMC count, and incubated for 30 minutes at 37°C. The CD14-
selected and -depleted populations were obtained from PBMC as before by 
magnetic selection, and virus titre analysed by plaque assay (Figure 6.3.1). 
Although the total virus load on CD14+ cells was decreased following the 
addition of patient serum, CD14+ cells did carry a significantly increased load as 
a proportion of the total cell-associated virus (p = 0.049 by Student’s t-test). 
This suggests that patient serum does favour the routing of reovirus to the 
myeloid population in the context of whole blood. 
It was therefore hypothesised that the previously observed carriage of reo-NAb 
(section 6.2) was reliant upon the interaction of virus-bound antibody with 
monocyte Fc receptors. The expression of the four major surface-expressed Fc 
receptor isoforms was first established. CD14-selected monocytes were stained 
with antibodies (Table 8) against CD64 (FcγR I), CD32 (FcγR II), CD16 (FcγR 
III) and CD89 (FcαR) and fluorescence analysed by flow cytometry (Figure 
6.3.2). CD32, CD64 and CD89 were present on the entire cell population; CD32 
was most highly expressed, followed by CD64 and CD89. In contrast, CD16 
was found to be present on a limited sub-population of approximately 13%. 
These observations are consistent with monocyte Fc receptor expression at the 
RNA and protein level, and the existence of multiple monocyte subsets in blood, 
between which CD16 is a key discriminator (Cros et al., 2010; Wong et al., 
2011; Ziegler-Heitbrock and Hofer, 2013).  
To prove a role for Fc receptors in the carriage of reo-NAb, monoclonal 
antibodies or F(ab’)2 fragments were used to functionally block receptors prior 
to the addition of cargo during the hand-off assay (section 5.3). Whole 
monoclonal antibodies were used as isotype control or used to block CD89; the 
anti-CD89 REA234 clone (see Table 4) binds the same epitope as the function-
blocking MIP8a clone (Zhang et al., 2000). CD64, CD32 and CD16 were 
targeted using F(ab’)2 fragments with documented blocking activity (Laborde et 
al., 2007). Cells were incubated with blocking agents for 45 minutes at 4°C prior 
to the addition of reo-NAb at MOI 10, and further incubation for 2-3 hours at 
4°C. Monocytes were washed in PBS, resuspended in RPMI-10 and added to 
targets for 72 hours as described previously (section 3.4.1.4). 
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Figure 6.3.3 describes the effect of Fc receptor blockade on the ability of 
monocytes to convey neutralised reovirus to kill Mel-624 target cells. Only the 
blockade of monocyte FcγR III (CD16) with the higher dose of the well-
characterised antibody clone 3G8 (Chauhan et al., 2015) was sufficient to yield 
a significant decrease in endpoint Mel-624 death (p = 0.0089 vs isotype by 
Student’s t-test). All other manipulations failed to generate any significant 
change in Mel-624 death. Similarly, subsequent experiments blocking the 
neonatal Fc receptor (FcRn) with three concentrations of an inhibitor peptide 
SYN1436 (Mezo et al., 2008) indicated no role for this receptor in monocyte 
loading with reo-NAb (data not shown). 
In the same experiments, samples of monocytes were also obtained 
immediately after loading, and were segregated for analysis of virus titre. These 
samples were subjected to three freeze-thaw cycles and vortexed (to release 
any rapidly internalised virus) prior to standard plaque assay. The resulting 
pattern of virus loading (Figure 6.3.4) is extremely similar to that of Mel-624 cell 
death: only a high dose of F(ab’)2 fragments against FcγR III generates a 
significant decrease in loading of reo-NAb treated monocytes (p = 0.031 vs 
isotype by Student’s t-test). Consequently, it can be summarised that blockade 
of FcγR III leads to a significant decrease in target cell killing via a reduction in 
the virus cargo carried. 
To further substantiate a role for monocyte FcγR III in the interaction and 
carriage of reo-NAb, two monocyte sub-populations were studied: the larger 
classical monocyte subset (CD14++ CD16−) and the non-classical subset 
(CD14+ CD16+). It was hypothesised that the non-classical subset would form 
superior mediators of reo-NAb hand-off, on account of their expression of FcγR 
III. 
Both cell populations were selected from PBMC using magnetic beads, each by 
a two-step sorting process, to generate populations expressing the appropriate 
markers (data not shown). They were rested overnight in order to permit the 
dissociation of selection beads from functional surface receptors such as FcγR 
III itself. Subsequently these CD16+ and CD16− populations were tested for their 
ability to hand off reo-NAb as described previously. As shown in Figure 6.3.5, 
CD16+ monocytes carrying reo-NAb do yield a significantly higher degree of cell 
death than their CD16− counterparts (p = 0.0072 by Student’s t-test). This effect 
cannot be attributed to a non-specific effect of co-culture with this population, as 
CD16+ monocytes are not otherwise toxic to Mel-624 cells. Similarly, no 
significant difference could be found in the ability of CD16+ and CD16− cells to 
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mediate killing via free reovirus, suggesting that only antibody-bound virus is 
subject to differential carriage by these populations.  
Together, these results indicate that FcγR III is at least partly responsible for 
facilitating reo-NAb carriage by monocyte cells. These results substantiate 
evidence from a murine model, in which Fc receptors were found to be 





Figure 6.3.1 Neutralising patient antibodies favour routing of virus to 
CD14+ cells in whole blood 
 
Whole blood from healthy donors was combined with patient-derived serum and 
incubated with reovirus for 30 min. at 37°C. The CD14+ and CD14− populations 
were then selected and virus titre determined by plaque assay. The virus load 
on the CD14+ population is displayed, as a percentage of the total cell-
associated virus load.  
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Figure 6.3.2 Expression of Fc receptors on primary human monocytes 
 
Following CD14 selection, monocytes were stained with fluorophore-conjugated 
antibodies against specific Fc receptors (red), or isotype control (grey). 
Monocytes were gated as in (a) and surface expression of protein was 
determined by FITC or PE staining respectively (b). The percentage staining 





























Figure 6.3.3 Effect of monocyte Fc receptor blockade upon Mel-624 killing 
via reo-NAb hand-off 
 
CD14-selected monocytes from healthy donors were treated with Fc receptor-
blocking monoclonal antibodies or F(ab’)2 fragments, or isotype control, at two 
concentrations (10 or 100 µg/ml) for 45 minutes at 4°C. Monocytes were then 
loaded with reo-NAb (MOI 10), washed and added to Mel-624 targets. Target 
cell death was assessed by flow cytometry after 72 hours in co-culture. 
Mean values ± SEM from four donors are shown. **p < 0.01 by Student’s t-test 
(multiple comparisons with Holm-Šidák correction). nd = not determined. 
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Figure 6.3.4 Effect of monocyte Fc receptor blockade upon virus loading 
 
CD14-selected monocytes from healthy donors were treated with Fc receptor-
blocking monoclonal antibodies or F(ab’)2 fragments, or isotype control, at two 
concentrations (10 or 100 µg/ml) for 45 minutes at 4°C. Monocytes were then 
loaded with reo-NAb (MOI 10) and washed. Virus load was determined by 
plaque assay. 
Data ± SEM from four donors are shown. *p < 0.05 by Student’s t-test (multiple 
comparisons with Holm-Šidák correction). nd = not determined. 
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Figure 6.3.5 CD16+ monocytes are superior mediators of reo-NAb hand-off 
 
CD16+ or CD16− monocytes were selected from PBMC, and rested overnight. 
Cells were then resuspended and pulsed with reo or reo-NAb (MOI 5), washed 
and added to Mel-624 targets for 72 hours. The proportion of dead Mel-624 
cells was determined by flow cytometry. 
Mean values ± SEM from four donors are shown. **p < 0.01 by Student’s t-test 
(multiple comparisons with Holm-Šidák correction). 
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6.4 Monocytes as replication factories? 
The process by which antiviral antibody can promote the binding and entry of 
virus to phagocytes is termed the ‘cell-extrinsic’ mechanism of ADE. A second, 
‘cell-intrinsic’ mechanism refers to intracellular signalling processes which result 
in an increased viral load being released from infected cells (Halstead et al., 
2010). This increase is a relative one compared to the often abortive or highly 
restricted degree of virus replication permitted by myeloid cells (Byrd et al., 
2014; Jenne et al., 2000; Royo et al., 2014), ostensibly as an immunogenic 
strategy (Yewdell and Brooke, 2012). In the context of dengue virus in vitro, Fc 
receptor-mediated entry suppresses antiviral cascades, such as by stimulating 
negative regulators of the pivotal antiviral axis controlled by RIG-I and MDA5, 
and enhances replication (Chareonsirisuthigul et al., 2007; Ubol et al., 2010). 
This phenomenon is also observed in vivo: compared to primary dengue 
infection, the presence of antiviral antibody upon secondary infection leads to 
an elevated viraemia, and often precipitates the more severe clinical syndrome 
of dengue haemorrhagic fever (Cohen and Halstead, 1966; Green et al., 1999).  
Reovirus type 3 Dearing does not appear capable of significant amplification in 
the heterogenous human PBMC population (Douville et al., 2008). However, 
given that primary human monocytes appear to permit infection by free reovirus 
and reo-NAb, it was postulated that monocytes alone may be capable of 
amplifying virus titres during transit, and that the parameters of viral persistence 
or replication in the presence of reo-NAb may be different to those in the face of 
free reovirus. In order to examine this system, the requirement for virus 
replication in the hand-off assay was first examined.  
After the addition of reovirus- or reo-NAb loaded monocytes, or viral cargo 
alone, to target cells, all supernatant and cells were harvested from wells either 
immediately (0 hour ‘input’) or at the same endpoint used for analysis of cell 
viability (72 hours) and virus titre determined by plaque assay. As was predicted 
based on the viability data (Figures 5.3.4 and 5.3.5), significant viral replication 
is observed after 72 hours following treatment of Mel-624 cells with either 
reovirus, reovirus-pulsed monocytes or reo-NAb pulsed monocytes (Figure 
6.4.1). The titre resulting from reo-NAb pulsed monocytes is no less than – and 
in fact exceeds – that resulting from conditions involving free reovirus; a 
statistically significant six-log increase over the ‘input’ titre (p = 2.58 x 10-6 by 
Student’s t-test). By contrast, the direct addition of reo-NAb to Mel-624 cells 
yields no significant increase in virus titre, consistent with the absence of cell 
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death observed previously. Consequently it can be considered that while virus 
in the form of an immune complex (reo-NAb) is fully neutralised, monocytes are 
capable of carrying and liberating virus in a form which is either already 
amplified, or is capable of rapid amplification. 
The importance of viral replication was further investigated using reovirus which 
had been rendered incapable of replicating by UV irradiation. This virus 
(‘UVreo’) was subjected to a two-minute dose of UV-C, the equivalent of 500 
mJ, and proven to be non-replicative by plaque assay (data not shown). UVreo 
was then compared to free reovirus in its ability to generate cell death via the 
monocyte hand-off assay. Three modes of virus application to Mel-624 cells 
were again considered, at equal input doses: direct addition of virus; monocytes 
pulsed with free virus; and monocytes pulsed with reo-NAb complexes. As 
before, populations were harvested from co-culture wells after 72 hours and 
analysed for viability by flow cytometry. 
Examining first the direct addition of virus to target cells (clear bars), UVreo is 
equally capable of generating melanoma cell death as compared to replicating 
virus (Figure 6.4.2). This observation is likely a consequence of the high virus 
dose used, in that it appears sufficient to engender cytopathic effect (CPE), a 
rapid, non-lytic mode of cell death independent of virus replication. When 
conveyed by monocytes, free UVreo remains able to kill over 50% of target cells 
after 72 hours (light grey bars), albeit significantly fewer than when using 
replicating virus (p =  5.90 x 10-4 by Student’s t-test). It could be considered that 
a higher dose may be able to entirely eliminate the Mel-624 population by CPE. 
Lastly, when carried by monocytes, UVreo-NAb does not generate any target 
cell death above baseline, unlike with the use of the replicating virus (p = 2.45 x 
10-7 by Student’s t-test). This indicates that the dose of virus delivered here is 
considerably lower than by other routes, such that the killing of melanoma target 
cells is entirely reliant on replication within them.  
However, this assay does not address the question of whether monocytes act 
as amplifiers of virus, or mere carriers. Thus the permissivity of monocytes to 
reovirus, either free or antibody-neutralised, was examined by the detection of 
viral genomes and plaque-forming units respectively. Monocytes were pulsed 
with reovirus or reo-NAb as before, washed, and cultured on their own in RPMI-
10 for 48 hours. After 2, 16 or 48 hours, cells and supernatants were harvested, 
and either processed to obtain RNA for qPCR, or analysed by plaque assay. 
RNA from infected monocytes was extracted and converted to cDNA with an 
unbiased method based on random hexamer primers. The comparative CT 
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method of qPCR analysis was subsequently used to quantify the number of 
copies of the reovirus S4 gene present relative to the cellular gene for β-actin, 
assuming equal primer efficiency. As shown in Figure 6.4.3, after treatment with 
reovirus, monocytes exhibit a peak in reovirus gene expression after 16 hours 
which is approximately 100-fold higher than that at the 2-hour baseline. This 
peak is largely diminished after 48 hours, indicating that a wave of viral 
transcription occurs within one day of infection that is subsequently suppressed.  
Unfortunately, the number of reovirus genomes present in reo-NAb treated 
monocytes was insufficient to reach the limit of detection in this qPCR assay. 
Consequently, in lieu of data regarding nucleic acids, the plaque assay method 
was employed to obtain data on the titre of replicating virus particles (pfu) 
present over time in both the cells and supernatant (Figure 6.4.4a). In the cell 
fraction, in comparison to the 100-fold increase in genomes detected by qPCR, 
the 16-hour peak in pfu is very limited – within a 2-fold increase, for both 
reovirus- and reo-NAb treated monocytes. For reovirus-treated cells, this titre 
then drops sharply after 48 hours, while the decline is more gradual for reo-NAb 
treated cells. 
A decline in pfu within cells can either indicate degradation, or virus release into 
the supernatant. In the context of both virus inputs, titre in the supernatant is 
already substantial within 2 hours of loading, Particularly in the context of reo-
NAb, where the 2-hour supernatant titre is already at its highest, this suggests 
that the processing and release of virus occurs rapidly. Supernatant titres do 
however remain stable, indicating that there may be a low degree of ongoing 
virus release over the following time points.  
These data can also be examined as a percentage of the total virus titre in both 
cells and supernatants (Figure 6.4.4b). For reovirus, the proportion of virus in 
the cell fraction drops over time, from 66% to 32%. Given that the increase in 
supernatant titre is minimal, this is suggestive of degradation rather than virus 
release. By contrast, in reo-NAb treated monocytes the cell-associated fraction 
increases from 19% to 39%, indicating that monocytes are perhaps more 
permissive to low level virus replication following internalisation of antibody-







Figure 6.4.1 Reovirus amplification following reo-NAb hand-off by 
monocytes 
 
Following addition of reovirus/reo-NAb or monocytes pulsed with reovirus/reo-
NAb (MOI 10), Mel-624 cultures were harvested either immediately (0 h) or after 
72 hours. Titre of replicating virus was determined by plaque assay. For 
conditions where neat reovirus was used, data from one representative 
experiment is shown; for reo-NAb conditions, data represent mean values ± 
SEM from at least five independent experiments. ns = not significant; ***p < 
0.001 by Student’s t-test (multiple comparisons with Holm-Šidák correction). nd 






Figure 6.4.2 Tumour cell killing via hand-off using live or UV-inactivated 
virus 
 
Data indicate the percentage of Mel-624 cells killed following 72 hours in culture 
with live or UV-inactivated reovirus. Virus was delivered either by (a) direct 
addition to Mel-624 cells, (b) monocyte hand-off of free virus, or (c) monocyte 
hand-off of antibody-neutralised virus. The virus dose used in all conditions was 
MOI 10 with respect to monocyte number. 
Mean values ± SEM from at least six independent experiments are shown. ns = 
not significant; **p < 0.01; ***p < 0.001 by Student’s t-test (multiple comparisons 
with Holm-Šidák correction). 
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Figure 6.4.3 Viral genomes in monocytes following reovirus or reo-NAb 
loading 
 
Monocytes were CD14-selected from PBMC and loaded with reo or reo-NAb 
(MOI 2.5). Cells were then washed and cultured at 2 x 106 cells per ml for the 
number of hours stated on the x axis. Cells were harvested and the number of 
viral genomes present determined by qPCR, using reovirus S4 as the target 
gene and human β-actin (ACTB) as a reference gene. Values are normalised to 
the 2 hour time point. Mean values ± SEM from three donors are shown. bld = 






Figure 6.4.4 Replicating virus titre in monocytes following reovirus or reo-
NAb loading 
 
Monocytes were CD14-selected from PBMC and loaded with reo or reo-NAb 
(MOI 2.5). Cells were then washed and cultured at 2 x 106 cells per ml for the 
times stated. Cells and cell-free supernatants were harvested and virus titre of 
each determined by plaque assay. Data are presented as either (a) the total 
number of pfu present or (b) the percentage of the total pfu present in either the 
cell or supernatant fraction. 




















6.5 Mechanism of reovirus transfer 
In terms of a purely oncolytic paradigm for cancer therapy, cellular loading of a 
viral cargo is worthless without its transit and effective release at the intended 
site. Antigen-presenting cells readily migrate from the circulation to the 
periphery. The trafficking of DC from the blood is pivotal to their role in T-cell 
stimulation during an inflammatory response (Steinman and Banchereau, 
2007). Both of the major cell types deriving from monocytes (DC and 
macrophages) are recruited to tumours (Bingle et al., 2002); monocyte-derived 
macrophages in particular accumulate at the tumour site (Leek et al., 1999; 
Muthana et al., 2011; Peng et al., 2009). Maturation is often concomitant with 
extravasation, and can be facilitated by virus infection (Hou et al., 2012; Sun et 
al., 2011). Macrophages have thus been harnessed to deliver adenovirus and 
measles virus for therapy of prostate and myeloma lesions respectively 
(Muthana et al., 2013; Peng et al., 2009). Other cells of this lineage, such as 
myeloid-derived suppressor cells – which accumulate in tumours following 
intraperitoneal reovirus administration (Clements et al., 2015) – also represent 
capable OV vehicles (Eisenstein et al., 2013). 
After intravenous administration, replicating reovirus can be recovered not only 
from patient PBMC but also from solid tumours (Adair et al., 2012). The 
mechanisms by which virus transfer can occur between carrier and target are 
myriad. Most obviously, these include a crude yet well-timed release of free 
virus (Muthana et al., 2013), which may nevertheless be vulnerable to 
subsequent neutralisation. More sophisticated mechanisms include viral 
transfer within exosomes or by immunological synapses, both of which may 
protect virus from antiviral factors in the tumour milieu (Groot et al., 2008; 
Kottke et al., 2006; Masciopinto et al., 2004). 
The role of virus – or alternatively, other soluble factors – in Mel-624 cell killing 
by virus-loaded monocytes was initially examined. Monocytes were pulsed with 
virus and washed, and were either added directly to target cells as in the hand-
off assay, or were cultured for 48 hours in order to generate cell-free 
conditioned medium (CM). Mel-624 cells were then treated with CM, or CM pre-
filtered to remove virus (FCM), for 72 hours as in the hand-off assay. The ability 
of virus filters to reduce virus titre beyond detectable levels was confirmed by 
plaque assay on the CM and FCM of one sample of monocytes treated with 
reovirus (Figure 6.5.1a). 
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Flow cytometry was used to quantify Mel-624 viability (Figure 6.5.1b). As shown 
previously (Figure 5.3.5), target cells are comprehensively eliminated by 
monocytes loaded with free reovirus. CM from reovirus-loaded monocytes 
proves equally toxic, while filtration of CM significantly mitigates killing (p < 
0.001 by two-way ANOVA), indicating that the viral component of CM is the 
main mediator. This is consistent with the substantial virus titre present in 
supernatant from virus-treated monocytes (Figure 6.4.4).  
The cytotoxic effect of reo-NAb loaded monocytes is somewhat diminished 
when 48-hour CM from loaded cells is used in place of the cells themselves (p < 
0.001 by two-way ANOVA). The remaining degree of killing can be attributed to 
a viral component, as target cell killing is returned to background levels upon 
filtration of CM (p < 0.05 by two-way ANOVA). Thus although the virus present 
in the supernatant does appear at least partly responsible for killing, this leaves 
another part unaccounted for, represented by the discrepancy between CM and 
hand-off. This could either be attributed to the fact that CM contains virus 
released over 48 hours, in contrast to the 72-hour hand-off. Alternatively, 
another process may facilitate virus egress from monocytes in co-culture (hand-
off) conditions, as compared to in culture alone. 
The mechanism of virus transfer was further interrogated using two further 
manipulations to the hand-off assay. First, a receptor-blocking approach was 
taken in order to confirm the role of freely released reovirus. Prior to the addition 
of reovirus- or reo-NAb loaded monocytes, target cells in culture were incubated 
for 30 minutes with an antibody blocking JAM-A. Tumour cell viability was 
analysed as standard after 90 hours in co-culture (Figure 6.5.2). JAM-A 
blockade significantly abrogates tumour cell killing during incubation with reo-
NAb loaded monocytes (p = 0.00082 by Student’s t-test). The same is true for 
reovirus-loaded monocytes (p = 0.00078), although the effect size is smaller – 
perhaps due to the effective ‘dose’ of virus being delivered in this case being 
large enough to eventually out-compete the blocking antibody. Nevertheless it 
can be concluded that JAM-A is a key mediator of Mel-624 virus entry during 
hand-off by monocytes, supporting the notion that hand-off is reliant on the free 
release of virus. 
Lastly, the effect of separating the monocyte carrier cells in suspension from the 
adherent target cells during hand-off was examined. Virus-loaded monocytes 
were added to the insert of a transwell system with a 0.4 µm pore size, 
preventing them from making direct contact with the target cells below. As 
previously, Mel-624 viability was assessed by flow cytometry after a 90 hour 
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incubation (Figure 6.5.3). While the addition of a transwell membrane did not 
influence killing by reovirus-loaded monocytes at this virus dose, there is a 
significant difference in killing between the standard and transwell conditions in 
the context of reo-NAb loaded monocytes (p = 0.0040 by Student’s t-test). This 
observation is somewhat unexpected, given the stated evidence for the release 






Figure 6.5.1 Ability of conditioned medium from virus-loaded monocytes 
to kill tumour targets 
 
Monocytes were pulsed with reovirus or reo-NAb (MOI 10) and washed. Mel-
624 cells were treated either with these loaded cells directly (‘hand-off’ 
condition), or with 48-hour conditioned medium from these cells, without (CM) 
or with (FCM) subsequent removal of virus by filtration. Proof of virus 
elimination is shown in (a). Mel-624 viability was assessed after 72 hours (b). 
Mean values ± SEM from two independent donors are shown. *p < 0.05, ***p < 



















Figure 6.5.2 Effect of tumour JAM-A blockade on tumour cell killing via 
hand-off 
 
CD14-selected monocytes were pulsed with reovirus or reo-NAb (MOI 10) and 
washed. Target cells were incubated with isotype control antibody (clear bars) 
or antibody against JAM-A (grey bars) at 10 µg/ml for 30 minutes, prior to the 
addition of loaded monocytes. The percentage of Mel-624 cells killed after 90 
hours is displayed. 
Mean values ± SEM from four independent donors are shown. ***p < 0.001 by 






Figure 6.5.3 Tumour cell killing via hand-off in transwell assay format 
 
CD14-selected monocytes were pulsed with reovirus or reo-NAb (MOI 5) and 
washed. Cells were either added to wells containing Mel-624 targets as usual 
(clear bars) or to the insert of a transwell system with pore size 0.4 µm (grey 
bars). The percentage of Mel-624 cells killed after 90 hours is displayed. 
Mean values ± SEM from three independent donors are shown. **p < 0.01 by 






By definition, components of the humoral immune system such as antibody and 
complement maintain a broad antiviral function. This study seeks to identify the 
potential for antiviral antibody to also function in a pro-viral capacity, based on 
carriage of neutralised reovirus by monocyte cells. In this chapter, the 
mechanisms by which reovirus, in the form of reo-NAb immune complexes, can 
bind to, persist within and be released from monocytes are investigated.  
A variety of circulating immune populations are known sinks of virus in vivo 
(Kou et al., 2008). In the context of a non-physiological dose of OV this remains 
the case, in that cells readily carry virus irrespective of the presence of NAb 
(Adair et al., 2012; Roulstone et al., 2015). These observations are mirrored in 
the in vitro imaging and titration assays in this study, demonstrating that 
reovirus is able to bind to and persist within monocytes, whether presented as 
free virus or as reo-NAb. 
The presence or absence of neutralising antibody can however considerably 
influence the routing of virus in circulation. 30 minutes after reovirus 
administration to virus-immune mice, replicating virus is absent from plasma, 
but in blood cells is present at significantly higher titre than in naïve mice; most 
of this being in the myeloid fraction (Ilett et al., 2014). The data in this study do 
not reproduce this absolute increase in myeloid cell loading by NAb, but do 
indicate that NAb may promote virus routing to this population as a proportion of 
the whole. 
The apparent parallels between the monocyte uptake of reo-NAb complexes 
observed here and the existing literature documenting antibody-mediated entry 
of various viruses prompted an investigation of the receptors enabling myeloid 
cells to interact with an antibody-coated virus. The family of Fc receptors, which 
are heavily implicated in ADE, were therefore marked as primary candidates. 
Blocking studies, and the use of populations discriminated by their Fc receptor 
expression, strongly identified the CD16 molecule (FcγR III) as the most 
important mediator of reo-NAb hand-off of those tested.  
Along with the transitory ‘intermediate’ monocyte subset, CD16 is expressed on 
a minor population (~ 10%) of circulating monocytes, known as the non-
classical subset (Wong et al., 2011). It should be noted that although non-
classical monocytes express comparatively lower levels of CD14 (Cros et al., 
2010), the presence of CD16+ cells indicates that they are still present in the 
CD14-selected monocyte population employed for hand-off in section 5.3. 
179 
 
The non-classical subset exhibits a ‘patrolling’ phenotype in vivo, functioning as 
a sensor for viruses and immune complexes (Cros et al., 2010). In a range of 
inflammatory conditions including viral infections, the CD16+ population is 
expanded (Kwissa et al., 2014; Wong et al., 2012). Additionally, the ability of 
common polymorphisms in CD16 to predict the therapeutic response to 
oncolytic adenovirus may signal its relevance, not just to virus-stimulated ADCC 
but also potentially in antibody-dependent adenovirus infection (Hirvinen et al., 
2013). 
However, to date, Fc receptor-mediated virus ADE has largely been restricted 
to the other two Fcγ receptors, CD64 and CD32 (reviewed in Taylor et al., 
2015). Evidence for the role of CD16 in ADE is limited. However, like its better-
characterised cousin CD32, CD16 is a low-affinity Fc receptor and is associated 
with the intracellular γ-chain which is crucial for both receptor assembly and 
signalling (Wirthmueller et al., 1992). Indeed, CD16 is capable of mediating 
ADE of unrelated viruses in both porcine and human cell types (Gu et al., 2015; 
Tóth et al., 1994). Most recently, CD16 was specifically implicated in the 
recognition of virus-bound IgG in the development of severe dengue disease 
(Wang et al., 2017). To our knowledge, the present study represents the first 
report of CD16-mediated OV entry in human myeloid cells.  
It is notable that some degree of reo-NAb hand-off remains, both in the 
presence of CD16-blocking antibodies, or in the context of hand-off by CD16− 
monocytes. The basis for this observation is unclear. In this scenario as before 
(Fanger et al., 1996; Rodrigo et al., 2006) there may exist a degree of 
redundancy between Fc receptors, in that others such as CD64 and CD32 may 
also play a lesser role. It remains possible that the hand-off assay in this study 
is insufficiently sensitive to detect a role for these receptors, perhaps due to 
their incomplete saturation by blocking antibody prior to loading. It is also clear 
that the assay used to compare hand-off by populations differentially expressing 
CD16 does not take into account the potential for variable efficiency of virus 
delivery by these two monocyte subsets, which may confound the readout. As 
such although this study implicates CD16 in the uptake of reo-NAb by 
monocytes, a role for other receptors cannot be excluded. 
Returning to the relevance of the ADE phenomenon to the hand-off paradigm, 
two major discrepancies are apparent. First, reovirus loading and delivery is 
demonstrated in the context of complete neutralisation. By contrast, ADE is 
almost exclusively identified in the presence of sub-neutralising concentrations 
of antibody, or non-neutralising antibody (Halstead and O’Rourke, 1977; Mori et 
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al., 2008). There are few reports of virus entry by a fully neutralised virus. These 
include the observation of adenovirus infection of FcγR-expressing cells despite 
antibody neutralisation (Leopold et al., 2006). However, to our knowledge, this 
study is the first to report the infection of primary human phagocytes by a fully 
neutralised OV. 
Second – as shown by both the somewhat artificial hand-off assay and the 
more physiologically relevant test with whole blood – the loading and delivery of 
virus by monocytes is not enhanced by the presence of NAb. In fact, by 
assessment of viral titre and (by extension) target cell killing, the viral load of 
reo-NAb pulsed monocytes is consistently a factor of two logarithms below that 
of cells pulsed with the equivalent amount of neat virus. Given the virus is fully 
neutralised in reo-NAb, this suggests that antibody opsonisation is highly 
limiting to reovirus loading of carrier cells by the classical route which likely 
involves sialic acid (Ilett et al., 2011) and possibly JAM-A. Thus, although reo-
NAb is reliably delivered to targets, NAb cannot be said to be remotely 
‘enhancing’ in terms of monocyte virus uptake (extrinsic ADE). While not strictly 
ADE, reo-NAb loading of monocytes does appear to share the same 
mechanism: supplying an alternative route of loading, via Fc receptors. It can be 
speculated that in the case of a virus whose cognate receptor is not abundant 
on the phagocyte surface, NAb – even at fully neutralising concentrations – 
could expand virus tropism to include phagocytes and hence promote OV 
persistence in vivo. 
Our results describing the ability of myeloid cells to enable reo-NAb complexes 
to exert anti-tumour activity in the context of human cell types are highly 
comparable to those observed in the murine setting (Ilett et al., 2014). Elevation 
of Fc receptor expression by GM-CSF was associated with the enhanced ability 
of myeloid cells to take up neutralised reovirus for hand-off to kill target cells, 
and also to stimulate immune-mediated cytotoxicity. The aforementioned data 
are consistent with this study in that they support a substantial role for Fc 
receptor function in reo-NAb uptake, upon which hand-off depends. 
Following loading with reovirus or reo-NAb, the murine myeloid population 
clearly plays host to significant amplification of the virus (Ilett et al., 2014). This 
finding is not replicated in human monocytes – albeit in a shorter time frame – 
as virus titres remain relatively stable. Indeed, limited evidence was found for 
the relevance of intrinsic ADE to reo-NAb loaded monocytes. There is a minimal 
(46%) increase in cell-associated virus titre over 48 hours in the context of reo-
NAb, in contrast to a considerable decrease in the context of free reovirus. 
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Thus, although these data provide tentative evidence for low level virus 
replication following treatment of monocytes with reo-NAb complexes, it is clear 
that in this in vitro system with reovirus, these cells do not host the type of 
explosive amplification that occurs in ADE infection with dengue. In this sense, 
human myeloid cells do not mirror murine DC, which do support considerable 
reovirus amplification in vitro (Ilett et al., 2009). Rather, it is likely that the bulk of 
virus replication in the hand-off assay occurs in target tumour cells. This is 
despite the observation that – at least in the context of free reovirus – there is a 
substantial increase in reovirus genomes within the first 24 hours of infection, 
which is not manifested at the protein level. Such a disparity between the RNA 
and protein level would suggest a somewhat abortive replication cycle, perhaps 
due to the uncoupling of transcription and translation, which is explored further 
in the next chapter. 
Spatial information regarding the subcellular trafficking and fate of viral cargo 
would be useful in interpreting the patterns of viral persistence that were 
detected. Detection of the viral component of reo-NAb by antibody staining is 
precluded by the coating of the virus by neutralising serum antibodies. Owing to 
this – and to the unavailability of a reovirus construct encoding a fluorescent 
transgene – trafficking data could not be generated in this study. The 
expression of GFP in reovirus is detrimental to the stability of its RNA genome; 
the insertion of smaller constructs is possible but may require the replacement 
of endogenous genes (D. van den Wollenberg, personal communication, and 
van den Wollenberg et al., 2015). The semi-permanent labelling of reovirus 
RNA using nucleic acid stains and subsequent purification (Brandenburg et al., 
2007), which has proven difficult to achieve to date, represents a promising 
option by which reo-NAb trafficking may be investigated in future should a 
labelled virus remain unavailable. 
Following internalisation, free reovirus undergoes endo-lysosomal trafficking 
(Ehrlich et al., 2004; Mainou and Dermody, 2012a) and proteolysis (Mainou and 
Dermody, 2012b; Sturzenbecker et al., 1987), following which escape to the 
cytosol enables the formation of factory-like ‘viral inclusions’ which host 
replication (Becker et al., 2001; Broering et al., 2004; Silverstein and Schur, 
1970). The ability of reo-NAb to access both the endosome and possibly the 
cytosol may therefore explain the limited ability of the virus to replicate within 
monocytes. It should subsequently be possible, either by the co-localisation of 
virus with specific endocytic GTPases (Mainou and Dermody, 2012a) or the use 
of trafficking inhibitor compounds such as monensin (Wang et al., 2007), to 
determine the process by which a degree of virus load is so promptly released. 
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The capability of monocytes to rapidly liberate a significant proportion of their 
cargo is reinforced by the finding that successful hand-off is reliant on target cell 
JAM-A. These observations suggest that hand-off depends on the release of 
free virus, likely in the form of an intact virion rather than a disassembly 
intermediate able to infect independent of JAM-A (Alain et al., 2007; Borsa et 
al., 1979). In light of this, the observation that hand-off killing is limited upon 
separation of carriers and targets by a transwell membrane appears 
incongruent: if release of free virus represents the sole mechanism leading to 
killing, then the transwell should have no effect. Barring artifacts such as the 
aberrant adhesion of virus to the membrane, these data are challenging to 
reconcile. Processes of viral transfer commonly involve either a virus release- or 
cellular contact-dependent mechanism (reviewed in Zhong et al., 2013); a more 
complex process requiring both appears unlikely. It is therefore speculated that 
hand-off occurs via release of free virus, and that decreased killing in the 
transwell condition simply reflects the impact of increased diffusion distance 
between the carrier and target cells. Further manipulations would need to be 
made to the hand-off assay in order to consolidate this conclusion. 
However, given the critical nature of systemic anti-tumour immunity (Andtbacka 
et al., 2015b), perhaps of greater value to the field are the potential 
immunological consequences of monocyte carriage of reo-NAb. The ability of 
reo-NAb to influence monocyte phenotype and subsequently to stimulate the 





 Immunological consequences of antibody-bound 
reovirus on immune populations 
 
7.1 Introduction 
Whether therapeutic or pathogenic, a virus – like other microorganisms – 
presents a variety of exogenous ‘danger signals’ to the host immune system. 
Individually known as pathogen-associated molecular patterns (PAMP), these 
evolutionarily conserved features of pathogens are readily detected by a range 
of cellular sensors collectively termed pattern recognition receptors (PRR), 
according to Janeway’s ‘infectious non-self model (Janeway, 1989). The initial 
sensing of viruses is fundamental to their potent ability to stimulate the host 
immune system in both a specific and non-specific manner. 
While there are effective immune mechanisms that specifically target the 
invading pathogen – the generation of antiviral NAb being a key example – 
viruses also act as non-specific inflammatory devices within the immune milieu. 
In the context of cancer, such inflammatory properties are highly valuable as 
they are well suited to reversing the suppressive tumour microenvironment. 
Alongside the direct oncolytic traits that earned the name of OV, they add a 
second string to their bow: an immunostimulatory capacity, which is increasingly 
regarded as central to OV therapy (Prestwich et al., 2008b). The mechanisms 
by which OV can induce immune-mediated anti-tumour activity are manifold. 
Aside from direct lysis, these include the modulation of the cytokine 
environment and the activation of DC, which, as key linkers of innate and 
adaptive immunity, can elicit cytotoxic responses from both NK and T 
lymphocytes. 
The ability of reovirus to promote these immunological processes has been well 
documented (Adair et al., 2013; Errington et al., 2008a; Jennings et al., 2014; 
Prestwich et al., 2009a). The impact of antibody neutralisation upon reovirus 
immunogenicity is less well understood. Therefore the ability of both free 
reovirus and reo-NAb complexes to modulate monocyte phenotype and 





7.2 Activation of monocyte carrier cells 
During the evolution of innate pathogen surveillance mechanisms, significant 
functional redundancy has been generated. This comprises a host of germline-
encoded PRR ‘sentinels’ which are most richly expressed by APC. The 
individual PRR classes include C-type lectin receptors (CLR) at the cell surface, 
toll-like receptors (TLR) at the surface and within endosomes, and NOD-like 
receptors (NLR) and RIG-I-like receptors (RLR) in the cytosol. This spatial 
segregation leaves some (such as TLR) primarily suited to sensing extracellular 
pathogens, and others (such as RLR) responsible for detection of intracellular 
ligands, usually nucleic acids (reviewed in Akira et al., 2006). By converging on 
a set of ‘hub’ transcription factors – principally interferon response factors (IRF) 
and NF-κB – in the cytosol, these sensors trigger the transcription of 
inflammatory genes including type I interferons (IFN), pro-inflammatory 
cytokines and microbial defence peptides. In immature cells such as 
monocytes, this antiviral response is accompanied by a concomitant elevation 
of co-stimulatory markers and transition to a more mature phenotype (Errington 
et al., 2008a; Hou et al., 2012). 
The virus is an obligate intracellular parasite, entirely reliant on the host cell to 
replicate its DNA or RNA. Although proteinaceous viral components are readily 
recognised, the necessary exposure of nucleic acids is likely linked to the acute 
cellular sensitivity to these types of PAMP. The double-stranded RNA (dsRNA) 
of Class III virus genomes, and replication intermediates of some ssRNA 
viruses (Weber et al., 2006), are sensed by membrane-bound TLR3 and the 
cytosolic helicases termed retinoic acid-inducible protein I (RIG-I) and 
melanoma differentiation associated gene 5 (MDA5). The helicases have 
different ligand specifications – the 5’ triphosphorylated ends of short RNA for 
RIG-I, longer dsRNA species for MDA5 (Hornung et al., 2006; Kato et al., 2006) 
– and detect different RNA viruses accordingly (Loo et al., 2008).  
The downstream signal from RIG-I and MDA5 is integrated by the mitochondrial 
antiviral signalling (MAVS) adaptor protein (Kawai et al., 2005), while TLR3 
signals via the TIR domain-containing adaptor inducing IFN-β (TRIF) protein. 
Signalling cascades from MAVS and TRIF converge upon IRF3, whose 
phosphorylation triggers the transcription of antiviral response genes including 
PRR themselves (de Veer et al., 2001). 
TLR3 appears dispensable for virus sensing by many cell types (Edelmann et 
al., 2004; López et al., 2004). Despite its predominantly endo-lysosomal 
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localisation there is limited evidence to suggest a role for TLR3 in sensing 
viruses with specific entry routes; it may instead function in a cellular context, 
such as in detection of dsRNA upon presentation by dying, virus-infected cells 
(Schulz et al., 2005). By contrast, cytosolic helicases appear less dispensable. 
IFN responses are amplified or abrogated upon RIG-I overexpression or knock-
out respectively (Kato et al., 2005; Yoneyama et al., 2004) and knock-out of 
either helicase results in increased cellular susceptibility to virus (Kato et al., 
2006). 
Complementing the helicases RIG-I and MDA5, PKR represents an alternative 
dsRNA sensor in the cytosol. Following autophosphorylation, PKR responds to 
dsRNA ligand by phosphorylating eukaryotic initiation factor 2-alpha (eIF2α), a 
master regulator of translation, and thus precluding protein synthesis (Williams, 
2001). Simultaneously, PKR activation leads to the stimulation of NF-κB 
signalling by releasing the inhibitory action of IkB-β, yielding pro-inflammatory 
cytokine release (Bonnet et al., 2006; Deb et al., 2001; Williams, 1999). 
In order to examine the role of virus-sensing PRR in the interaction between 
monocytes and reovirus, the expression of individual sensor proteins was 
examined by western blot, as shown in Figure 7.2.1. Freshly isolated human 
monocytes were treated with patient serum, free reovirus or reo-NAb complexes 
at a high MOI of 10, cultured for 24 hours, and cell lysates probed with 
antibodies against PRR or downstream effectors. Free reovirus induces the 
robust upregulation of PKR and RIG-I, and there is evidence to suggest limited 
induction of MDA5. Reo-NAb treatment results in similar changes in the 
synthesis of PKR and RIG-I protein, to a slightly lesser degree; this can be 
attributed to the viral component, as free NAb has negligible impact. No bands 
could be detected when probing for TLR3 (data not shown).  
Looking further downstream at key transcription factors, the upregulation of 
IRF3 and the p50 subunit of NF-κB was observed upon reovirus or reo-NAb 
treatment, further demonstrating the induction of a global antiviral state. 
Investigation of the phosphorylation status of PKR or IRF3 by western blot, 
which would directly demonstrate their active involvement in proximal signalling, 
was not informative (data not shown). Consequently, while it appears likely, it 
cannot be concluded with certainty that cytosolic sensors are exposed to viral 
dsRNA following reovirus and reo-NAb treatment.  
In order to gain further information on the impact of reovirus or reo-NAb carriage 
on human monocyte phenotype, cells were cultured for 48 hours after treatment 
and expression of key surface markers analysed by flow cytometry. The 
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isotype-corrected median fluorescence intensity was determined on the myeloid 
CD11b+ population (Figure 7.2.2). The lipopolysaccharide receptor and 
immature myeloid marker CD14 is strongly downregulated by reovirus or reo-
NAb (p = 0.0001 and 0.0143 respectively by one-way ANOVA). This is mirrored 
by a reduction in surface CD11c protein, which does not reach significance 
upon reo-NAb treatment (p = 0.043 and 0.052 respectively). Together, these 
markers indicate that both free and neutralised reovirus induces monocyte 
maturation, but not towards a conventional DC (cDC) phenotype. 
Surface expression of the co-stimulatory protein CD86 is increased by over 
100% versus mock-treated cells (p = 0.0012 and 0.0023 for reovirus and reo-
NAb respectively), while only free reovirus induces elevated expression of the 
MHC class II antigen HLA-DR (p = 0.0368). These results suggest that virus-
treated monocytes may be more readily able to stimulate T cell activation. In all 
cases, it should be noted that the influence of free reovirus upon the surface 
expression of these proteins is greater than that of reo-NAb. 
During maturation and recruitment to lymphatic tissues, sites of damage or 
tumour lesions, monocytes must extravasate from the vasculature. The steps of 
endothelial adhesion and transmigration demand an increase in cellular 
migratory capacity. In keeping with its role in response to pathogens, migration 
is profoundly influenced by virus insult (reviewed in Smith and Sanderson, 
1999). The migratory capacity of reovirus- and reo-NAb treated monocytes was 
thus investigated, in order to detect potential modulation by the presence of 
antiviral antibody.  
Monocytes were treated with virus at MOI 5 and cultured for 16 hours, then 
transferred to the insert of a 5 µm transwell system in which the lower chamber 
contained either medium conditioned for 48 hours by Mel-624 cells, or 
unconditioned medium. The number of monocytes successfully migrating into 
the lower chamber after 5 hours was quantified. As shown by the data from one 
representative donor (Figure 7.2.3), in this assay, with respect to mock-treated 
cells, reo-NAb treatment was associated with increased migration, while 
reovirus was associated with a potential decrease. As these differences appear 
to be independent of the chemotactic gradient established by the melanoma 
cells, it can be concluded that they represent changes in motility – and likely 
chemokinesis via an autocrine cytokine response – but not necessarily in the 
directional process of chemotaxis. Further investigation would thus be required 
to tease apart these processes, partly as a non-directional autocrine response 
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Figure 7.2.1 Analysis of treated monocyte phenotype by western blot 
 
Monocytes were treated with antibody (NAb), reovirus (reo) or reo-NAb 
complexes at MOI 10, washed, and cultured in RPMI-10 for 24 hours. Lysates 
were made and probed by western blot for the indicated proteins of interest. 
Protein densitometry values (normalised to mock samples) are shown. Images 
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Figure 7.2.2 Analysis of treated monocyte phenotype by flow cytometry 
 
Monocytes were treated with antibody (NAb), reovirus (reo) or reo-NAb 
complexes at MOI 10, washed, and cultured in RPMI-10 for 48 hours. 
Surface protein expression was assessed by flow cytometry. Isotype staining 
was subtracted from median fluorescence intensity (MFI) for each marker, and 
values normalised to mock-treated cells.  
Data ± SEM from three individual donors are shown. *p < 0.05, **p < 0.01, ***p 















Figure 7.2.3 Migratory capacity of treated monocytes 
 
Monocytes were treated with reovirus or reo-NAb (MOI 5), washed, and 
cultured overnight (16 hours). Cells were resuspended and 2 x 105 added to the 
upper chamber of a transwell system with 5 µm pore size. The lower chamber 
contained either no chemoattractant (clear bars) or medium conditioned for 48 
hours by Mel-624 cells (grey bars). The number of monocytes in the lower 
chamber after 5 hours was assessed by flow cytometry using CD11b FITC 
staining. Data are presented as a percentage of mock-treated cells, and are 





7.3 Effects of carriage on transcriptional profile 
From epigenetic regulation and transcription to translation and post-translational 
modification, transcription is perhaps the most fundamental process in 
regulating the creation of functional gene products. Virus infection of immune 
cells not only triggers the transcription of antiviral defence genes but influences 
other, more diverse elements of the host cell phenotype, from growth and 
differentiation to movement and cell death (Liew and Chow, 2006), and 
modulates the outcome of infection. 
The nature of the transcriptional response to a free virus can to some extent be 
predicted, based on virus and cell type, and the expression of relevant receptor 
and sensor proteins. By contrast, the outcome of the more complex interaction 
between an antibody-opsonised virus and any given cell is less easy to foresee. 
This likely stems from more limited knowledge of both the mechanisms enabling 
cells to ‘see’ these immune complexes and of their downstream sequelae. 
While the viral component is by definition the same, the difference in response 
to free and antibody-bound virus can range from minimal to total (Boonnak et 
al., 2011; Watkinson et al., 2015). 
Consequently, following the preliminary evidence for monocyte activation, the 
global transcriptional profile of monocytes was assessed in order to detect 
differential responses to free or neutralised reovirus. After treatment with 
antibody or virus, monocytes were cultured for 24 hours – rather than the 48 
hours for protein-level changes – prior to extraction of RNA for gene expression 
analysis by RNAseq.  
First, a number of analytical tools were employed to assess the magnitude of 
the response to treatment in terms of differentially expressed (DE) genes. The 
mean normalised gene count (expression) value was plotted against the log2 
fold-change between treatment and mock, to generate graphs termed 
diagnostic MA or ‘volcano’ plots (Figure 7.3.1). Individual data points in red 
represent DE genes. DE was defined as an adjusted p value (padj) of less than 
0.1. Remarkably, the addition of patient-derived serum (NAb, in the absence of 
virus) to human monocytes generated no DE genes whatsoever compared to 
mock, as indicated by a lack of deviation on the y axis (Figure 7.3.1a). 
By contrast, the transcriptional response to free reovirus is extreme: of the 
approximately 17,300 genes analysed, over 45% (7,907) are differentially 
expressed versus mock (Figure 7.3.1b). Some genes exceed the 26 (64)-fold 
change limit in the scale shown on the y axis. At first glance, the MA plot for 
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reo-NAb versus mock resembles an attenuated version of that for the free virus. 
DE transcripts represent approximately 30% (5,109) of those tested, and the 
fold-change values appear reduced (Figure 7.3.1c). 
Other tools enabled the transcription-level data to be harnessed in order to 
illustrate the scale of the transcriptional changes. For each of the three donors 
(A-C), the log-transformed expression data shown in Figure 7.3.1 were 
integrated, and samples from each of the four treatment groups (1-4) compared 
by clustering and principal component analysis (PCA). Heat maps resulting from 
clustering analysis between mock- and antibody- or virus-treated cells (1 vs 
2/3/4) are shown in Figure 7.3.2a. Lighter colours indicate greater differences 
between individual samples. Comparing mock- and NAb-treated monocytes (1 
vs 2), samples convincingly cluster by donor rather than by treatment group, 
indicating that the endogenous genetic variation between donors exceeds that 
induced by treatment. Conversely, when comparing mock- to reovirus- or reo-
NAb treated monocytes (1 vs 3/4), the hierarchical clustering patterns and dark 
colours shared within treatment groups demonstrate that the transcriptional 
effects of these agents far exceed the underlying variation between donors. 
A complementary mode of quantifying sample-to-sample distance, PCA 
reduces the dimensionality of the data by integrating sample variation into a 
limited number of principal components. Figure 7.3.2b shows biplots – that is, 
based on the top two PC only – of the six samples (1 vs 2/3/4 respectively), 
indicating the similarity between each. The results mirror those of the clustering 
analysis. Mock- and NAb-treated sample ‘nodes’ scatter according to donor, 
while mock- and reovirus-/reo-NAb treated nodes scatter by condition. In these 
plots, nodes for mock- and virus-treated samples are spatially separated along 
the x axis – PC1, accounting for most of the observed variation – showing that 
the influence of virus (whether free or neutralised) on monocyte expression 
profile predominates over other covariates. 
The comparisons used to this point have examined individual treatment 
conditions against mock-treated monocytes as an expression profile baseline. 
Recognising the apparent qualitative similarities between the effects of reovirus 
and reo-NAb, in terms of surface marker expression and transcriptional profile, 
the finer discrepancies between the two viral groups were pursued. This 
comparison is a relevant one in that it is an in vitro representation of the 
differential responses of naïve and pre-immune patients to reovirus. 
Transcriptional differences may prove informative as to the potential for virus to 
yield immunogenic responses from each type of patient. 
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In order to obtain an overview of these potential differences, the gene 
expression data sets from reovirus and reo-NAb treated monocytes were 
initially interrogated at a global level. First, using the same tools, inter-sample 
variation was assessed by including mock-, reovirus- and reo-NAb treated 
samples in a single analysis. The resulting clustering heat map and PCA plot 
are shown in Figure 7.3.3a and 7.3.3b. Both plots indicate that, rather than 
clustering together, reovirus- and reo-NAb treated samples cluster in their two 
distinct groups. The PCA plot is particularly informative, identifying a minor 
degree of variation (PC2, 9%) that discriminates between reo-NAb nodes and 
mock/reovirus nodes. Indeed, these plots suggest that the free and neutralised 
forms of reovirus do not provoke identical transcriptional profiles.  
The degree of similarity between the profiles was quantified by identifying the 
individual DE genes shared by, or unique to, reovirus/reo-NAb treatment (Figure 
7.3.3c). Here, modified criteria were used to define DE: (i) padj < 0.1, and (ii) 
log2 fold-change of > 1.0 or < -1.0. A total of 6,037 DE genes were detected in 
either group. Of these, while 1,764 (29.2%) were common to both groups, a 
majority (3,992 genes, 66.1%) were unique to the reovirus group. A minor 
subset of 281 genes (4.7%) were found to be DE for reo-NAb but not reovirus. 
This DE gene set unique to reo-NAb was of particular interest, given its 
potential value in identifying the putative qualitative differences in impact 
between free and neutralised reovirus. In order to detect a ‘reo-NAb unique’ 
gene signature, the 281-gene subset was submitted for enrichment analysis 
using the online multi-database tool Enrichr 
(http://amp.pharm.mssm.edu/Enrichr; Chen et al., 2013; Kuleshov et al., 2016). 
Within Enrichr, the Kyoto Encyclopaedia of Genes and Genomes (KEGG) and 
the Gene Ontology (GO) repositories were selected as databases of particular 
focus, given their ability to distil gene lists into information regarding over-
represented cellular functions and pathways. Figure 7.3.4a shows the enriched 
GO terms based on the reo-NAb DE gene set, within each of the three GO 
categories: cellular context (CC), biological process (BP) and molecular function 
(MF). The enriched terms are assigned adjusted p values (corrected values 
from the Fisher exact test) and z-scores (a measure of the deviation from the 
expected rank of a term). The listed GO terms are ranked by padj values, with 
‘combined score’ (a hybrid metric of padj values and z-scores) also provided for 
reference. 
Figure 7.3.4a strongly suggests that upon reo-NAb treatment of monocytes, in 
terms of subcellular localisation (CC), genes related to the lysosomal 
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compartment are significantly enriched – that is, these genes represent a 
significantly higher proportion of the DE gene set than expected. These genes 
include those encoding Rab family GTPases (RAB12, RAB27A, RAB38) and 
cathepsin family proteases (CTSB, CSTC, CTSD, CTSK, CTSZ) which are 
modulators of vesicle trafficking and intravesicular degradation respectively. In 
the BP category, the enriched gene terms following reo-NAb treatment include 
inflammatory response genes, largely cytokines; as corroborated by the results 
in the MF category, these sets are partly composed of various chemokines 
implicated in binding CXCR receptors. This is consistent with the top hit 
generated by KEGG pathway analysis, namely ‘cytokine-cytokine receptor 
interaction’ (padj = 0.00114, data not shown).  
Upon direct analysis of the changes in gene expression, a specific upregulation 
of the FCGR3A and FCGR3B genes upon reo-NAb treatment was identified, in 
contrast to a slight decrease upon reovirus treatment (Figure 7.3.4b). Given that 
FCGR3B expression in monocytes is negligible, this apparent increase is likely 
an artifact resulting from the gene’s high homology with FCGR3A. The changes 
in transcription of FCGR3 genes by reo-NAb were not mirrored in FCGR1 and 
FCGR2 genes, which exhibited fold-change values between 1.0 and 1.9 and did 
not reach the threshold for differential expression (data not shown). This 
selective induction of genes encoding FcγR III further suggests, but does not 
prove, the involvement of this receptor in reo-NAb trafficking. Despite the 
upregulation of specific Fc receptor transcripts by reo-NAb, this did not translate 
into a significant enrichment of GO terms annotated under ‘FcγR-mediated 
phagocytosis’ in this analysis (padj = 0.442, data not shown).  
In order to obtain a complete picture of the transcriptional response to each 
‘type’ of virus, it was resolved that both DE gene sets, including genes common 
to both lists, should be compared directly. As per Figure 7.3.3c, the reovirus DE 
and reo-NAb DE lists – composed of 5,756 and 2,045 genes respectively as per 
Figure 7.3.3c – were submitted to Enrichr and analysed using the KEGG and 
GO databases. Figure 7.3.5 shows the degree of enrichment by padj value in 
numerous KEGG pathways and GO terms. 
The KEGG pathways shown in Figure 7.3.5a are ordered according to padj 
value of the reo DE list. In the majority of cases, gene sets enriched by reovirus 
also appear significantly enriched by reo-NAb. In particular, pathways 
representing cytokine or chemokine signalling are highly significantly enriched 
in both conditions; other gene sets such as those representing JAK-STAT 
signalling are more biased towards reovirus alone. Notably, in a minority of 
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terms including those for the phagosome and cell adhesion molecules, higher 
padj values are observed following reo-NAb treatment. This suggests that reo-
NAb can provoke a larger response than reovirus from certain cellular 
processes, and that the differences between the two are not purely quantitative. 
The concept that reovirus and reo-NAb are qualitatively different in impact is 
reinforced when examining the enrichment of GO terms (Figure 7.3.5b). 
Specifically in terms of subcellular localisation, there is a substantial enrichment 
of genes relating to the mitochondrion in reovirus- but not reo-NAb treated 
monocytes. By contrast, reo-NAb appears to strongly influence the secondary 
lysosome, while both reovirus and reo-NAb impinge upon genes relating to the 
phagocytic vesicle membrane. 
Looking at signalling cascades, as suggested by western blot (Figure 7.2.1), 
both reovirus and reo-NAb stimulate NF-κB, while signalling via the chemokine 
receptor CXCR3 is more significantly enriched upon reo-NAb treatment. Both 
stimuli appear to target genes involved in the restriction of viral replication, 
corroborating the evidence for PKR signalling by western blot (Figure 7.2.1). It 
can also be observed that GO terms implicated in viral transcription and host 
autophagy are induced much more strongly by the free virus than by the 
neutralised form. 
Finally in this data set, there are notable disparities in IFN-related pathways. 
While the type I IFN signalling pathway in general appears to be more 
significantly enriched by reo-NAb than reovirus, actual binding of IFN receptors 
may be lower, and viral suppression of type I IFN may be enhanced. Thus there 
seem to be quite different (and potentially revealing) effects on IFN signalling 
between the two treatments, which are explored further below in the wider 
context of virus-induced cytokine production. 
First, in order to have confidence in interpreting transcriptional changes at the 
single-gene level, the data obtained by RNAseq were validated using qPCR on 
a small sample gene set. This necessitated the identification of a suitable 
housekeeping gene (HKG) in the monocyte samples. The mean expression 
values of various well-studied HKG were taken from RNAseq samples and 
coefficient of variation (CV = SD/mean) used to compare their deviation across 
treatment conditions (Figure 7.3.6a). While the expression of more ‘traditional’ 
choices such as GADPH and ACTB varied widely (CV approaching 50%), 
YWHAZ was selected as an appropriate HKG on the basis of low CV in addition 
to sufficient baseline expression. This gene, encoding the 14-3-3ζ protein, has 
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been identified previously as a strong HKG candidate in leukocytes 
(Vandesompele et al., 2002). 
Armed with a suitable HKG, the same RNA samples used for RNAseq from one 
donor (C) were submitted to qPCR analysis, in order to confirm the findings 
made by RNAseq. The qPCR primers used corresponded to genes of interest 
with either a high (CXCL10), intermediate (CCL2 / MCP-1) or low (IL-8) 
magnitude of change in expression level upon virus treatment in the RNAseq 
analysis. These genes were each compared to YWHAZ by the ΔΔCT method, 
corrected to mock-treated cells and converted to gene copies. As shown in 
Figure 7.3.6b, there appears to be consistent agreement in gene expression 
changes between qPCR and RNAseq. Indeed, plotting these paired values 
against each other yields an excellent Pearson correlation (R) of 0.992 (Figure 
7.3.6c). Altogether, this evidence suggests that qPCR substantiates the quality 
of the outputs from RNAseq, and demonstrates that the two modes of analysis 









Figure 7.3.1 Volcano plots of differential gene expression by monocytes 
 
Monocytes were treated with antibody (a), reovirus (b) or reo-NAb complexes 
(c) at MOI 10, washed and cultured for 24 hours. RNA was extracted and 
mRNA analysed by RNAseq. Normalised gene counts in treated samples were 
compared to mock-treated samples and log2 fold change plotted on MA plots, 
with differentially expressed genes in red (padj < 0.1). The mean values from 


















Figure 7.3.2 Clustering and principal component analysis of the treated 
monocyte transcriptome 
  
Monocytes were treated with antibody (NAb), reovirus (reo) or reo-NAb  
complexes at MOI 10, washed and cultured for 24 hours. RNA 
was extracted and mRNA analysed by RNAseq. Similarity between  
normalised gene counts in mock-treated and treated samples (1-4) was  
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Figure 7.3.3 Induction of a minor gene subset by reo-NAb but not reovirus 
  
A three-way comparison was made between the gene signatures of mock-, 
reovirus- and reo-NAb treated monocytes. The Euclidean distance between 
each of the nine samples tested is represented by (a) sample clustering and (b) 
principal component analysis. The number of DE genes unique to and shared 
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Figure 7.3.4 Limited differential expression in reo-NAb treated monocytes 
  
The DE gene set unique to reo-NAb treatment was submitted for enrichment 
analysis. (a) From each GO category, the top five ontology terms ranked by 
padj value are shown. GO terms of particular relevance are highlighted in 
yellow. (b) The fold change values (vs mock) of two Fc receptor genes following 


























Figure 7.3.5 Enrichment analysis of DE gene sets induced by reo or reo-
NAb treatment of monocytes 
 
Enrichment analysis of DE gene sets identified in Figure 7.3.3, including DE 
genes common to both conditions. Reovirus (grey bars) and reo-NAb (black 
bars) are compared. Gene sets were interpreted using KEGG pathway analysis 
(a) and the three gene ontology (GO) categories (b). Adjusted p values for 
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Figure 7.3.6 Validation of RNAseq expression analysis by qPCR 
  
RNA samples used for RNAseq from one donor (C) were used for validation by 
qPCR. cDNA was created from RNA and subjected to qPCR. (a) YWHAZ was 
selected as an appropriate housekeeping gene, on the basis of high mean 
expression and low coefficient of variation (CV). (b) Three genes of interest 
(GOI) were compared to YWHAZ by the ΔΔCT method. The number of gene 
copies was normalised to mock-treated cells, and fold change calculated. (c) 
The fold change values determined by qPCR were plotted against those by 



















7.4 Effects of carriage on secretory profile 
It is clear from whole transcriptome analysis that while there is considerable 
overlap in the gene signatures induced by reovirus and reo-NAb, there are also 
significant differences in their effects. There appears to be strong induction of 
pathways involved in cytokine and chemokine signalling by both stimuli (Figures 
7.3.4, 7.3.5 and 7.3.6), consistent with the role of monocytes as proficient 
generators of soluble factors during the defence response to pathogens 
(Hansmann et al., 2008). As supported by the western blot data, reovirus itself 
is known to impinge upon PKR and NF-κB (Steele et al., 2011), and promotes 
the secretion of influential pro-inflammatory cytokines including IFN-α and TNF 
from monocyte-derived DC in a dose-dependent fashion (Errington et al., 
2008a). 
Interferons (IFN) in particular are the archetypal secreted factors involved in 
orchestrating the cellular defence process to virus. Following IFN secretion, 
sensing and JAK-STAT signalling, the resultant expression of IFN-stimulated 
genes (ISG) can mediate wholesale changes to cell growth, protein synthesis 
and cell fate, as part of a wider antiviral state. Many ISG encode proteins with 
direct activity against various aspects of the intracellular viral ‘life cycle’, 
including virus entry, replication and egress (reviewed in Schneider et al., 
2014). 
It is through the action of this multitude of effector proteins that IFN are capable 
of precipitating front-line clearance of virus. Numerous in vivo studies 
demonstrate the critical requirement for IFN signalling by antigen-presenting 
cells in limiting viral replication and consequently disease severity (Cervantes-
Barragán et al., 2009; Lang et al., 2010). Further, in human blood, monocytes – 
not DC – are the main source of IFN-α following stimulation with poly(I:C), an 
analogue of viral dsRNA (Hansmann et al., 2008). 
Building upon the insights made above by gene expression analysis, the same 
RNAseq data sets were interrogated for information on the transcriptome of 
secreted factors, again using the mean values across three donors. Figure 7.4.1 
shows the fold change in raw count values (over mock) for transcripts of specific 
genes following 24-hour treatment of monocytes with reovirus or reo-NAb. The 
subsets of IFN genes (Figure 7.4.1a) and other cytokines and chemokines 
(Figure 7.4.1b) shown include the most highly expressed genes in each 
category in addition to some selected on the basis of relevance.  
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First, it is important to note that the vast majority of IFN genes scored mean of 
zero counts in mock-treated samples; these were ascribed an arbitrary value of 
1 in order to facilitate the analysis of differences in IFN upregulation. Indeed, all 
of the IFN genes listed in Figure 7.4.1a scored below 10 counts in mock-treated 
samples, indicating a total absence of IFN signalling at baseline; for context, 
scores for reovirus were commonly in the thousands. Consequently, while the 
values shown refer to fold change, they are also typically the same or very close 
to the gene count values for both the reo and reo-NAb conditions. 
In the context of this baseline, it can be observed that free reovirus provokes 
the extensive generation of various types of IFN from monocytes. Consistent 
with their classical role in virus resistance, genes corresponding to type I IFN 
isoforms are particularly strongly expressed; IFN-α and IFN-β predominate, 
accompanied by the less well known type I subtypes IFN-ε and IFN-ω. A 
number of additional genes encoding other IFN-α isoforms have been omitted 
for brevity. Reovirus also induces the expression of members of the type III IFN 
family, in particular IL-29 (IFN-λ1), which possess antiviral activity by signalling 
via a separate IFN receptor. The sole type II species IFN-γ (the IFNG gene) is 
expressed to a negligible degree. 
Having revealed the apparent equivalence of the monocyte response to reo-
NAb in some diverse gene sets – including those relating to cytokine and 
chemokine activity (Figure 7.3.5) – it is striking to note the scale of the 
difference in the IFN response between reovirus and reo-NAb (Figure 7.4.1a). 
Across all IFN isoforms, while the patterns are the same for both, reo-NAb 
values are 100- to 1,000-fold lower than those for free reovirus. Indeed, for reo-
NAb, counts for all IFN genes were below 100, and the majority were below 10; 
a level at which the ‘biological relevance’ of transcripts is doubtful (R. Chauhan, 
personal communication).  
The comparison of changes in various other cytokine and chemokine transcripts 
is shown in Figure 7.4.1b. Fold change values are again displayed, although 
unlike in Figure 7.4.1a, baseline expression was present but low. Towards the 
left of the graph are genes in which the increase upon reo-NAb and reovirus 
treatment was comparable, a group including genes encoding TRAIL 
(TNFSF10), the CXC-family chemokines CXCL9, 10 and 11, and CCL2, CCL8 
and CCL7 (monocyte chemotactic protein (MCP)-1, 2 and 3). Other genes, 
including those encoding CCL3 and CCL4 (macrophage inflammatory protein 
(MIP)-1α and 1β), CCL5 (RANTES) and TNF, more closely resemble the 
pattern seen in IFN expression, being strongly biased towards free reovirus. 
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While RNAseq has the benefit of providing high volumes of gene expression 
data, it can only inform as to the impact of stimuli at the transcriptional level, 
with no guarantee that protein-coding RNA is translated into corresponding 
levels of protein. Consequently, the protein factors secreted by isolated 
monocytes were profiled in order to confirm the trends observed in RNA. First, 
luminex assays were used to gain a broad overview of the ‘secretome’.  
Monocytes were treated as previously with reovirus or reo-NAb at MOI 10, and 
cultured for 48 hours to permit maximal cytokine release. Supernatant was 
harvested, and the level of specific analytes quantified. Mean values were 
determined from two donors, and used to calculate the fold change in each 
analyte compared to supernatant from mock-treated monocytes. As for the 
RNAseq data, it was necessary to assign a lower limit of detection value of 5 
pg/ml to the mock-treated samples for some proteins (marked with a dagger), to 
enable the calculation of fold change values. 
The data shown in Figure 7.4.2 are ordered according to reovirus-induced fold 
change values. The most conspicuous result at first glance is the extreme 
elevation in the abundance of IFN-α2, the representative type I IFN in this 
assay, by reovirus – in contrast to reo-NAb which appears to yield none. The 
luminex data are also consistent with RNA-level data in indicating the 
equivalence of reovirus and reo-NAb in stimulating the release of CXCL9 and 
CXCL10, along with CCL2 (MCP-1). The bias towards reovirus in the induction 
of CCL5/RANTES, TNF and MIP isoforms (CCL3/4) is also maintained at the 
protein level. It is notable that other specific analytes relevant to monocyte (GM-
CSF, IL-10) and NK cell (IL-15) behaviour exhibit limited changes which are 
comparable between reovirus and reo-NAb. 
Having broadly illustrated that transcriptional trends are maintained in terms of 
secreted proteins, a more quantitative assessment of virus-induced cytokine 
production was obtained by ELISA. The results obtained substantiated the 
luminex results, both in terms of trends between conditions, and in protein 
concentration (Figure 7.4.3). While substantial CXCL10 was generated by both 
reovirus and reo-NAb (p = 0.99 between reovirus and reo-NAb by one-way 
ANOVA), significant elevations in IFN-α, TNF (both p < 0.0001) and 
CCL5/RANTES (p < 0.01) were found to be highly specific to reovirus treatment. 
The same pattern – albeit not significant due to variation between donors – was 
observed in IL-29 (p = 0.311). As suggested by RNAseq, reovirus-induced IFN-
γ levels appear to be functionally negligible. Thus, as detected at the transcript 
level (by RNAseq) and the protein level (by luminex and ELISA), while many 
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cytokines are selectively induced by free reovirus, others are equally produced 
in response to reo-NAb. 
One protein from each of these groups, IFN-α and CXCL10 respectively, was 
selected for further investigation. This was done primarily in order to detect a 
potential role in cytokine production for virus replication – at least at the 
genomic level, if not the protein level (Figure 6.4.3 and 6.4.4). Monocyte cells 
were thus analysed for the presence of IFNA1 and CXCL10 transcripts by 
qPCR; samples were taken after 2 or 16 hours of treatment with UV-inactivated 
or live reovirus, in the form of free virus or reo-NAb. Number of copies2 from 
three independent donors are displayed, following normalisation by ΔΔCT to 
YWHAZ and comparison to mock (Figure 7.4.4).  
As shown by the consistency between the clear and grey bars, there is no 
significant difference in effect between live and UV-inactivated virus on the yield 
of IFN-α (p = 0.37 by two-way ANOVA) or CXCL10 (p = 0.95). Thus, UV 
inactivation appears to have no impact upon the magnitude or kinetics of 
secretion by monocytes in response to reovirus or reo-NAb. This strongly 
suggests that cytokine secretion following either stimulus is independent of the 
replication of viral genomes or proteins, consistent with prior studies on the 
activation of whole PBMC or isolated DC by reovirus (Errington et al., 2008a; 
Parrish et al., 2015) and specifically the production of CXCL10 (Douville et al., 
2008). 
It can also be concluded from the data after 2 hours that CXCL10 is induced as 
quickly by reo-NAb as it is by free reovirus, implying that neutralisation has no 
detrimental effect on the kinetics of cytokine production (p = 0.99). Unlike prior 
results however, the data do suggest that the magnitude of CXCL10 transcript 
induction may be lower in the context of reo-NAb, at least after 16 hours (p < 
0.05). 
The critical role for IFN signalling in front-line antiviral defence is in part 
mediated by antigen-presenting cells. Cells of this type have evolved intricate 
and often paradoxical strategies in the ‘arms race’ against pathogens. One of 
these tactics involves allowing a degree of virus replication, ostensibly to boost 
the innate reaction or to enhance the supply of virus antigen for priming of the 
adaptive immune system (Honke et al., 2012). At the risk of anthropomorphism, 
                                            
2 It should be noted that the low scale of change observed in copies of IFNA1 by qPCR 
is due to a retrospective baseline correction. This was required as the IFNA1 
primers detected not only the IFNA1 sequence in cDNA, but also IFNA1 in gDNA 
remaining in the sample, as the IFNA1 gene is monocistronic. 
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the cell gives the viruses ‘just enough replicative rope to hang themselves with’ 
(Yewdell and Brooke, 2012). This limited permissivity is partly enabled by the 
suppression of IFN signalling, which is mediated by negative regulators of RLR-
induced cascades, such as USP18 (Honke et al., 2012; Komuro et al., 2008). 
 
A further dimension is added to this topic when considering the differential 
effects induced by the reo-NAb immune complex versus the free virus. There is 
contradictory evidence regarding the quality of the IFN response following 
antibody-dependent entry of virus in cells of the monocyte/macrophage lineage. 
While some studies report equivalent IFN responses to free and antibody-bound 
virus (Boonnak et al., 2011; Kou et al., 2008), others provide evidence for the 
robust suppression of IFN following antibody-dependent entry (Rolph et al., 
2011; Tsai et al., 2014; Ubol et al., 2010). IFN repressor proteins are strongly 
implicated in these studies. 
Consequently, observing the stark disparity in IFN production between reovirus- 
and reo-NAb treated monocytes, it was postulated that IFN generation in 
response to reo-NAb may be precluded by a specific IFN-suppressing factor. 
RNAseq data were therefore used to examine the expression of various factors 
which have been found to antagonise IFN signalling: IRF2 (Harada et al., 1989), 
SOCS1/2/3 (Piganis et al., 2011), DAK and ATG5/12 (Huang et al., 2016; Ubol 
et al., 2010), LGP2/DHX58 (Komuro and Horvath, 2006), RNF125 (Arimoto et 
al., 2007), OASL1 (Lee et al., 2013) and PIAS1 (Liu et al., 2004). 
It was hypothesised that, through differences in the mode of virus entry, reo-
NAb may trigger the upregulation of specific protein(s) which antagonise IFN 
expression. In particular, as the majority of interferon-stimulated genes (ISG) 
induced by reovirus are also upregulated by reo-NAb (data not shown) – a 
puzzling finding given the absence of IFN – the focus was on factors acting 
upstream rather than downstream of IFN expression. However, as shown in 
Figure 7.4.5, no substantial differences were observed in any of the factors 
listed. As such, although some other cytokines are produced comparably by 
reovirus and reo-NAb, it cannot be concluded that the significant disparity 






Figure 7.4.1 Transcriptomic analysis of cytokine induction by reovirus 
and reo-NAb 
  
Monocytes from 3 donors were treated with reovirus or reo-NAb (MOI 10) and 
cultured for 24 hours prior to gene expression analysis by RNAseq. Raw gene 
counts were analysed. All genes with raw counts of zero were assigned an 
arbitrary value of 1 to permit calculation of the fold change upon reovirus or reo-
NAb treatment compared to mock-treated monocytes. Raw gene counts were 
determined for two groups of genes: (a) interferon genes and (b) selected 
























Figure 7.4.2 Broad analysis of monocyte ‘secretome’ by luminex 
 
Monocytes were treated with antibody (NAb), reovirus (reo) or reo-NAb  
complexes at MOI 10, washed, resuspended in RPMI-10 at 1 x 106 cells per  
ml and cultured for 48 hours. Supernatant was analysed using magnetic bead- 
based cytokine analysis kits. Analyte concentration (pg/ml) was compared to 
that of mock-treated monocytes and fold change following reovirus or reo-NAb  
treatment calculated. Data represent mean values ± SEM from two donors.  



































Figure 7.4.3 Validation of monocyte-secreted factors by ELISA 
 
Monocytes were treated with antibody (NAb), reovirus (reo) or reo-NAb  
complexes at MOI 10, washed, resuspended in RPMI-10 at 1 x 106 cells per  
ml and cultured for 48 hours. Cytokine concentrations (pg/ml) were determined  
by ELISA. Data are mean values ± SEM from 2-3 donors. ns = not significant;  










Figure 7.4.4 Induction of cytokine secretion by live and UV-inactivated 
virus 
 
Monocytes were treated with reovirus (reo) or reo-NAb complexes at MOI 10, 
using live or UV-inactivated reovirus. Cells were washed, resuspended in RPMI-
10 at 1 x 106 cells per ml and cultured for 2 or 16 hours. RNA was extracted and 
transcript copy number evaluated by qPCR. Data are mean values ± SEM from 
three donors. ns = not significant; *p < 0.05, **p < 0.01, ***p < 0.001 by two-way 






Figure 7.4.5 Lack of evidence for an IFN-repressing factor specific to reo-
NAb treated monocytes 
 
Human monocytes treated with MOI 10 reovirus or reo-NAb for 24 hours were 
analysed for the expression of the gene transcripts indicated using RNAseq. 
The fold change in the expression of each target with respect to mock-treated 






7.5 Functional effects on immune effector populations 
Somewhat distinct from the oncolytic properties originally thought to be key to 
their efficacy in vivo, the clinical benefit of OV is increasingly attributed to their 
role as immunotherapy agents. Given that viruses are generally activatory 
towards immune cells, this is consistent with infiltrating lymphocyte levels as a 
prognostic factor in the typically immunosuppressive microenvironment of solid 
tumours (Gooden et al., 2011). Thus OV represent one modality with the 
potential to either promote the infiltration of effector immune cells (when virus is 
present in circulation) or to provoke their pro-inflammatory capacity once there 
(if virus reaches the tumour bed).  
The specific presence of the major adaptive and innate immune effector cells – 
T cells and NK cells respectively – has been associated with improved survival 
across multiple indications (reviewed in Fridman et al., 2012; Larsen et al., 
2014). It is increasingly clear that tumour cell clearance is not only reliant on 
infiltration of immune cells but moreover the condition of these cells; lymphocyte 
dysfunctionality and exhaustion are critical roadblocks to successful immune 
surveillance (Zarour, 2016). 
To this point, the impact of reovirus has been characterised solely in terms of 
the circulating monocyte population. This sub-section briefly explores the 
capacity of free or neutralised reovirus to influence the wider PBMC population. 
Like monocytes, NK cells are key to innate defence. This fraction was the 
subject of particular focus given its gathering importance to the therapeutic 
outcomes of OV, and of reovirus in particular (Gujar et al., 2011; Ilett et al., 
2014; Kottke et al., 2010; Zhang et al., 2014). 
In this context, the interplay between antigen-presenting cells and NK cells is 
highly relevant. The stimulation of NK cell anti-tumour efficacy by reovirus is 
facilitated by the activation of DC in vitro (Errington et al., 2008a; Hall et al., 
2012; Prestwich et al., 2009a). Less well-characterised is the impact of NK cells 
upon DC. Activated NK cells are capable of stimulating the differentiation and 
function of monocytes and DC, through contact- and cytokine-dependent 
mechanisms (Holmes et al., 2014; Prestwich et al., 2009a; Zhang et al., 2007). 
Thus, in order to supplement the previously stated data on monocyte 
phenotype, the influence of NK cells towards the effect of virus on monocytes 
was first explored. 
Positively selected monocytes were treated with serum, reovirus or reo-NAb at 
MOI 10, prior to 48-hour co-culture with NK cells. A 2:1 monocyte:NK ratio was 
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selected to best represent the proportions of these populations in peripheral 
blood. The phenotype of CD11b+ cells was assessed by flow cytometry staining 
(Table 8); median fluorescence intensity was normalised to that of NAb-treated 
monocytes alone, as selection yielded insufficient NK cells to set up untreated 
control samples. Monocyte activation across three monocyte donors in the 
absence (clear bars) or presence (grey bars) of NK cells is shown in Figure 
7.5.1. 
The consistency between the paired bars demonstrates the general lack of a 
substantial impact when reovirus-treated monocytes are combined with NK cells 
in this system. The virus-mediated decrease in CD14 and increase in co-
stimulatory molecules (as observed in Figure 7.2.2) were unaffected by NK cell 
co-culture (all pair-wise comparisons not significant by two-way ANOVA). 
However, while the reovirus-mediated elevation in HLA-DR is irrespective of NK 
cells, their presence is sufficient to increase its expression in response to either 
NAb or reo-NAb (p = 0.0012 for NAb and 0.012 for reo-NAb respectively).  
The ability of NK cells to upregulate HLA-DR on monocytes/DC (and 
accordingly enhance cross-presentation) has been reported, albeit in the 
context of activated NK cells (Srivastava et al., 2013; Zhang et al., 2007). The 
NK-derived surface proteins or secreted factors which may be responsible, or 
the downstream effects on the antigen-presenting ability of monocytes/DC, 
were not pursued. 
Next, the reverse comparison was made, examining the activation of NK and T 
cells within PBMC upon co-culture with virus-treated monocytes. This process 
has been examined before, but solely in the context of free reovirus. Reovirus 
treatment of whole PBMC activates NK cells via a contact-independent 
mechanism reliant on DC-derived IFN-α (Parrish et al., 2015; Prestwich et al., 
2009a). Indeed, NK activation can be promoted by DC treated with the TLR3 
agonist poly(I:C), demonstrating the importance of viral RNA (Gerosa et al., 
2005). The stimulatory effects of reovirus-treated DC can also extend to T cell 
activation and cytotoxicity (Errington et al., 2008a). It was therefore resolved 
firstly to confirm that monocytes, as DC precursors, are able to mediate the 
same effect, and secondly to compare the activatory potential of reovirus and 
reo-NAb upon NK and T cells in this context. 
Monocytes were pulsed as before with NAb, reovirus or reo-NAb at MOI 10, 
washed, and recombined with the CD14− fraction of PBMC to permit cross-talk 
of monocytes with lymphocytes. After 48 hours in culture, cells were harvested 
and lymphocyte populations phenotyped by flow cytometry (Figure 7.5.2). The 
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markers examined included the canonical lymphocyte activation marker and 
functional regulator CD69 (Borrego et al., 1999) and the antiviral response 
factor CD317, or tetherin (El-Sherbiny et al., 2015), which are both linked to 
reovirus. Recorded on the x axis are the treatments initially given to the 
monocytes, rather than to the phenotyped cell population with which they were 
cultured. 
Starting with NK cells (gated on the CD3− CD56+ population), it is clear that 
reovirus-treated monocytes induce a significant elevation of NK CD69 
expression (p = 0.0004 vs mock by one-way ANOVA). There is a trend towards 
increased NK CD69 following co-culture with reo-NAb treated monocytes which 
does not reach statistical significance (p = 0.731). The pattern of tetherin 
expression shows a similar trend, though again is not significant for reo-NAb (p 
= 0.0002 and 0.133 respectively). 
Monocytes treated with free reovirus also stimulate CD69 expression from CD4+ 
and CD8+ T cells (CD3+), although due to donor variability this does not reach 
significance in CD8+ T cells (p = 0.039 and 0.544 respectively). Further, there 
appears to be some activation of CD8+ T cells by reo-NAb pulsed monocytes, 
although this is again highly variable (p = 0.620). It can thus be surmised that, 
like DC, monocytes are in general capable of acting as the conduit for reovirus-
mediated lymphocyte activation. (This is corroborated by the IFN-γ produced in 
cultures containing reovirus-treated monocytes as detected by ELISA; mean 
without PBMC 64 pg/ml vs with PBMC 1,429 pg/ml – data not shown.) The 
evidence for the same effect in the context of reo-NAb is less convincing. 
Gaining an understanding of the reason for this diminished effect of reo-NAb on 
lymphocyte activation (via monocytes) requires insight into the underlying 
molecular mechanism. Previous evidence suggests that type I IFN is the 
primary secreted factor involved (Parrish et al., 2015; Prestwich et al., 2009a). 
However CXCL10, here likely triggered directly by NF-κB signalling rather than 
via IFN (Brownell et al., 2014), can not only act as an NK cell chemoattractant 
but can also trigger NK cell activation and killing of tumour cells (Saudemont et 
al., 2005). As both reovirus and reo-NAb yield the generation of considerable 
CXCL10, the respective roles of monocyte-derived IFN-α and CXCL10 in NK 
cell activation were compared. 
The cell-free supernatant from virus-treated monocytes was aspirated and 
added to fresh PBMC, following the optional removal of virus by filtration (F). 
The ability of this conditioned medium (CM) to stimulate the expression of CD69 
on the CD3− CD56+ population was determined by flow cytometry after 48 
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hours. The influence of pre-incubating target PBMC with blocking antibodies 
against the type I IFN receptor IFNAR2 or the CXCL10 receptor CXCR3 is 
shown in Figure 7.5.3. It should first be noted that filtration appears to have no 
effect on NK cell CD69 levels. This suggests that the virus that is rapidly 
released by monocytes (Figure 6.4.4) is not the responsible factor, 
corroborating previously published data showing that NK cells require 
monocytes/DC to facilitate their response to reovirus (Parrish et al., 2015).  
Therefore which monocyte-secreted factor is responsible? Blocking NK cell 
CXCR3 does not impact CD69 modulation by the CM from virus-treated 
monocytes, strongly indicating that CXCL10 (along with other CXCR3 ligands) 
is not involved. By contrast, IFNAR2 blockade significantly diminishes NK 
activation in the presence of supernatant from virus-treated monocytes (p = 
0.0123 for reo CM and 0.0011 for reo FCM respectively by two-way ANOVA). 
Although there are non-significant trends to suggest a similar theme where reo-
NAb is concerned, the degree of NK activation by CM from reo-NAb treated 
monocytes is too limited to allow conclusions to be drawn from only two donors.  
While surface marker expression and IFN-γ secretion by NK cells is a 
reasonable indicator of functional activity (Dons’koi et al., 2011), the most 
clinically relevant indicator of the effect of reovirus as a promoter of innate anti-
tumour immunity is NK cell cytotoxicity. Activated NK cells can readily eliminate 
AML blasts (Hall et al., 2012) and are the main cytolytic effector cells in 
reovirus-treated PBMC (Adair et al., 2012). Alongside monocytes, they play an 
essential role in tumour cell killing in GM-CSF/reovirus therapy for murine 
melanoma (Ilett et al., 2014). Therefore it was important to confirm that the 
enhanced phenotype of NK cells is translated into cytotoxic activity. 
NK cells utilise three major mechanisms to induce target cell death: (i) 
exocytosis of cytolytic granules containing granzymes and perforin; (ii) induction 
of apoptosis by the expression of Fas ligand; and (iii) generation of secretory or 
surface-expressed TNF-family cytokines and IFN-γ (Lowin et al., 1995; Oshimi 
et al., 1996; Zamai et al., 1998). The importance of cytolytic granule release to 
anti-tumour NK effector function is demonstrated by the decreased tumour 
surveillance in perforin-deficient animals (Smyth et al., 1999; van den Broek et 
al., 1996).  
The lysosomal-associated membrane proteins LAMP-1/-2 (CD107a/b) which at 
rest are associated with the granule membrane, are mobilised and ectopically 
expressed on the cell surface during degranulation. As surface expression of 
CD107a/b correlates well with cytotoxicity, it can be used as a surrogate marker 
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of NK cell functional activity (Alter et al., 2004; Mittendorf et al., 2005). This is a 
complementary assay to the traditional chromium release assay developed 50 
years ago, in which the degree of 51Cr release from labelled target cells 
following NK cell co-culture represents the proportion of targets successfully 
killed upon degranulation (Brunner et al., 1968). Thus in evaluating cytotoxicity, 
one assay measures the ‘cause’ (degranulation), and the other measures the 
‘effect’ (target cell lysis). 
Monocytes were treated with NAb, reovirus or reo-NAb at MOI 10, washed and 
co-cultured with autologous NK cells at a 1:2.5 ratio; in some conditions, NK 
cells were cultured alone with the same treatments. After 40 hours, cells were 
harvested, and their level of degranulation against targets of melanoma, 
pancreatic or glioma cell origin was determined. Figure 7.5.4 shows the 
proportion of NK cells staining positively for CD107, following exposure to the 
stimuli indicated on the x axis and subsequent interaction with the target cells 
as shown. 
It can be observed that the CD107 expression seen is specifically in response 
to tumour cell targets, as in their absence (clear bars) expression is minimal. 
Exposure of NK cells to NAb, or monocytes treated with NAb, remains at this 
baseline. By contrast, exposure of NK cells to reovirus, or to reovirus-treated 
monocytes, yields CD107 expression on up to 30% of NK cells. Lastly, while NK 
cells show no activation in response to direct application of reo-NAb, reo-NAb 
treated monocytes do induce some NK activity, particularly towards the U87 
glioma target line. 
These results are corroborated by the outcomes from the 51Cr release assay 
(Figure 7.5.5). Here, activated NK cells were supplied with U87 or SU.8686 
targets at various effector:target (E:T) ratios. A 4-hour incubation is used, as 
this is insufficient time for viral lysis to confound the results. As for the 
degranulation assay, NK cell cytotoxicity appeared equivalent following 
stimulation with reovirus and reovirus-treated monocytes (each significant vs no 
treatment across all E:T ratios by two-way ANOVA). The only other condition in 
which NK cells generated significant target cell lysis was in the presence of reo-
NAb treated monocytes, at higher E:T ratios, whereupon up to 40% of targets 
were lysed (p < 0.01 at 20:1, p < 0.05 at 10:1 respectively, for both targets). 
In parallel, these two assays demonstrate that the avidity of monocytes for 
reovirus allows them to convey this stimulus, inducing the degranulation and 
resulting cytotoxicity of autologous human NK cells against a range of tumour 




Figure 7.5.1 Effect of NK cell co-culture on phenotype of virus-treated 
monocytes 
 
Monocytes were pulsed with NAb, reovirus or reo-NAb (MOI 10), washed and 
cultured with or without autologous NK cells at a 2:1 ratio for 48 hours. The 
surface expression of the proteins indicated was assessed by flow cytometry on 
the CD11b+ population. Median fluorescence intensity values were isotype-
corrected and normalised to ‘NAb –NK’, and the mean ± SEM of three individual 







Figure 7.5.2 Activation of immune cell populations via virus-loaded 
monocytes 
 
Monocytes pulsed with NAb, reovirus or reo-NAb (MOI 10) were washed and 
returned to culture with autologous PBMC for 48 hours. Cells were harvested 
and phenotyped for surface proteins of interest by flow cytometry on the 
populations indicated. Isotype-corrected median fluorescence intensity values 
are shown. Data are mean values ± SEM from three donors. ns = not 
significant; *p < 0.05, ***p < 0.001 vs mock by one-way ANOVA (Dunnett’s 






Figure 7.5.3 Mechanism of NK cell activation by monocyte-secreted 
factors 
 
Monocytes were treated with reovirus or reo-NAb (MOI 5) and cultured 
overnight (16 hours). Cell-free conditioned medium (CM) was collected and 
virus removed using filters (FCM). CM/FCM from treated monocytes was added 
to fresh PBMC which had been pre-treated with blocking antibodies against 
CXCR3 (light grey bars), IFNAR2 (dark grey bars) or isotype control (clear 
bars). After 48 hours, NK cell activation was determined by CD69 PerCP 
staining on the CD3− CD56+ population. The mean ± SEM of the isotype-
corrected median fluorescence intensity values from two donors is displayed. *p 






Figure 7.5.4 Ability of treated monocytes to stimulate NK cell 
degranulation 
 
NK cells were co-cultured with monocytes treated with NAb, reovirus or reo-
NAb, or were given those treatments directly, and incubated for 40 hours. Target 
cells (as indicated) were added for 1 hour, prior to analysis of CD107 
expression % on the CD3− CD56+ NK population by flow cytometry. The mean 
value across three individual donors ± SEM is displayed. ***p < 0.001 vs 






Figure 7.5.5 Ability of treated monocytes to stimulate NK cell-mediated 
cytotoxicity 
 
NK cells were co-cultured with monocytes treated with NAb, reovirus or reo-
NAb, or were given those treatments directly, and incubated for 40 hours. 51Cr-
labelled U87 or SU.8686 target cells were added at the E:T ratios indicated for 4 
hours. Supernatant was analysed for chromium release by scintillation, and 
converted to % killing. The mean values ± SEM from six donors are shown. *p < 
0.05, **p < 0.01, ***p < 0.001 vs NK cells alone by two-way ANOVA (Dunnett’s 










Previous chapters have identified the human monocyte as a circulating cell type 
which is capable of the carriage and release of free or neutralised reovirus for 
the oncolytic killing of tumour cell targets in vitro. However, while certain OV-
mediated effects are likely to be dependent on viral access to the tumour, the 
capacity of monocytes as hitch-hiking vehicles may prove less important than 
their prospective ability to impart the immunogenic effects of the virus in the in 
vivo setting. This is because in efficacy terms, lytic killing is increasingly 
recognised as secondary to immune activation. This is demonstrated by (i) the 
successful use of poorly lytic, inactivated or attenuated viruses, (ii) the need for 
an intact immune system in tumour purging, and (iii) the benefit of encoding 
various immunostimulatory molecules, such as GM-CSF, as transgenes within 
OV (Breitbach et al., 2011; Liu et al., 2003; Prestwich et al., 2009b; Zamarin et 
al., 2017). Monocytes are abundant in blood, are capable of interacting with 
other immune fractions, and can secrete significant quantities of functionally 
relevant cytokines (Boyette et al., 2017). The effects of virus carriage on 
monocytes, and in particular the differential effects of reovirus and reo-NAb, 
were therefore investigated.  
Preliminary assessments of virus sensing mechanisms and phenotype were 
made, showing qualitative similarities between the two. Supporting the visual 
evidence from electron microscopy (Figure 6.2.3), activation of RIG-I suggests 
that the virus gains access to the cytosol, and that dsRNA may be exposed. For 
reo-NAb, this is consistent with evidence suggesting that antibody-opsonised 
virions can be uncoated for detection of viral RNA by RIG-I (McEwan et al., 
2013; Watkinson et al., 2015).  
The apparent induction of PKR, consistent with its role in sensing reovirus 
dsRNA by mouse DC (Diebold et al., 2003), is predictive of the shutdown of 
host cell translation, a common response to viral infection. Although no direct 
evidence for the restriction of monocyte translation is presented, the disparity 
observed between reovirus genomes and intact virions generated by infected 
monocytes (Figures 6.4.3 and 6.4.4) does suggest an ‘uncoupling’ of 
transcription and translation, giving rise to an abortive cycle of virus replication. 
The activation of these dsRNA sensors and subsequent impingement upon key 
signalling hubs such as NF-κB suggests that carriage of virus is not 
phenotypically silent but induces significant changes in transcriptional 
programs. Indeed, RNAseq analysis (reinforced by qPCR) demonstrated 
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comprehensive changes in gene expression – approaching half of the genes 
tested – by reovirus and reo-NAb. Here, the reo-NAb set resembled an 
attenuated version of the reovirus set. 
This study contains a number of limitations. It is important that the outputs 
generated from lists of ‘differentially expressed genes’ are interpreted with 
caution. Given the size of the data set, these gene lists were not processed 
further prior to enrichment analysis; the magnitude (as long as classified as DE) 
and directionality of the change in expression were not considered. For 
instance, genes upregulated 3-fold and 100-fold, as well as those significantly 
downregulated, were all grouped together. Secondly, although validation of 
transcription was performed by qPCR and correlations made with protein 
output, the role of post-translational modifications in virus-mediated signalling 
was not assessed in this study. 
With this noted, the reo-NAb set did exhibit some subtle differences compared 
to reovirus. Although the existence of a positive feedback loop in Fc receptor 
expression has not been formally explored, it can be speculated that the 
specific upregulation of FCGR3A transcripts in response to reo-NAb does give 
further weight to the prior assays in which FcγR III (CD16) was implicated in 
reo-NAb entry (section 6.3). This adds to evidence from a murine model in 
which Fc receptor expression on myeloid cells was elevated by GM-CSF, and 
was associated with enhanced transfer of reo-NAb to targets (Ilett et al., 2014). 
A number of the differences observed in gene expression were related to 
cytokine secretion or intracellular trafficking, processes which are potentially 
interrelated. In this study, the response to free reovirus includes the 
considerable generation of type I IFN and also the modulation of expression in 
gene ontology terms relating to mitochondria. By contrast, reo-NAb is 
specifically linked to the lysosomal compartment and induces negligible IFN, yet 
a substantial ISG response remains. No evidence for the involvement of IFN-
repressing proteins in this disparity was identified. The key to this conundrum 
may lie in the spatial distribution of MAVS, the adaptor protein for RIG-I and 
MDA5, which is classically located on the mitochondrial membrane and can 
trigger IFN production (Seth et al., 2005).  
MAVS is also present on peroxisomes; from here, MAVS signals to rapidly 
induce the expression of ISG – including CXCL10, NF-κB and others – in the 
absence of IFN (Dixit et al., 2010). Indeed, this signalling ‘shortcut’ may underlie 
the IFN-independent induction of ISG by a number of other viruses (Noyce et 
al., 2011, 2006; Paladino et al., 2006; Peltier et al., 2013). Based on these data, 
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one possibility is that the antibody opsonisation of reovirus redirects entry via 
FcγR III, modulating intracellular trafficking of virus from mitochondria to 
peroxisomes, and thus leading to the induction of an antiviral state in the 
absence of significant IFN. Substantiation of this hypothesis would require 
robust evidence for the involvement of peroxisomal MAVS, such as by 
blocking/knock-out assays and/or its co-localisation with reo-NAb. 
A number of studies describe the potent ability of reovirus to activate NK cells 
within PBMC, via the induction of type I IFN (Adair et al., 2013; Parrish et al., 
2015). The behaviour of reovirus-treated monocytes in this context was 
specifically investigated, demonstrating the convincing induction of CD69 and 
the corresponding generation of anti-tumour activity via degranulation. As 
shown by an IFN receptor-blocking assay, monocyte-derived IFN-α is at least 
partly responsible for the stimulatory effects of the virus.  
The activation observed following direct application of the virus contradicts prior 
studies in which it was observed exclusively in the presence of PBMC (Adair et 
al., 2013; Errington et al., 2008b). Various others have however reported the 
converse finding, with NK activation seen in isolation (Bar-On et al., 2017; 
Prestwich et al., 2009a; Zhao et al., 2015), which is consistent with the 
recognition of the reovirus σ1 protein by NKp46. It is difficult to identify the 
source of this discrepancy, although it appears likely to stem from the mode of 
NK cell selection, which may influence cell activation, and/or the presence or 
absence of ‘contaminating’, possibly IFN-supplying PBMC in NK cell 
preparations. The reactivity of NK cells to free reovirus does however preclude 
the definitive conclusion that IFN-α is solely responsible for NK activation by 
reovirus-treated monocytes, as a degree may be due to the direct effects of the 
released virus. 
Monocytes do appear essential to the limited generation of NK cell cytotoxicity 
by reo-NAb, as treatment with reo-NAb in isolation is ineffectual. Notably, 
although FcγR III (CD16) is the sole Fc receptor present on NK cells, they lack 
the phagocytic machinery to permit antibody-dependent virus entry. Thus in the 
case of reo-NAb, as the production of IFN-α is negligible, it is likely that the 
observed NK activation is owing to the ability of monocytes to ‘process’ reo-NAb 
into free infectious virus, to which NK cells can respond. In this sense, 
monocytes may enable antiviral NAb to be circumvented by ‘recycling’ the 
naked form of the virus. 
Aside from surface CD69 expression, the effect of reovirus and reo-NAb upon T 
cell function was not evaluated in this study. There are however signs that 
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reovirus can boost not just the innate but the adaptive anti-tumour response 
through the enhancement of anti-tumour responses by CD8+ T cells via 
induction of type I and II IFN (Ilett et al., 2009; Prestwich et al., 2008a; Rajani et 
al., 2016). Further, reo-NAb and reovirus-treated monocytes are themselves 
capable of priming T cell responses against tumour antigens (V. Jennings, 
personal communication). 
In conclusion, these studies demonstrate that not only free but also fully 
neutralised reovirus holds significant immunogenic activity, mediated by the 
stimulation of the circulating monocyte population. The potential potency of reo-
NAb complexes shows that pre-existing antiviral immunity may not entirely 








Melanoma inflicts a heavy burden on its victims, with the typical reduction in life 
expectancy approximating two decades, and its incidence is rising globally 
(Ferlay et al., 2015; Guy and Ekwueme, 2011; Thiam et al., 2016). However, 
mortality rates are decreasing. Screening and diagnosis of early-stage disease 
are improving, and effective therapies for advanced melanoma are emerging, 
shifting median survival from months to a number of years (Curiel-
Lewandrowski et al., 2012; Robert et al., 2017). These trends suggest that the 
‘unmet clinical need’ of melanoma is beginning to be met, with safe and 
effective immunotherapies playing a major role in doing so. Such progress does 
not mean that innovative research into new therapies and novel approaches 
should relent. For the majority of patients with metastatic melanoma, the 
prospect of a long-term ‘cure’ remains out of reach for now. Further, the 
‘tumour-agnostic’ activity of some agents (Tao et al., 2018) adds to the rationale 
for continuing research apace, even in relatively favourable indications. 
Immune checkpoint inhibitors have shifted the paradigm across tumour types. 
The critical question now asks how best to potentiate immunotherapies to 
generate long-lasting remissions in a larger proportion of patients. OV offer 
unique anti-neoplastic traits, such as the potential to amplify within the tumour, 
and an unparalleled tolerability, which addresses a major concern of today’s 
oncologists (Jones et al., 2015). Confidence in OV as a modality is developing, 
as exemplified by Merck’s recent acquisition of the company behind CVA21, 
Viralytics, for $394 million (www.viralytics.com). Such events bode well for the 
future use of OV as combination agents. When used in monotherapy, many OV 
– including reovirus – show limited efficacy (Galanis et al., 2012). The reasons 
for this are incompletely understood, although the neutralising capability of the 
humoral immune system has been heavily implicated, particularly in the context 
of i.v. administration (Magge et al., 2013; Tomita et al., 2012). Consequently, i.t. 
delivery has been favoured for some OV, such as T-VEC, with systemic anti-
tumour immunity successfully elicited. However, by virtue of viraemia, i.v. 
infusion is theoretically better suited to global immune activation and accessing 
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disseminated disease. These traits appear prizes to be won, if we can find the 
key to unlock the efficacy of OV when given by this route. 
It is increasingly clear that i.v. OV need ‘help’ to transition successfully from the 
eye of a needle to the heart of a tumour, with cellular chaperones a popular 
strategy (Willmon et al., 2009). Myeloid cells are natural viral sinks, and boast a 
number of favourable properties: virus uptake machinery (Fanger et al., 1996; 
Ilett et al., 2011), tumour trafficking (Clements et al., 2015; Ilett et al., 2014), and 
co-ordination of other immune effectors (Ilett et al., 2011; Parrish et al., 2015). 
In the presence of NAb, human monocyte-derived DC carry reovirus and deliver 
it to kill tumour cell targets in vitro (Ilett et al., 2011). This observation led to a 
murine study in which i.v. reovirus therapy for melanoma was potentiated 
through prior mobilisation of the myeloid compartment with GM-CSF, 
particularly in reovirus-immune animals (Ilett et al., 2014). The current project 
therefore aimed to corroborate and explore a model in which circulating 
monocytes convey antibody-neutralised reovirus to tumours, to initiate both 
oncolytic and immune-mediated cell death. 
As a result of environmental exposure, seroprevalence to reovirus among the 
adult population is high. Thus, in an average cancer patient being considered 
for reovirus therapy, the first infusion of virus would occur in the context of 
detectable but low-level NAb. It is known that virus successfully accesses 
tumour beds in this scenario, even in the relatively restricted environs of the 
brain (Samson et al., 2018). Should subsequent therapeutic infusions be 
necessary, virions would encounter anamnestic NAb at high titre. In either case, 
the dynamic events occurring in the bloodstream immediately after viraemia is 
established – the recognition of virus by antibody, and the binding of cells by 
virus – are critical determinants of its spread and persistence. 
First, the interaction between reovirus and antiviral factors in serum derived 
from reovirus-treated patients was explored. Electron microscopy and 
biochemical depletion assays were used to demonstrate the presence of highly 
neutralising anti-reovirus antibodies in patient serum, which bind the virion to 
form ‘reo-NAb’ immune complexes. The comparison of control- and patient-
derived sera following the addition of reovirus in vitro provides an illustration of 
the difference between a first infusion and subsequent infusions. As the i.v. 
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administration of OV moves closer to regulatory approval, such models provide 
basic information with which to optimise delivery strategies. 
The 100-fold increase in neutralising capacity in patients versus controls, albeit 
in unpaired samples, reflects the scale of the antibody response observed in 
previous reovirus trials (Adair et al., 2012; White et al., 2008). Characterisation 
of serum antibodies identified reovirus-specific IgG and IgA, with IgG in 
particular recognising a wide repertoire of reovirus proteins, as determined by 
western blot. These observations demonstrate the ability of a single i.v. infusion 
of reovirus to profoundly bias the serum antibody response in patients, and 
substantiate the hypothesis that reo-NAb complexes are formed in the 
circulation shortly after infusion. Our inability to isolate ‘endogenous’ reo-NAb, 
together with the absence of reovirus genomes in serum one day after infusion 
(Adair et al., 2012), is suggestive of a rapid process of cellular association and 
potentially egress from circulation.  
Prior studies identified the blood monocyte as a key cell type in sequestering 
reovirus in circulation. Further, in mice, GM-CSF pre-conditioning prior to i.v. 
reovirus enhanced myeloid cell trafficking to melanoma tumours, with an 
associated increase in virus within the tumour (Ilett et al., 2014). Consequently 
the putative role of monocytes as vehicles for reovirus was investigated in the 
human setting, using patient-derived sera, primary human monocytes, and a 
human melanoma cell line. These formed elements of a novel in vitro ‘hand-off’ 
assay, which was used to model the loading of blood monocytes in vivo. The 
assay successfully demonstrated the ability of monocytes to deliver otherwise 
neutralised reovirus to kill melanoma targets by oncolysis. This study is believed 
to be the first to describe this interaction between human monocytes and 
oncolytic reovirus. 
Further, this study represents a rare report of therapeutic OV carriage following 
antibody neutralisation. This phenomenon has been described previously using 
measles virus, again in the context of human monocytic cells (Iankov et al., 
2007). Importantly, monocytes were also found to be capable of delivering 
neutralised CVA21 to tumour targets, using virus and patient-derived material 
from other trials. This transferability suggests that the hand-off of neutralised 
OV represents not a reovirus-specific quirk but a phenomenon of genuine 
230 
 
relevance across OV. The absence of killing with HSV1716 requires further 
investigation. Anti-HSV serum should be obtained to eliminate any confounding 
effects of using pleural fluid; other viruses may be tested to identify a role for the 
viral envelope in preventing hand-off by modulating antibody binding. While 
these are possible, the most likely explanation may lie in a poorly lytic stock of 
HSV1716, as shown by direct cytotoxicity assay. If monocyte-mediated hand-off 
is proven to be applicable across OV, this would be suggestive of an underlying 
immune mechanism rather than virus-specific factors. 
The use of monocytes in this project not only stems from previous studies on 
the carriage of OV by myeloid cells, but also their abundance in circulation and 
their status as primary targets of viral infection (Hou et al., 2012; Kou et al., 
2008). Using a number of imaging techniques, human monocytes were found to 
bind both free reovirus and reo-NAb complexes. The virus gains access to large 
intracellular compartments, likely endosomes, in which biochemical assays 
suggest they are rapidly stripped of any bound antibody, enabling delivery to 
tumour cells. This is consistent with the ‘recycling’ ability of myeloid cells to 
regurgitate intact antigen (Le Roux et al., 2012), and indicates their potentially 
unique capacity to liberate intact virus from its neutralising coat. Despite a 
transient increase in viral RNA, it does not appear that reovirus is capable of 
productive amplification within monocyte carriers, consistent with intact antiviral 
signalling identified by immunophenotyping and western blot. 
It was determined using function-blocking antibodies that reo-NAb loading is at 
least partly dependent on monocyte Fc receptors, consistent with a hypothesis 
in which cellular interaction occurs via the Fc domains of virus-bound 
antibodies. FcγR IIIa (FCGR3A) was identified as the major mediator, with the 
superior potency of non-classical versus classical monocytes supporting this 
theory. However, significant functional redundancy appears to exist in this 
regard, suggestive of shared features between Fc receptors, as has been 
reported elsewhere (Fanger et al., 1996; Rodrigo et al., 2006). Interestingly, this 
is not the first study to demonstrate the antibody-mediated entry of reovirus: two 
separate studies have done so, but both as a virological model rather than in an 
oncolytic context, and neither in primary cells (Burstin et al., 1983; Danthi et al., 
2006). The findings herein regarding FcγR IIIa involvement are consistent with 
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the artificial endowment of Fc receptors enabling entry (Danthi et al., 2006), and 
the ability of FcγR II / III blockade to abrogate the therapeutic activity of GM-
CSF plus reo-NAb in murine cells (Ilett et al., 2014). The finding that reo-NAb 
treatment (but not reovirus treatment) upregulates the expression of this Fc 
receptor alone further implies its involvement, based on a putative positive 
feedback loop. 
As discussed above, there are considerable mechanistic parallels between 
these data and reports of antibody-dependent enhancement (ADE) across the 
virological spectrum. Although ADE of infection may seem a niche mechanism 
lacking physiological impact, it does appear to be of genuine clinical relevance, 
in that by providing a pathogenic virus access to blood monocytes, antibodies 
can significantly exacerbate disease (Katzelnick et al., 2017). Further, in 
comparison to an environmental exposure, the titre of OV administered 
systemically is greater by many orders of magnitude, suggesting it is realistic 
that the impact of such a phenomenon may be equally great. Yet the process 
observed here is unlike ADE, in that the pathogenic amplification of virus 
appears to be thwarted. Most significantly, entry is not strictly antibody-
dependent, as free virus can gain access to the monocyte interior; nor is it 
enhancement, given that the presence of serum substantially reduces monocyte 
viral load and consequently hand-off efficacy. Rather, the specific uptake of 
neutralised reovirus is better described as an antibody-mediated process, when 
the viral epitopes required for canonical entry are masked by NAb.  
It is in this discrimination that the key difference in reo-NAb activity between the 
mouse and human settings appears to lie. In mice, the loading of myeloid cells 
by reovirus is roughly doubled in the presence of NAb, a difference which is 
amplified by the apparent ability of reovirus to replicate in these cells (Ilett et al., 
2014). By contrast, although human monocytes do carry reo-NAb, the degree of 
loading is considerably lower than with free virus, and no appreciable increase 
in titre is observed over time. Thus while ADE is truly applicable to reovirus in 
mice, it cannot be applied wholesale to the human setting. 
Human monocytes possess both Fc receptors and JAM-A and sialic acid. 
Theoretically, the antibody-mediated uptake of OV would have maximal impact 
in the context of a virus for which immune cells (particularly monocytes) do not 
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carry the cognate receptor, as Fc receptor access would not come at the cost of 
access to this receptor. This would be interesting to test as a proof of principle, 
but given the ubiquity of the receptors that viruses employ, few current OV meet 
this criterion; even the avian paramyxovirus NDV uses sialic acid (Mahon et al., 
2011). 
The activity of reo-NAb was further examined in vivo using well-characterised 
melanoma flank models. After i.v. administration, reovirus neutralised ex vivo 
reliably accessed tumour beds, as shown by detection of viral RNA and 
replication-competent viral particles, mirroring the isolation of virus from 
tumours in virus-immune patients (Adair et al., 2012; Samson et al., 2018). A 
trend towards increased tumour viral load by GM-CSF pre-conditioning provided 
corroborative evidence for its enhancement of reovirus therapy, as shown 
previously with regard to cell carriers (Ilett et al., 2014). A subsequent 
experiment designed to show therapeutic equivalence between reo-NAb 
complexes formed ex vivo and those formed in vivo (per Ilett et al., 2014) was 
confounded by tumour ulceration, although initial trends suggested similar 
effects upon tumour growth. It will be necessary to repeat this experiment with 
added precautions against ulceration, to gain a robust assessment of tumour 
burden and survival benefit; mouse group size should also be increased, as the 
effect size between reovirus groups may be small.  
If it can be shown that ex vivo-formed complexes are not therapeutically inferior 
to those formed in virus-immune mice upon reovirus infusion, this may provide 
an opportunity to further examine the type of antibody mediating enhanced viral 
loading of monocytes. Complexes could be formed ex vivo using either 
neutralising (e.g. the anti-σ1 Ab G5; see Figure 5.5.3) or non-neutralising 
monoclonal antibodies (Tyler et al., 1993), and administered i.v. following GM-
CSF pre-conditioning in naïve animals. Comparison of viral loading and therapy 
mediated by these artificial complexes, or free virus, would provide valuable 
data. They should reveal whether neutralising or non-neutralising antibodies 
enable Fc receptor-mediated loading, and thus underpin systemic GM-
CSF/reovirus therapy as described previously (Ilett et al., 2014). Should non-
neutralising antibodies be implicated – as is common in ADE of non-oncolytic 
viruses – a reovirus-binding, non-neutralising monoclonal antibody, 
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administered prior to i.v. reovirus, might represent a prospective therapeutic. A 
successful precedent for this strategy has already been set with VSV in mice 
(Eisenstein et al., 2013). The potential, then, for a paradoxical mirror image: 
while a protective vaccine against the pathogenic dengue virus can 
unintentionally deliver harm (Ferguson et al., 2016), supposedly restrictive 
antibodies against a helpful virus may in fact support therapy. 
 
If the likely therapeutic impact of the hand-off process in vivo was simply a 
product of the viral titre loaded on to human monocytes, it would be expected 
that NAb would be limiting towards therapy, based on the hand-off assay. 
However, in many models, oncolysis is of secondary importance to immune-
mediated killing, and is sometimes not required at all (Prestwich et al., 2009a). 
In the precursor study to this one, in mice, GM-CSF/reovirus therapy for 
melanoma was reliant upon an immune-mediated mechanism, via the activity of 
monocytes and NK cells (Ilett et al., 2014). Thus the monocyte ‘sink’ for virus 
was further investigated for its immunomodulatory potential, given its ability to 
generate a potent cytokine milieu and activate other immune effectors (Adair et 
al., 2013; Errington et al., 2008a; Parrish et al., 2015). 
Like free reovirus, reo-NAb induced the upregulation of cellular RNA sensors, 
and elicited phenotypic maturation and activation of co-stimulatory molecules. 
Given the evidence of a robust response in these primary cells, exploratory 
transcriptional profiling was conducted, using a carefully selected housekeeping 
gene. This revealed qualitatively similar responses to free and neutralised virus, 
with some subtle differences suggestive of alternative trafficking, possibly 
resulting from the presence of virus-bound antibody. Although reo-NAb induced 
the release of some proteins, such as CXCL and MCP family chemokines, at 
similar concentrations to free virus, others such as TNF and IFN were only 
secreted in response to free virus. These differential secretory patterns provide 
further evidence that the presence of NAb modulates the monocyte response to 
virus. Monocyte cytokine release was not lost with UV-inactivated virus, 
suggesting that it is driven through PRR activation by incoming viral motifs 
rather than initial replication of the viral genome. 
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Compared to free reovirus, reo-NAb induced significantly less type I IFN at the 
RNA and protein level, consistent with prior reports of IFN suppression upon 
antibody-dependent entry of virus (Rolph et al., 2011; Tsai et al., 2014). No 
evidence could be found for the transcriptional activation of a specific IFN 
repressor by reo-NAb. Given that reo-NAb triggers monocyte ISG expression in 
our system, it is postulated that Fc receptor-mediated entry modulates reo-NAb 
trafficking and thus activation of specific PRR, which may support ISG activation 
in the relative absence of IFN. Based on prior studies (Dixit et al., 2010; Noyce 
et al., 2011; Stuart et al., 2018), the subcellular localisation of MAVS and the 
subsequent activation state of IRF3 should be interrogated as hallmarks of an 
IFN-independent ISG response. 
The patients from whom serum was obtained for this study received a single 
infusion of i.v. reovirus prior to brain tumour resection (Samson et al., 2018). 
This bolus of virus induced a significant elevation in serum IFN-α at 48 hours 
post-infusion versus baseline. As data on patient NAb levels at baseline were 
not published, it is not clear whether IFN-α was generated in the context of total 
or partial neutralisation. It would be informative to compare IFN-α 
concentrations in serum taken after a first infusion versus after a second 
infusion; this would establish, with direct relevance to the in vitro data in this 
study, whether IFN-α is elevated in the context of complete neutralisation in 
vivo.  
Reovirus-induced IFN-α is of functional significance, as it is necessary for virus-
induced activation of NK cell cytotoxicity against human leukaemia and 
colorectal targets in vitro (Adair et al., 2013; Parrish et al., 2015). This was 
corroborated by the activation of NK cells by type I IFN secreted by reovirus-
treated monocytes. Thus, while a relative lack of IFN-α in the context of reo-
NAb could help to delay viral clearance in vivo, it may concomitantly diminish 
the NK-mediated element of reovirus therapy. Reovirus-mediated NK cell 
degranulation and cytotoxicity was indeed attenuated, but not fully abrogated, 
by the presence of virus-bound NAb. Monocytes were essential for the activity 
of reo-NAb, although it was not possible to determine whether this was a result 
of their ability to regenerate uncoated virus for subsequent activation, or their 
low-level IFN secretion.  
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These data are therefore indicative of human correlates for the cell populations 
required for systemic GM-CSF/reovirus therapy in mice: monocytes as ‘first 
responders’ to reo-NAb, and NK cells as effectors of tumour cell killing (Ilett et 
al., 2014). Further investigation of GM-CSF/reovirus therapy in mice has 
revealed that this regimen promotes homing of not only myeloid cells but also 
CD8+ T cells into tumours, and generates a low-level TH1 response to tumour 
antigens, which is significantly enhanced by adding subsequent PD-1 inhibition, 
translating into therapeutic benefit against melanoma and glioma in syngeneic 
mouse models (Ilett et al., 2017; Samson et al., 2018). Indeed, emerging 
evidence suggests that IFN-induced PD-L1 provides a mechanism of resistance 
against some OV (Zamarin et al., 2018), supporting the combination of 
virotherapy with checkpoint inhibitors. Thus, while innate immune cells appear 
fundamental as early effectors in the GM-CSF/reovirus regimen, potentiating 
adaptive immunity may be the key to realising a truly durable benefit. 
 
In summary, this study confirms that circulating human monocytes are capable 
of the uptake of reovirus, despite total neutralisation, and its release for the 
oncolysis of tumour targets in culture. These findings endorse a model whereby, 
in the bloodstream of virus-immune patients, monocytes are capable of acting 
as carriers for the virus, and delivering it to tumour beds for both oncolytic and 
immune-mediated killing. They are consistent with the presence of reovirus in 
widespread tumour deposits following i.v. administration in the presence of 
NAb, and its association with immune cells, including the myeloid population. In 
contrast to the aforementioned murine study, this project found no overall 
benefit from the presence of NAb in a human in vitro system: it limits monocyte 
loading, and appears to attenuate the IFN response, simultaneously an antiviral 
process and a key potential driver of innate anti-tumour activity. However, in 
antibody-mediated reovirus uptake, the above investigations identify a 
mechanism which may be necessary for the continued activity of systemically 
administered reovirus, and other OV, in patients with pre-existing antiviral 
immunity. Evidence is provided for the involvement of a mechanism which is 
well-defined in virology, but relatively unexplored in the context of OV.  
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It is critical to recognise that, for reovirus and many other therapeutic viruses, 
prevailing seropositivity means that even a first i.v. dose of virus encounters 
NAb – demanding strategies not just to manage this, but to capitalise upon it. A 
clinical study (NCT03282188) that aims to do so has been planned; this was 
designed to demonstrate the enhancement of systemic reovirus therapy by GM-
CSF pre-conditioning in virus-immune melanoma patients, substantiating the 
cell carrier paradigm. Translational outputs from such prospective trials, in 
particular the correlation of monocyte virus load and phenotype with the ultimate 
tumour load and response, would be highly informative. They would enable a 
definitive conclusion on the impact of reovirus carriage in melanoma patients, 
and could offer ways in which the antibody response can be shaped to promote 
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